

FileCopy

davis 10 / 783916

Page 1

=> b reg

FILE 'REGISTRY' ENTERED AT 10:29:29 ON 16 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2

DICTIONARY FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.




REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta 12

L1 STR

N---G1--G2--Cy---N---G3  
1 2 3 4 5 6



REP G1=(1-6) C

VAR G2=O/S/N

VAR G3=7/13/19

NODE ATTRIBUTES:

NSPEC IS RC AT 1

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 4

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L2 2366 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 1126020 ITERATIONS

2366 ANSWERS




SEARCH TIME: 00.00.15

=> d que sta 19

L1 STR

noble jarrell 16/08/2006

N---G1--G2--Cy---N---G3  
1 2 3 4 5 6






REP G1=(1-6) C  
VAR G2=O/S/N  
VAR G3=7/13/19  
NODE ATTRIBUTES:  
NSPEC IS RC AT 1  
DEFAULT MLEVEL IS ATOM  
GGCAT IS UNS AT 4  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 24



STEREO ATTRIBUTES: NONE  
L2 2366 SEA FILE=REGISTRY SSS FUL L1  
L7 STR

G4--G1--G2--Cy---N---G3  
1 2 3 4 5 6



N---G5 G5---N---G5  
@25 26 27 @28 29

Ak~Cy  
@30 31



REP G1=(1-6) C  
VAR G2=O/S/N  
VAR G3=7/13/19  
VAR G4=N/25/28/32/38  
VAR G5=AK/30  
REP G6=(0-1) C  
VAR G7=N/O  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
GGCAT IS UNS AT 4  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 43


STEREO ATTRIBUTES: NONE  
L9 2327 SEA FILE=REGISTRY SUB=L2 SSS FUL L7

100.0% PROCESSED 2366 ITERATIONS  
SEARCH TIME: 00.00.01

2327 ANSWERS

=> d que sta l15  
L1 STR

N---G1--G2--Cy---N---G3  
1 2 3 4 5 6




REP G1=(1-6) C  
VAR G2=O/S/N  
VAR G3=7/13/19  
NODE ATTRIBUTES:  
NSPEC IS RC AT 1  
DEFAULT MLEVEL IS ATOM  
GGCAT IS UNS AT 4  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 24


STEREO ATTRIBUTES: NONE  
L2 2366 SEA FILE=REGISTRY SSS FUL L1  
L7 STR

G4--G1--G2--Cy---N---G3  
1 2 3 4 5 6



N---G5 G5---N---G5  
@25 26 27 @28 29




Ak~Cy  
@30 31



REP G1=(1-6) C  
VAR G2=O/S/N  
VAR G3=7/13/19  
VAR G4=N/25/28/32/38  
VAR G5=AK/30  
REP G6=(0-1) C  
VAR G7=N/O  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
GGCAT IS UNS AT 4  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE  
L9 2327 SEA FILE=REGISTRY SUB=L2 SSS FUL L7  
L13 STR



Page 2-A

```
REP G1=(1-6) C
VAR G2=O/S/N
VAR G3=7/13/19
VAR G4=N/25/28/32/38
VAR G5=AK/30
REP G6=(0-1) C
VAR G7=N/O
VAR G8=H/AK/30/CY/60/62/55/53/OH
```

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 54

CONNECT IS M1 RC AT 56

CONNECT IS M1 RC AT 60

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 4

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 63

STEREO ATTRIBUTES: NONE

L15 694 SEA FILE=REGISTRY SUB=L9 SSS FUL L13

100.0% PROCESSED      2327 ITERATIONS

694 ANSWERS

SEARCH TIME: 00.00.01

=> b hcap

FILE 'HCAPLUS' ENTERED AT 10:30:05 ON 16 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Aug 2006 VOL 145 ISS 8  
FILE LAST UPDATED: 15 Aug 2006 (20060815/ED)



New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitrn hitrn l35 tot

L35 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:220202 HCAPLUS  
DN 142:298126  
TI Preparation of derivatives of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene, useful as urotensin-II receptor antagonists  
IN Wu, Chengde; Anderson, C. Eric; Bui, Huong; Dupre, Brian; Gao, Daxin; Holland, George W.; Kassir, Jamal; Li, Wen; Wang, Junmei  
PA USA  
SO U.S. Pat. Appl. Publ., 118 pp., Cont.-in-part of U.S. Ser. No. 783,916.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005054850	A1	20050310	2004US-0924181	20040823 <--
	US2004186102	A1	20040923	2004US-0783916	20040220 <--
PRAI	2003US-451089P	P	20030228	<--	
	2004US-0783916	A2	20040220	<--	
OS	MARPAT 142:298126				
GI					



AB The invention relates to a preparation of derivs. of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene of formula I [wherein: A is (hetero)aryl, benzoheteroaryl, pyridone, pyridazinone, and pyrimidone; Z is (CH<sub>2</sub>)<sub>1-6</sub>; R<sub>1</sub> and R<sub>2</sub> are independently H, alkyl, or R<sub>1</sub> and R<sub>2</sub> along with N can form pyrrolidone or piperazine, etc.; R<sub>3</sub> is H, alkyl, or arylalkyl; X and Y are independently C or N; R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are independently selected from H, alkyl, (hetero)aryl, halogen, or alkoxy, etc.; L<sub>1</sub> is a single bond or O, C(O), SO<sub>2</sub>, or (hetero)arene; L<sub>2</sub> and L<sub>3</sub> are independently selected from a single bond, CH<sub>2</sub>, C(O), SO<sub>2</sub>, or NH], useful as urotensin-II receptor antagonists. Thus, e.g., II was prepared by substitution of a 4-halo-7-trifluoromethylquinoline with 3-(2-dimethylaminoethoxy)-4-chloroaniline. The prepared compds. were tested for inhibition of human [125I]-urotensin-II binding to urotensin-II receptor and inhibition of human urotensin-II-induced Ca<sup>2+</sup> mobilization (for instance, for II IC<sub>50</sub> was 6.5 μM).


IT 758712-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of derivs. of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene, useful as urotensin-II receptor antagonists)

RN 758712-45-7 HCAPLUS

CN 4-Piperidinol, 1-[2-[3-[(2-methyl-4-pyridinyl)amino]phenoxy]ethyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 758712-45-7P 758712-57-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of derivs. of pyridine, pyrimidine, quinoline, quinazoline, and

naphthalene, useful as urotensin-II receptor antagonists)

L35 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:754408 HCAPLUS

DN 141:277630

TI A preparation of derivatives of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene, useful as urotensin-II receptor antagonists

IN Wu, Chengde; Anderson, C. Eric; Bui, Huong;  
Gao, Daxin; Holland, George W.; Kassir, Jamal;  
Li, Wen; Wang, Junmei; Dupre, Brian

PA Encysive Pharmaceuticals Inc., USA

SO PCT Int. Appl., 110 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004078114	A2	20040916	2004WO-US05150	20040220 <--
	WO2004078114	A3	20050217		
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW:	
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2004218456	A1	20040916	2004AU-0218456	20040220 <--
	CA---2517166	AA	20040916	2004CA-2517166	20040220 <--
	EP---1603884	A2	20051214	2004EP-0713383	20040220 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
PRAI	2003US-451089P	P	20030228 <--		
	2004WO-US05150	W	20040220 <--		
OS	MARPAT 141:277630				
GI					



AB The invention relates to a preparation of derivs. of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene of formula I [wherein: A is (hetero)aryl, benzoheteroaryl, pyridone, pyridazinone, and pyrimidone; Z is (CH<sub>2</sub>)<sub>1-6</sub>; R<sub>1</sub> and R<sub>2</sub> are independently H, alkyl, or R<sub>1</sub> and R<sub>2</sub> along with

N can form pyrrolidone or piperazine, etc.; R3 is H, alkyl, or arylalkyl; X and Y are independently C or N; R4, R5, and R6 are independently selected from H, alkyl, (hetero)aryl, halogen, or alkoxy, etc.; L1 is a single bond or O, C(O), SO2, or (hetero)arene; L2 and L3 are independently selected from a single bond, CH2, C(O), SO2, or NH, useful as urotensin-II receptor antagonists. The prepared compds. were tested for inhibition of human [125I]-urotensin-II binding to urotensin-II receptor and inhibition of human urotensin-II-induced Ca2+ mobilization (for instance, for II IC50 was 6.5 µM).


IT 758712-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of derivs. of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene, useful as urotensin-II receptor antagonists)

RN 758712-45-7 HCAPLUS

CN 4-Piperidinol, 1-[2-[3-[(2-methyl-4-pyridinyl)amino]phenoxy]ethyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 758712-45-7P 758712-57-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of derivs. of pyridine, pyrimidine, quinoline, quinazoline, and naphthalene, useful as urotensin-II receptor antagonists)

L35 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:269913 HCAPLUS

DN 140:287277

TI Preparation of carboxylic acid derivatives that inhibit the binding of integrins to their receptors

IN Biediger, Ronald J.; Chen, Qi; Decker, E. Radford; Holland, George W.; Kassir, Jamal M.; Li, Wen; Market, Robert V.; Scott, Ian L.; Wu, Chengde; Li, Jian

PA Encysive Pharmaceuticals Inc., USA

SO U.S. Pat. Appl. Publ., 98 pp., Cont.-in-part of U.S. Ser. No. 707,068. CODEN: USXXCO

DT Patent



LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2004063955	A1	20040401	2001US-0973142	20011009
	US---6972296	B2	20051206		
	ZA2001008777	A	20030124	2001ZA-0008777	20011024
	NZ---515252	A	20040130	2001NZ-0515252	20011102
	NO2001005394	A	20020507	2001NO-0005394	20011105
	EP---1203766	A2	20020508	2001EP-0125494	20011106
	EP---1203766	A3	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	TR-200103179	A2	20020621	2001TR-0003179	20011106



BR2001006840	A	20050201	2001BR-0006840	20011106
AU2001097084	A5	20020207	2001AU-0097084	20011205
AU---782616	B2	20050811		
CN---1412181	A	20030423	2001CN-0145182	20011229
CA---2366800	AA	20030410	2002CA-2366800	20020107
SG---107574	A1	20041229	2002SG-0000313	20020116
JP2003119181	A2	20030423	2002JP-0031953	20020208
PRAI 1999US-132971P	P	19990507		
2000US-0565920	A2	20000505		
2000US-0707068	A2	20001106		
2000AU-0052679	A3	20000505		
2001US-0973142	A	20011009		
OS MARPAT 140:287277				
GI				



AB The invention relates to a method for the inhibition of the binding of  $\alpha 4\beta 1$  integrin to its receptors [e.g., VCAM-1 (vascular cell adhesion mol.-1) and fibronectin], compds. that inhibit this binding, and the use of such compds. for the control or prevention of diseases states in which  $\alpha 4\beta 1$  is involved. The claims include compds. of general formula I [n is 3-10; Y is CO, N, CR1, CR2R3, NR5, CH, O, S; A is O, S, CR16R17, NR6; E is CH2, O, S, NR7; J is O, S, NR8; T is CO, (CH2)0-3; M is R9R10, (CH2)0-3; L is O, NR11, S, (CH2)0-1; X is CO2B, PO3H2, SO3H, SO2NH2, SO2NHCOR12, OPO3H2, CONHCOR13, CONHSO2R14, OH, tetrazolyl, H; W is C, CR15, N; B, R1-R17 are H, halo, alkyl, alkoxy, acyl, CF3, CO2H, etc.]. Thus, pyridine-containing 3-aminopropionic acid derivative II was prepared by a multistep procedure and showed IC50 = 10 nM in a fibronectin inhibition assay.

IT 307521-32-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxylic acid derivs. that inhibit the binding of integrins to their receptors)

RN 307521-32-0 HCAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[1-[(2-chlorophenyl)methyl]-1,2-dihydro-2-oxo-4-(2-pyridinylamino)-3-pyridinyl]amino]carbonyl]amino]-4-methyl-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 307521-32-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxylic acid derivs. that inhibit the binding of integrins to their receptors)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:349146 HCAPLUS

DN 136:369608

TI Preparation of 3-(N'-oxodihydropyridinylureido)-3-phenylpropanoates as inhibitors of  $\alpha_4\beta_1$  integrin binding

IN Biediger, Ronald J.; Chen, Qi; Holland, George W.; Kassir,

Jamal M.; Li, Wen; Market, Robert V.; Scott, Ian L.;

Wu, Chengde; Decker, Radford E.; Li, Jian

PA Texas Biotechnology Corporation, USA

SO Eur. Pat. Appl., 131 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP---1203766	A2	20020508	2001EP-0125494	20011106
	EP---1203766	A3	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US2004063955	A1	20040401	2001US-0973142	20011009
	US---6972296	B2	20051206		
	ZA2001008777	A	20030124	2001ZA-0008777	20011024
	BR2001006840	A	20050201	2001BR-0006840	20011106
PRAI	2000US-0707068	A	20001106		
	2001US-0973142	A	20011009		
	1999US-132971P	P	19990507		
	2000US-0565920	A2	20000505		

OS MARPAT 136:369608

AB Title compds. were prepared Thus, 2-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>ZNH<sub>2</sub> (Z = 4-ethyl-2-oxo-1,2-dihydropyridine-1,3-diyl) (preparation given) was condensed with (S)-4-MeC<sub>6</sub>H<sub>4</sub>CH(NH<sub>2</sub>)CH<sub>2</sub>CO<sub>2</sub>Et and COCl<sub>2</sub> to give, after saponification, (S)-2-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>ZNHCONHCH(C<sub>6</sub>H<sub>4</sub>Me-4)CH<sub>2</sub>CO<sub>2</sub>H (Z as above). Data for biol. activity of title compds. were given.

IT 307521-32-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(N'-oxodihydropyridinylureido)-3-phenylpropanoates as inhibitors of  $\alpha_4\beta_1$  integrin binding)

RN 307521-32-0 HCAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[1-[(2-chlorophenyl)methyl]-1,2-dihydro-2-oxo-4-(2-pyridinylamino)-3-pyridinyl]amino]carbonyl]amino]-4-methyl-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 307521-32-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(N'-oxodihydropyridinylureido)-3-phenylpropanoates as inhibitors of  $\alpha 4 \beta 1$  integrin binding)

L35 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:814302 HCAPLUS

DN 133:362963

TI Preparation of  $\beta$ -amino acid derivatives that inhibit the binding of integrins to their receptors

IN Biediger, Ronald J.; Chen, Qi; Holland, George W.; Kassir, Jamal M.; Li, Wen; Market, Robert V.; Scott, Ian L.; Wu, Chengde

PA Texas Biotechnology Corporation, USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2000067746	A1	20001116	2000WO-US12303	20000505
WO2000067746	C2	20020829		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA---2373360	AA	20001116	2000CA-2373360	20000505
EP---1176956	A1	20020206	2000EP-0937527	20000505
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR-200103178	T2	20020521	2001TR-0003178	20000505
SI-----20744	C	20020630	2000SI-0020021	20000505
BR2000010293	A	20020716	2000BR-0010293	20000505
TR-200201920	T2	20020923	2002TR-0001920	20000505
JP2002544161	T2	20021224	2000JP-0616772	20000505
NZ---515248	A	20040130	2000NZ-0515248	20000505
RU---2263109	C2	20051027	2001RU-0133360	20000505
ZA2001008774	A	20030124	2001ZA-0008774	20011024

	NO2001005418	A	20011221	2001NO-0005418	20011106
	AU2001097084	A5	20020207	2001AU-0097084	20011205
	AU----782616	B2	20050811		
PRAI	1999US-132971P	P	19990507		
	2000AU-0052679	A3	20000505		
	2000WO-US12303	W	20000505		
OS	MARPAT 133:362963				
GI					



AB Title compds. I [Y, at each occurrence, independently = CO, N, CR1, CR2R3, NR5, CH, O, or S; q = 3-10; A = O, S, CR16R17, NR6; E = CH2, O, S, NR7; J = O, S, NR8; M = CR9R10 or (CH2)0-3; T = CO or (CH2)0-3; L = O, NR11, S, (CH2)0-1; X = CO2B, PO3H2, SO3H, SO2NH2, SO2NHCOR12, OPO3H2, CONHCOR13, CONHSO2R14, tetrazolyl, hydroxyl, H; W = C, CR15, N; B, R1-17 = H, halo, hydroxyl, alkyl, alkoxy, aliphatic acyl, CF3, nitro, cycloalkyl, alkylheteroaryl, sulfonyl, carboxyl, etc.] or their pharmaceutically acceptable salts were prepared for inhibition of the binding of  $\alpha 4 \beta 1$  integrin to its receptors. Thus, II was prepared and assayed ( $IC_{50} = 0.2 \mu M$ ) for its ability to suppress binding using a 26-amino acid peptide containing the CS-1 sequence of fibronectin with N-terminal cysteine coupled to maleimide activated ovalbumin.


IT 307521-32-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of  $\beta$ -amino acid derivs. that inhibit the binding of integrins to their receptors)

RN 307521-32-0 HCAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[1-[(2-chlorophenyl)methyl]-1,2-dihydro-2-oxo-4-(2-pyridinylamino)-3-pyridinyl]amino]carbonyl]amino]-4-methyl-, (BS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 307521-32-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of  $\beta$ -amino acid derivs. that inhibit the binding of integrins to their receptors)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d bib abs hitstr 139 tot

L39 ANSWER 1 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1004351 HCAPLUS

DN 143:306328

TI Preparation of 4-pyrimidinamines as neuroprotectants.

IN Benjamin, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael Kurt; Zhong, Zhong; Reitz, Allen B.; Ross, Tina Morgan

PA USA

SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 922,874, abandoned.


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005203092	A1	20050915	2004US-0987562	20041112 <--
	US2003008883	A1	20030109	2001US-0922874	20010806 <--
	US2003212079	A1	20031113	2003US-0396158	20030325 <--
	US2004006094	A1	20040108	2003US-0395971	20030325 <--
PRAI	2000US-223791P	P	20000808	<--	
	2001US-0922874	B2	20010806	<--	
OS	MARPAT 143:306328				
GI					



I


AB This invention provides novel neuroprotective 4-pyrimidineamine derivs. (I, variables defined below) and neuroprotective pharmaceutical compns. comprising 4-pyrimidinamines. This invention also provides methods of using these compns. to prevent ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbonyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07  $\mu$ M to >1  $\mu$ M. For I the variables are: R20 = disubstituted amino; R21 = H, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl, wherein the aryl portion is optionally substituted; p = 0-3; q = 0-3; R22 and R23 = halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxy, alkoxycarbonyl, aryloxy carbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl.

IT 397850-40-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-40-7 HCAPLUS

CN 1,4-Benzenediamine, N-(2-aminoethyl)-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




IT 397850-34-9P 397850-35-0P 397850-36-1P  
397850-37-2P 397850-38-3P 397850-41-8P  
397850-42-9P 397850-43-0P 397850-44-1P  
397850-45-2P 397850-46-3P 397850-47-4P  
397850-48-5P 397850-49-6P 397850-50-9P  
397850-51-0P 397850-52-1P 397850-53-2P  
397850-54-3P 397850-55-4P 397850-56-5P  
397850-57-6P 397850-58-7P 397850-59-8P  
397850-60-1P 397850-61-2P 397850-62-3P  
397850-63-4P 397850-64-5P 397850-65-6P  
397850-66-7P 397850-67-8P 397850-68-9P  
397850-69-0P 397850-70-3P 397850-71-4P  
397850-72-5P 397850-73-6P 397850-74-7P  
397850-75-8P 397850-76-9P 397850-77-0P  
397850-78-1P 397850-79-2P 397850-80-5P  
397850-81-6P 397850-82-7P 397850-83-8P  
397850-84-9P 397850-85-0P 397850-86-1P  
397850-87-2P 397850-88-3P 397850-89-4P  
397850-90-7P 397850-92-9P 397850-94-1P  
397850-97-4P 397850-98-5P 397850-99-6P  
397851-00-2P 397851-01-3P 397851-02-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-34-9 HCAPLUS

CN Benzamide, N-[2-[[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 397850-35-0 HCAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 397850-36-1 HCAPLUS

CN Hexadecanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl] - (9CI) (CA INDEX NAME)




RN 397850-37-2 HCAPLUS

CN Butanamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(1-oxobutyl)amino]ethyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 397850-38-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(cyclohexylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-41-8 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-42-9 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxypropyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-43-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3-chlorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)







RN 397850-44-1 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-45-2 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-ethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-46-3 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(propylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-47-4 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2,5-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-48-5 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




RN 397850-49-6 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-50-9 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-51-0 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3-(diethylamino)propyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-52-1 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(4-

bromo-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-53-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-(dimethylamino)ethyl)(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-54-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[butyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-55-4 HCAPLUS

CN 1,4-Benzenediamine, N-[2-([1,1'-biphenyl]-4-ylamino)ethyl]-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-56-5 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-furanylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-57-6 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-

[[ (3-iodophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-58-7 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-59-8 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[ (3,4-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-60-1 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-thienyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-61-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[ (3,5-dimethyl-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-62-3 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[ (2-phenylethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-63-4 HCAPLUS  
 CN Acetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl]-2-ethoxy-N-(phenylmethyl)-(9CI) (CA INDEX NAME)




RN 397850-64-5 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-ethyl-N-[2-[[2-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-65-6 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-[2-[[4-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-66-7 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-[2-[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-67-8 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-ethyl-N-[2-

[[2-(3-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 397850-68-9 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
[[3,4,5-trimethoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-69-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
[[2-(4-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—OMe

RN 397850-70-3 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
[[2-(1H-imidazol-4-yl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-71-4 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-72-5 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-73-6 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [[[3-methoxyphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-74-7 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [[[3-methylphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-75-8 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[3,5-  
 dimethoxyphenyl]methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-76-9 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[2-  
 bromophenyl]methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-77-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(4-bromophenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 397850-78-1 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-79-2 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(1-naphthalenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A



RN 397850-80-5 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-81-6 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-82-7 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(butylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-83-8 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-bis(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-84-9 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(3-pyridinylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-85-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-86-1 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-87-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-88-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-ethyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-89-4 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-90-7 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-92-9 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-94-1 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 397850-97-4 HCAPLUS  
 CN Benzeneacetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- $\alpha$ -chloro- (9CI) (CA INDEX NAME)




RN 397850-98-5 HCAPLUS  
 CN 3-Pyridinecarboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-6-nitro- (9CI) (CA INDEX NAME)



RN 397850-99-6 HCAPLUS  
 CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)




RN 397851-00-2 HCAPLUS  
 CN Benzamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-4-butoxy- (9CI) (CA INDEX NAME)




RN 397851-01-3 HCAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(4-(trifluoromethyl)benzoyl)amino]ethyl]amino]phenyl]-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 397851-02-4 HCAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(3-fluorobenzoyl)amino]ethyl]amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



L39 ANSWER 2 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STM

AN 2005:260034 HCAPLUS

DN 142:336376

TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don

PA Axxima Pharmaceuticals AG, Germany

SO PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2005026129	A1	20050324	2004WO-EP10353	20040915 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP---1678147	A1	20060712	2004EP-0786953	20040915 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI	2003EP-0020888	A	20030915	<--
	2003US-504527P	P	20030922	<--
	2004EP-0010308	A	20040430	
	2004US-569806P	P	20040512	
	2004WO-EP10353	W	20040915	

OS MARPAT 142:336376  
 GI



II

AB The invention is related to the preparation of title compds. I, and/or stereoisomeric forms and/or pharmaceutically acceptable salts [wherein R<sub>1</sub> = H, (un)substituted alk(en/yn)yl; R<sub>2</sub>, R<sub>4</sub> = independently H, F, Cl, Br, I, CN, NH<sub>2</sub>, NO<sub>2</sub>, (un)substituted alk(en/yn)yl; R<sub>3</sub> = F, Cl, Br, I, (un)substituted hetero/aryl, etc.; X = R<sub>5</sub>-[LR<sub>6</sub>]<sub>m</sub>; R<sub>5</sub> = (un)substituted hetero/aryl, heterocyclyl, cycloalkyl, etc.; R<sub>6</sub> = H, (un)substituted alkyl, hetero/aryl, heterocyclyl, etc.; L = NRSO<sub>2</sub>, NRSO; R = H, (un)substituted alkyl, SO<sub>2</sub>-alkyl, etc.] as protein kinase inhibitors for use in the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. The invention is also related to a medium comprising at least one of compds. I in an immobilized form and its use for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized I. General preparation procedures and 5 individual synthetic examples are given. I have an inhibitory effect on the protein kinase activity of various protein kinases, such as Abl, CDK1, CDK5, etc. Selected I had an inhibitory effect on CDK9 and CDK2 with IC<sub>50</sub> values in the range of 1 to 1000 nM. I were potent inhibitors of HIV and HCMV replication in cell cultures; for example II showed inhibition of HCMV replication in HFF cells.


IT **848636-51-1P**, 1-Cyclohexyl-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]urea **848636-59-9P**, 2-Dimethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]acetamide **848636-66-8P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]guanidine **848636-77-1P**, 3-Diethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-

ylamino]phenyl]propionamide **848636-94-2P**, (S)-2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylethanamide **848636-95-3P**, (S)-N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-methylamino-2-phenylethanamide **848637-14-9P**, 2-Dimethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylacetamide **848637-15-0P**, 3-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]propionamide **848637-24-1P**, 1-(Benzodioxol-5-yl)-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]urea **848637-25-2P**, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-(4-methylbenzyl)urea **848637-26-3P**, 1-tert-Butyl-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]urea **848637-31-0P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-methyl-2-methylaminopropionamide **848637-52-5P**, (2S,3S)-2-Amino-3-methylpentanoic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide **848637-55-8P**, (S)-2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-methylbutanamide **848637-58-1P**, 2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-(naphthalen-2-yl)acetamide **848638-98-2P**, 1-Dimethylamino-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenoxy]-3-propan-2-ol **848639-24-7P**, 1-[4-[6-(2-Benzyloxyphenyl)pyrimidin-4-ylamino]phenoxy]-3-dimethylaminopropan-2-ol **848639-87-2P**, 1-(4-Chloro-3-trifluoromethylphenyl)-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea **848639-88-3P**, 1-Cyclohexyl-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea **848639-91-8P**, 1-Isopropyl-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea **848639-92-9P**, 1-[5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]-3-[2-(morpholin-4-yl)ethyl]urea **848639-93-0P**, 1-(2-Dimethylaminoethyl)-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848636-51-1 HCAPLUS

CN Urea, N-cyclohexyl-N'-[4-[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848636-59-9 HCAPLUS


CN Acetamide, 2-(dimethylamino)-N-[4-[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-66-8 HCAPLUS

CN Guanidine, [4-[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI)

(CA INDEX NAME)




RN 848636-77-1 HCAPLUS  
 CN Propanamide, 3-(diethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-94-2 HCAPLUS  
 CN Benzeneacetamide,  $\alpha$ -amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-95-3 HCAPLUS  
 CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- $\alpha$ -(methylamino)-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-14-9 HCAPLUS  
 CN Benzeneacetamide,  $\alpha$ -(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)







RN 848637-15-0 HCAPLUS  
 CN Propanamide, 3-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-24-1 HCAPLUS  
 CN Urea, N-1,3-benzodioxol-5-yl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848637-25-2 HCAPLUS  
 CN Urea, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N'-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 848637-26-3 HCAPLUS  
 CN Urea, N-(1,1-dimethylethyl)-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848637-31-0 HCAPLUS


CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2-methyl-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 848637-52-5 HCAPLUS

CN Pentanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-55-8 HCAPLUS


CN Butanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-58-1 HCAPLUS

CN 2-Naphthaleneacetamide, α-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848638-98-2 HCAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 848639-24-7 HCAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 848639-87-2 HCAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848639-88-3 HCAPLUS

CN Urea, N-cyclohexyl-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848639-91-8 HCAPLUS

CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 848639-92-9 HCAPLUS

CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 848639-93-0 HCAPLUS

CN Urea, N-[2-(dimethylamino)ethyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




IT 848639-99-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)

RN 848639-99-6 HCAPLUS

CN Carbamic acid, [[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 3 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:216619 HCAPLUS

DN 142:297864

TI Preparation of aniline derivatives and related compounds as c-kit modulators

IN Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William

PA Exelixis, Inc., USA

SO PCT Int. Appl., 169 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005020921	A2	20050310	2004WO-US28001	20040827 <--
	WO2005020921	A3	20051006		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2004268621	A1	20050310	2004AU-0268621	20040827 <--
	CA---2536954	AA	20050310	2004CA-2536954	20040827 <--
	EP---1663204	A2	20060607	2004EP-0782473	20040827 <--
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	2003US-499224P	P	20030829	<--	
	2004WO-US28001	W	20040827		
OS	MARPAT 142:297864				
GI					



AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are H, halo, trihalomethyl, cyano, nitro, etc.; L<sub>1</sub> is a single bond, (un)substituted alkylene, O, CH<sub>2</sub>O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L<sub>2</sub> is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro

compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)<sub>3</sub> and NaN<sub>3</sub> in AcOH followed by NaNO<sub>2</sub>/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-Kit kinase with a IC<sub>50</sub> of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.


IT 847607-75-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)

RN 847607-75-4 HCAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[3-(2-pyridinylamino)phenoxy]- (9CI) (CA INDEX NAME)



L39 ANSWER 4 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:29318 HCAPLUS

DN 142:134918

TI Preparation of novel 2,4,6-trisubstituted heterocycle amino acid derivatives for treatment of neurological disorders

IN Brown, Dean; Cacciola, Joseph; Jacobs, Robert T.; McLaren, Frances M.; Shenvi, Ashokkumar Bhikkappa; Smith, Reed W., Jr.

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005003103	A2	20050113	2004WO-GB02723	20040624 <--
	WO2005003103	A3	20051103		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2003US-484250P P 20030630 <--

OS MARPAT 142:134918

GI



AB Triazine, pyrimidine and pyridine amino acid derivs. I [Q is C, CH or N; W is N or S (R6 not present); X, Y, Z are independently C or N (at least one is N); R1, R2 are independently H, Me, (un)substituted alkyl, carbocyclyl or heterocyclyl or R1 and R2 in combination can form an (un)substituted heterocycle or carbocycle; R3 is H or (un)substituted alkyl; R4 is H, (un)substituted alkyl or carbocyclyl, CO2Me, CONHCH2Me or CONHCH2-heterocyclyl; R5 is H or Me; R6 is H; R7 is (un)substituted carbocyclyl] were prepared for the treatment of neurol. disorders related to amyloid  $\beta$  protein production, e.g., Alzheimer's disease. Thus, treatment of cyanuric chloride with 3-fluoroaniline in THF in the presence of DIEA for 1 h and then leucine Me ester hydrochloride at reflux for 4 h afforded Me N-[4-[(3-fluorophenyl)amino]-6-chloro-1,3,5-triazin-2-yl]-L-leucinate. The latter formed a resin with polystyrene-hydroxybenzotriazole and was reacted with 2-hydroxy-1-propylamine to afford compound II. Compds. of the invention inhibit amyloid  $\beta$  production (IC50 = 0.010-5.50  $\mu$ M in the  $\gamma$ -secretase detergent extract assay).

IT 825647-27-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazine, pyrimidine and pyridine amino acid derivs. for treatment of neurol. disorders)

RN 825647-27-6 HCAPLUS

CN Pentanamide, 2-[[4-[(4-methoxyphenyl)thio]-6-(2-pyridinylamino)-2-pyrimidinyl]amino]-4-methyl-N-[(tetrahydro-2-furanyl)methyl]-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. .



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 5 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965255 HCAPLUS

DN 141:410950

TI Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension

IN Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PA Pfizer Limited, UK; Pfizer Inc.

SO PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004096810	A1	20041111	2004WO-IB01433	20040422 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2004234158	A1	20041111	2004AU-0234158	20040422 <--
	CA---2523831	AA	20041111	2004CA-2523831	20040422 <--
	EP---1620437	A1	20060201	2004EP-0728868	20040422 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR2004009903	A	20060425	2004BR-0009903	20040422 <--
	CN---1780841	A	20060531	CN 2004-80011467	20040422 <--
	NL---1026074	A1	20041101	2004NL-1026074	20040428 <--
	NL---1026074	C2	20050809		
	US2005043325	A1	20050224	2004US-0834484	20040429 <--
	NO2005004404	A	20051124	2005NO-0004404	20050922 <--
PRAI	2003GB-0009780	A	20030429	<--	
	2003GB-0027748	A	20031128	<--	
	2003US-476678P	P	20030606	<--	
	2004US-538147P	P	20040120		
	2004WO-IB01433	A	20040422		
OS	MARPAT 141:410950				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein R1 = (un)substituted cycloalkyl, cycloalkenyl, (un)substituted pyridin-2-yl, (un)fused Ph, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or NR3R4 = piperazin-1-yl, monocyclic, saturated polycyclic; R5 = (un)substituted halo/alkyl, alkenyl, alkynyl, cycloalkyl; R6 = H, (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, etc.] were prepared as selective PDE5 inhibitors. For example, II•2HCl was prepared from (4-Methylpyridin-2-yl)amine, dichloride III (general preparation given), and tert-Bu piperazine-1-carboxylate. I gave IC50 values < 10,000 nM in an in vitro assay for PDE5 inhibition. Thus, I are used for treating hypertension.

IT 792967-25-0P 792967-27-2P 792967-41-0P

792967-43-2P 792967-45-4P 792967-47-6P

792967-49-8P 792968-03-7P 792968-08-2P

792969-14-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE5 inhibitor; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792967-25-0 HCAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N5-[2-(methylamino)ethyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)



CM 1

CRN 792967-24-9

CMF C18 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-27-2 HCAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-26-1

CMF C18 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792967-41-0 HCAPLUS  
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-40-9  
 CMF C19 H28 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 792967-43-2 HCAPLUS  
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-42-1  
 CMF C20 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-45-4 HCAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[3-(dimethylamino)propyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-44-3

CMF C20 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-47-6 HCAPLUS  
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[3-(dimethylamino)propyl]-  
 N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI)  
 (CA INDEX NAME)

CM 1

CRN 792967-46-5

CMF C21 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-49-8 HCAPLUS  
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N5-[2-(methylamino)ethyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-48-7

CMF C19 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 792968-03-7 HCAPLUS


CN Propanamide, 3-[[[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-N-methyl- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-08-2 HCAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(5-methyl-2-pyridinyl)-N5-[2-(4-morpholinyl)ethyl]-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-14-3 HCAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-N5,3-dimethyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 6 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:817889 HCAPLUS

DN 141:332200

TI N,N'-Di(hetero)aryl(thio)ureas useful as positive allosteric modulators of the  $\alpha 7$  subunit of the nicotinic acetylcholine receptor, and their pharmaceutical compositions, uses, and preparation

IN Rogers, Bruce Nelsen; Piotrowski, David Walter; Margolis, Brandon Jerome; Myers, Jason Kenneth; Groppi, Vincent Edward, Jr.; Rudmann, Daniel Gregory

PA Pharmacia & Upjohn Company, USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004085433	A2	20041007	2004WO-IB00838	20040315 <--
	WO2004085433	A3	20041216		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

CA---2519265	AA	20041007	2004CA-2519265	20040315 <--
EP---1611128	A2	20060104	2004EP-0720670	20040315 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR2004008815	A	20060404	2004BR-0008815	20040315 <--
PRAI 2003US-458766P	P	20030328	<--	
2004WO-IB00838	W	20040315		
OS MARPAT 141:332200				
GI				




AB The invention provides di(hetero)arylureas A-NH-C(:X)-NH-B [I; X = O or S; A = certain (un)substituted 6-membered (hetero)aryl rings containing 0-4 N atoms, e.g., Ph, pyridinyl; B = certain (un)substituted 5- or 6-membered (hetero)aromatic rings containing O, NH or derivs., N, or S, particularly 6-membered rings with 0-4 N as cited of A, or 5-membered azole-type heterocycles bound at C or N]. These compds. may be in the form of pharmaceutical salts or compns., or may be in pure enantiomeric form or racemic mixts. I are useful in pharmaceuticals used to treat a wide variety of diseases or conditions in which the  $\alpha 7$  subunit of the nicotinic acetylcholine receptor ( $\alpha 7$ nAChR) is known to be involved. I may be used in combination with a variety of other agents, including antipsychotics, agents which increase brain acetylcholine levels, or which inhibit acetylcholinesterase, or which activate production of acetylcholine, or monoamine reuptake inhibitors, psychostimulants, or  $\alpha 7$ nAChR agonists. A total of 25 compds. are described, 23 with preparatory details. Using a FLIPR, cell-based, Ca flux assay with mutated  $\alpha 7$ nAChR expressed in SHEP-1 cells, the example compds. had activity between 10 nM and 10  $\mu$ M. For instance, invention compound II was prepared in 4 steps. Thus, ethanolysis of 2-bromo-4-fluoro-1-nitrobenzene with NaOEt in EtOH (68%), and Pd complex-catalyzed coupling of the resultant 2-bromo-4-ethoxy-1-nitrobenzene with 4-aminopyridine (84%) gave N-(5-ethoxy-2-nitrophenyl)pyridin-4-amine. Hydrogenation of the nitro group to amino (89%) and carbamoylation by Ph (5-methylisoxazol-3-yl)carbamate (81%) gave II.

IT **769921-65-5P**, N-[4-Ethoxy-2-(pyridin-4-ylamino)phenyl]-N'-(5-methylisoxazol-3-yl)urea **769921-68-8P**, N-[4-Ethoxy-2-(pyridin-2-ylamino)phenyl]-N'-(5-methylisoxazol-3-yl)urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of diheteroarylureas and analogs as pos. allosteric modulators of  $\alpha 7$  subunit of nicotinic acetylcholine receptors)  
 RN **769921-65-5** HCAPLUS  
 CN Urea, N-[4-ethoxy-2-(4-pyridinylamino)phenyl]-N'-(5-methyl-3-isoxazolyl)-(9CI) (CA INDEX NAME)



RN 769921-68-8 HCAPLUS  
 CN Urea, N-[4-ethoxy-2-(2-pyridinylamino)phenyl]-N'-(5-methyl-3-isoxazolyl)-  
 (9CI) (CA INDEX NAME)



L39 ANSWER 7 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:780693 HCAPLUS  
 DN 141:296042  
 TI Preparation of quinazolines non-receptor tyrosine kinase inhibitors as  
 antitumor agents  
 IN Barlaam, Bernard  
 PA AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004081000	A1	20040923	2004WO-GB00942	20040305 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				
PRAI	2003EP-0290581	A	20030310 <--		
OS	MARPAT 141:296042				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*



AB Title quinazolines I [wherein Z = O, S, SO, SO<sub>2</sub>, NR<sub>2</sub>, CR<sub>2</sub>R<sub>3</sub>; R<sub>2</sub>, R<sub>3</sub> = independently H, alkyl; m = 1-3; R<sub>1</sub> = independently halo, CF<sub>3</sub>, CN, NC, NO<sub>2</sub>, OH, SH, NH<sub>2</sub>, CHO, CO<sub>2</sub>H, carbamoyl, sulfamoyl, alk(en/yn)yl, etc.; R<sub>a</sub> = H, halo; R<sub>b</sub>, R<sub>c</sub> = independently H, halo, alkyl, alkoxy; R<sub>d</sub> = alkoxy; or their pharmaceutically acceptable salts thereof] were prepared as non-receptor tyrosine kinase inhibitors. For example, 4-chloro-7-(2-chloroethoxy)-6-methoxyquinazoline (preparation given) was coupled with 2-amino-3-chloro-6-methoxypyridine using sodium hexamethyldisilazane in DMF to give II. Selected I inhibited the phosphorylation of a tyrosine containing polypeptide substrate by human recombinant c-Src kinase (IC<sub>50</sub> in the range of 0.001-0.5 μM), suppressed the proliferation of mouse 3T3 fibroblast cells stably-transfected with an activating mutant of human c-Src (IC<sub>50</sub> in the range of 0.1-5 μM), and inhibited the migration of the human tumor cell line A549 (IC<sub>50</sub> in the range of 0.1-5 M). In addition, no physiol. unacceptable toxicity was observed at the ED for compds. tested in an in vivo A549 xenograft growth assay using athymic nude mice. Thus, I and pharmaceutical compns. containing them are useful as anti-invasive agents in the containment and/or treatment of solid tumor disease.

IT 763123-55-3P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazoline 763123-56-4P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline 763123-58-6P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(3-chloro-6-methoxypyridin-2-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-62-2P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(3-chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxyquinazoline 763123-63-3P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[2-(morpholino)ethoxy]quinazoline 763123-64-4P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 763123-65-5P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[2-(piperidino)ethoxy]quinazoline 763123-66-6P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline 763123-67-7P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-6-methoxyquinazoline 763123-68-8P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 763123-69-9P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[3-(piperidino)propoxy]quinazoline 763123-70-2P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[3-(morpholino)propoxy]quinazoline 763123-71-3P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 763123-72-4P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(4-acetylpiperazin-1-yl)propoxy]-6-methoxyquinazoline 763123-76-8P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[2-(morpholino)ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-77-9P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[2-(pyrrolidin-1-yl)ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-79-1P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[2-(piperidino)ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-80-4P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-81-5P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-82-6P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(pyrrolidin-1-yl)propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-83-7P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(piperidino)propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-84-8P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(morpholino)propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-85-9P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-86-0P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(4-acetylpiperazin-1-yl)propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-87-1P


, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 763123-88-2P  
 , 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 763123-89-3P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[2-(piperidino)ethoxy]quinazoline 763123-90-6P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[2-(morpholino)ethoxy]quinazoline 763123-91-7P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline 763123-92-8P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazoline 763123-93-9P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 763123-94-0P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[3-(piperidino)propoxy]quinazoline 763123-95-1P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[3-(morpholino)propoxy]quinazoline 763123-96-2P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 763123-97-3P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-7-[3-(4-acetylpiperazin-1-yl)propoxy]-5-isopropoxyquinazoline 763123-98-4P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-5-isopropoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of quinazolines c-Src kinase inhibitors as antitumor agents)

RN 763123-55-3 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-56-4 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-58-6 HCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA


INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-62-2 HCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-63-3 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[2-(4-morpholinylethoxy)]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-64-4 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[2-(1-pyrrolidinylethoxy)]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-65-5 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[2-(1-piperidinylethoxy)]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-66-6 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[2-(4-methyl-1-piperazinylethoxy)]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-67-7 HCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-68-8 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-69-9 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-70-2 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-71-3 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-72-4 HCAPLUS


CN Piperazine, 1-acetyl-4-[3-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-76-8 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-77-9 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[2-(1-pyrrolidinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-79-1 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[2-(1-piperidinylethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]]-9CI (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-80-4 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[2-(4-methyl-1-piperazinylethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]]-9CI (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-81-5 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]]-9CI (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-82-6 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[3-(1-pyrrolidinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-83-7 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[3-(1-piperidinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-84-8 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-85-9 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[3-(4-methyl-1-piperazinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-86-0 HCAPLUS


CN Piperazine, 1-acetyl-4-[3-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-87-1 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-88-2 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-89-3 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-90-6 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-91-7 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-92-8 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-93-9 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-94-0 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-95-1 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-96-2 HCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[3-(4-methyl-1-piperazinyl)propoxy]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-97-3 HCAPLUS


CN Piperazine, 1-acetyl-4-[3-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]propyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 763123-98-4 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-2-pyridinyl)-5-(1-methylethoxy)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 8 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:681574 HCAPLUS

DN 141:207069

TI Preparation of 3-cyanoquinoline non-receptor tyrosine kinase inhibitors as antitumor agents

IN Barlaam, Bernard

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 71 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004069250	A1	20040819	2004WO-GB00396	20040130 <--
	W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	2003EP-0290261	A	20030203	<--	
OS	MARPAT 141:207069				
GI					



I



II

AB Title quinolinenitriles I [wherein Z = O, S, SO, SO<sub>2</sub>, NR<sub>2</sub>, CR<sub>2</sub>R<sub>3</sub>; R<sub>1</sub> = independently halo, CF<sub>3</sub>, CN, NC, NO<sub>2</sub>, OH, SH, NH<sub>2</sub>, CHO, CO<sub>2</sub>H, carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, etc.; R<sub>2</sub>, R<sub>3</sub> = independently H, alkyl; m = 1-3; R<sub>a</sub> = H, halo; R<sub>b</sub>, R<sub>c</sub> = independently H, halo, alkyl, alkoxy; R<sub>d</sub> = alkoxy; or R<sub>a</sub>R<sub>b</sub>, R<sub>b</sub>R<sub>c</sub>, or R<sub>c</sub>R<sub>d</sub> = alkylenedioxy; or pharmaceutically acceptable salts thereof] were prepared as non-receptor tyrosine kinase inhibitors. For example, 2-amino-3-chloro-6-methoxypyridine (preparation given) was coupled with 4-chloro-3-cyano-6-methoxy-7-(3-morpholinopropoxy)quinoline using sodium hexamethyldisilazane in DMF to give II. The latter inhibited the phosphorylation of a tyrosine containing polypeptide substrate by human recombinant c-Src kinase (IC<sub>50</sub> = 0.005 μM), suppressed the proliferation of mouse 3T3 fibroblast cells stably-transfected with an activating mutant of human c-Src (IC<sub>50</sub> = 0.2 μM), and inhibited the migration of the human tumor cell line A549 (IC<sub>50</sub> = 0.005 μM). In addition, no physiol. unacceptable toxicity was observed at the ED for compds. tested in an in vivo A549 xenograft growth assay using athymic nude mice. Thus, I and pharmaceutical compns. containing them are useful as anti-invasive agents in the containment and/or treatment of solid tumor disease.

IT 742070-72-0P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[3-(morpholino)propoxy]quinoline 742070-77-5P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinoline 742070-78-6P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[2-(piperidino)ethoxy]quinoline 742070-79-7P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[2-(morpholino)ethoxy]quinoline 742070-80-0P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline 742070-81-1P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]quinoline 742070-82-2P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[2-(4-acetylpiperazin-1-yl)ethoxy]quinoline 742070-83-3P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinoline 742070-84-4P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[3-(piperidino)propoxy]quinoline 742070-85-5P, 4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline 742070-86-6P,


4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]quinoline 742070-87-7P,  
4-[(3-Chloro-6-methoxypyridin-2-yl)amino]-3-cyano-6-methoxy-7-[3-(4-acetylpiperazin-1-yl)propoxy]quinoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of quinolinenitrile c-Src kinase inhibitors as antitumor agents)


RN 742070-72-0 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 742070-77-5 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 742070-78-6 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 742070-79-7 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 742070-80-0 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 742070-81-1 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 742070-82-2 HCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-3-cyano-6-methoxy-7-quinolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 742070-83-3 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-




methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 742070-84-4 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 742070-85-5 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 742070-86-6 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 742070-87-7 HCAPLUS  
 CN Piperazine, 1-acetyl-4-[[3-[[4-[(3-chloro-6-methoxy-2-pyridinyl)amino]-3-cyano-6-methoxy-7-quinolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




L39 ANSWER 9 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:681573 HCAPLUS  
 DN 141:207068  
 TI Preparation of 3-cyanoquinoline non-receptor tyrosine kinase inhibitors as  
 antitumor agents  
 IN Barlaam, Bernard  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2004069249	A1	20040819	2004WO-GB00367	20040130 <--
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2003EP-0290260	A	20030203 <--		
OS MARPAT 141:207068				
GI				



I



II

AB Title quinolinenitriles I [wherein Z = O, S, SO, SO<sub>2</sub>, NR<sub>2</sub>, CR<sub>2</sub>R<sub>3</sub>; R<sub>1</sub> = independently halo, CF<sub>3</sub>, CN, NC, NO<sub>2</sub>, OH, SH, NH<sub>2</sub>, CHO, CO<sub>2</sub>H, carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, etc.; R<sub>2</sub>, R<sub>3</sub> = independently H, alkyl; m = 1-3; R<sub>a</sub> = H, halo; R<sub>b</sub>, R<sub>d</sub> = independently H, halo, alkyl, alkoxy; R<sub>c</sub> = alkoxy; or R<sub>c</sub>R<sub>d</sub> = alkylendioxy; or pharmaceutically acceptable salts thereof] were prepared as non-receptor tyrosine kinase inhibitors. For example, reaction of 7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxy)pyridin-4-ylamino)-3-cyano-6-methoxyquinoline with morpholine using KI in DMA gave II. The latter inhibited the phosphorylation of a tyrosine containing polypeptide substrate by human recombinant c-Src kinase (IC<sub>50</sub> = 0.01 μM), suppressed the proliferation of mouse 3T3 fibroblast cells stably-transfected with an activating mutant of human c-Src (IC<sub>50</sub> = 0.2 μM), and inhibited the migration of the human tumor cell line A549 (IC<sub>50</sub> = 0.7 μM). In addition, no physiol. unacceptable toxicity was observed at the ED for compds. tested in an in vivo A549 xenograft growth assay using athymic nude mice. Thus, I and pharmaceutical compns. containing them are useful as anti-invasive agents in the containment and/or treatment of solid tumor disease.


IT 742072-77-1P, 4-[(5-Chloro-2-methoxypyridin-4-yl)amino]-3-cyano-6-methoxy-7-[3-(morpholino)propoxy]quinoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of quinolinenitrile c-Src kinase inhibitors as antitumor agents)

RN 742072-77-1 HCAPLUS

CN 3-Quinolinecarbonitrile, 4-[(5-chloro-2-methoxy-4-pyridinyl)amino]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L39 ANSWER 10 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:648322 HCAPLUS

DN 141:173872

TI A large-scale synthesis of 4-amino-2-butenoyl chlorides, useful as intermediates in preparation of [(dimethylaminocrotonyl)amido]quinoline derivatives

IN Considine, John Leo; Daigneault, Sylvain; Chew, Warren; Iera, Silvio; Duncan, Scott Mason; Ren, Jianxin

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004066919	A2	20040812	2004WO-US01133	20040116 <--
	WO2004066919	A3	20050127		
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI	
	US2004162442	A1	20040819	2004US-0758187	20040115 <--
	AU2004207475	A1	20040812	2004AU-0207475	20040116 <--
	CA---2514550	AA	20040812	2004CA-2514550	20040116 <--
	EP---1585479	A2	20051019	2004EP-0702974	20040116 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
	CN---1761644	A	20060419	CN 2004-80007723	20040116 <--
	NO2005003890	A	20051020	2005NO-0003890	20050819 <--
PRAI	2003US-441470P	P	20030121	<--	
	2004WO-US01133	W	20040116		
OS	CASREACT 141:173872; MARPAT 141:173872				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention provides a compds. of formula I [wherein: S1 and S2 are independently selected from H, alk(en/yn)yl, arylalkyl, (un)substituted aryl, or S1 and S2 together with the nitrogen to which they are attached form a N-containing heteroaryl] as intermediates in preparation of derivs. of [(dimethylaminocrotonyl)amido]quinoline, useful as protein kinase inhibitors. For instance, [(dimethylaminocrotonyl)amido]quinoline derivative II was prepared via amination of the obtained aminocrotonic acid chloride I•HCl (S1 = S2 = H) by aminoquinoline derivative III and subsequent recrystn. (example 1, no yield data).

IT 736156-77-7P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

## (Preparation)

(large-scale synthesis of (dimethylamino)butenoyl chloride, useful as intermediate in preparation of [(dimethylaminocrotonyl)amido]quinoline derivs.)

RN 736156-77-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-2-methoxy-4-pyridinyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



L39 ANSWER 11 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:546501 HCAPLUS

DN 141:106486

TI Preparation of 4-(pyridin-4-ylamino)quinazolines as antitumor agents

IN Barlaam, Bernard

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO2004056812	A1	20040708	2003WO-GB05534	20031218 <--	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU2003292435	A1	20040714	2003AU-0292435	20031218 <--	
PRAI	2002EP-0293220	A	20021223	<--		
	2003WO-GB05534	W	20031218	<--		
OS	MARPAT 141:106486					
GI						

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Quinazolines I [Z = O, S, SO, SO<sub>2</sub>, (un)substituted NH<sub>2</sub>, CH<sub>2</sub>; m = 1, 2 3; R<sub>1</sub> = halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, (un)substituted OH, SH, NH<sub>2</sub>, CHO, CO<sub>2</sub>H, CONH<sub>2</sub>, alkyl, alkenyl, alkynyl, SO<sub>2</sub>NH<sub>2</sub>; R<sub>2</sub> = H, halogen; R<sub>3</sub>, R<sub>5</sub> = H, halogen, alkyl, alkoxy; R<sub>4</sub> = alkoxy] were prepared for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease (no data). Thus, 5-chloro-2-methoxypyridine was converted to its N-oxide, nitrated to 5-chloro-2-methoxy-4-nitropyridine and reduced to the amine which was treated with the 4-chloroquinazoline fragment to give the quinazoline II.


The chloroquinazoline fragment was prepared by treating 5,7-difluoro-3,4-dihydroquinazolin-4-one with 4-tetrahydropyranol followed by 1-(2-hydroxyethyl)piperazine and acetylation.

IT 719304-91-3P 719304-95-7P 719304-97-9P  
 719305-01-8P 719305-03-0P 719305-04-1P  
 719305-08-5P 719305-09-6P 719305-10-9P  
 719305-11-0P 719305-12-1P 719305-13-2P  
 719305-14-3P 719305-15-4P 719305-16-5P  
 719305-17-6P 719305-18-7P 719305-19-8P  
 719305-20-1P 719305-21-2P 719305-22-3P  
 719305-23-4P 719305-24-5P 719305-25-6P  
 719305-26-7P 719305-27-8P 719305-28-9P  
 719305-29-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 4-(pyridin-4-ylamino)quinazolines as antitumor agents)


RN 719304-91-3 HCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(5-chloro-2-methoxy-4-pyridinyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 719304-95-7 HCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(5-chloro-2-methoxy-4-pyridinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 719304-97-9 HCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 719305-01-8 HCAPLUS  
 CN Piperazine, 1-acetyl-4-[2-[[4-[(2-methoxy-4-pyridinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 719305-03-0 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 719305-04-1 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 719305-08-5 HCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 719305-09-6 HCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 719305-10-9 HCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)







RN 719305-11-0 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 719305-12-1 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 719305-13-2 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 719305-14-3 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[3-(1-piperidinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 719305-15-4 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 719305-16-5 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[3-(4-methyl-1-piperazinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 719305-17-6 HCAPLUS

CN Piperazine, 1-acetyl-4-[[3-[[4-[(5-chloro-2-methoxy-4-pyridinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 719305-18-7 HCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-5-(1-methylethoxy)-7-[[3-[[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 719305-19-8 HCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[2-(1-pyrrolidinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 719305-20-1 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[2-(1-piperidinylethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]]-9CI (CA INDEX NAME)



RN 719305-21-2 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[2-(4-morpholinylethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]]-9CI (CA INDEX NAME)




RN 719305-22-3 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[2-(4-methyl-1-piperazinylethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]]-9CI (CA INDEX NAME)




RN 719305-23-4 HCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)




RN 719305-24-5 HCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[3-(1-pyrrolidinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)




RN 719305-25-6 HCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[3-(1-piperidinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)




RN 719305-26-7 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)




RN 719305-27-8 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[3-(4-methyl-1-piperazinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)



RN 719305-28-9 HCAPLUS  
 CN Piperazine, 1-acetyl-4-[3-[[4-[(5-chloro-2-methoxy-4-pyridinyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]propyl]-(9CI) (CA INDEX NAME)



RN 719305-29-0 HCAPLUS  
 CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyridinyl)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-(9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 12 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:252350 HCAPLUS  
 DN 140:264537  
 TI Pyrimidine and triazine compounds as inhibitors of TGFβ, preparation thereof, and therapeutic use  
 IN Axon, Jonathan; Chakravarty, Sarvajit; Dugar, Sundeep; McEnroe, Glen; Murphy, Alison  
 PA Scios Inc., USA  
 SO PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004024159	A1	20040325	2003WO-US28590	20030910 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA---2498460	AA	20040325	2003CA-2498460	20030910 <--
AU2003272324	A1	20040430	2003AU-0272324	20030910 <--
US2004132730	A1	20040708	2003US-0660115	20030910 <--

EP---1549316 A1 20050706 2003EP-0754501 20030910 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR2003014196 A 20050726 2003BR-0014196 20030910 <--  
 CN---1694708 A 20051109 2003CN-0824984 20030910 <--  
 JP2006503043 T2 20060126 2004JP-0536518 20030910 <--  
 PRAI 2002US-409870P P 20020910 <--  
 2003WO-US28590 W 20030910 <--  
 OS MARPAT 140:264537  
 AB Substituted pyrimidines and triazines are useful in the treatment to  
 conditions associated with enhanced TGFβ activity. Compound preparation is  
 included.  
 IT 674794-22-0 674794-23-1 674794-25-3  
 674794-29-7 674794-61-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (pyrimidine and triazine compds. as inhibitors of TGFβ, preparation,  
 and therapeutic use)  
 RN 674794-22-0 HCAPLUS  
 CN 4-Pyrimidinamine, 2-(5-chloro-2-fluorophenyl)-5-[2-(diethylamino)ethoxy]-N-  
 (3-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 674794-23-1 HCAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[[2-(5-chloro-2-fluorophenyl)-4-[(3-  
 methyl-4-pyridinyl)amino]-5-pyrimidinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 674794-25-3 HCAPLUS  
 CN 4-Pyrimidinamine, 2-(5-chloro-2-fluorophenyl)-N-(3-methyl-4-pyridinyl)-5-  
 [2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)






RN 674794-29-7 HCAPLUS

CN 4-Pyrimidinamine, 5-(2-aminoethoxy)-2-(5-chloro-2-fluorophenyl)-N-(3-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 674794-61-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(5-chloro-2-fluorophenyl)-5-methoxy-N-[3-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L39 ANSWER 13 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:20494 HCAPLUS

DN 140:77140

TI Preparation of thiazolyl aryl ureas as activators of glucokinase

IN Poliseti, Dharma Rao; Kodra, Janos Tibor; Lau, Jesper; Bloch, Paw; Valcarce-Lopez, Maria Carmen; Blume, Niels; Guzel, Mustafa; Santhosh, Kalpathy Chidambareswaran; Mjalli, Adnan M. M.; Andrews, Robert Carl; Subramanian, Govindan; Ankersen, Michael; Vedso, Per; Murray, Anthony; Jeppesen, Lone

PA Novo Nordisk A/S, Den.; Valcarce-Lopez, mariacarmen; et al.

SO PCT Int. Appl., 600 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004002481	A1	20040108	2003WO-DK00449	20030627 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



CA--2488642 AA 20040108 2003CA-2488642 20030627 <--  
AU2003243921 A1 20040119 2003AU-0243921 20030627 <--  
BR2003012023 A 20050322 2003BR-0012023 20030627 <--  
EP--1531815 A1 20050525 2003EP-0761446 20030627 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN---1678311 A 20051005 2003CN-0820170 20030627 <--  
JP2005537333 T2 20051208 2004JP-0548878 20030627 <--  
US2004122235 A1 20040624 2003US-0679887 20031006 <--  
NO2005000426 A 20050329 2005NO-0000426 20050126 <--

PRAI 2002DK-0000999 A 20020627 <--  
2002US-394144P P 20020703 <--  
2003DK-0000286 A 20030225 <--  
2003US-452228P P 20030305 <--  
2003WO-DK00449 W 20030627 <--

OS MARPAT 140:77140  
GI



AB The title compds. [I; A1 = arylene, heteroarylene, fused cycloalkylarylene, etc.; L1 = a bond, O, S, SO, etc.; G1 = alkyl, cycloalkyl, cycloalkylalkylene, etc.; L2 = a bond, alkylene, alkenylene, etc.; L3 = CO, COCO, COCH2CO, SO2; R1 = alkyl, alkenyl, alkynyl, etc.; G2 = heteroaryl, fused heterocyclylheteroaryl, cycloalkylheteroaryl, etc.] which are activators of glucokinase and may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial (no data), were prepared and formulated. Thus, reacting 2-phenoxyaniline with 2-aminothiazole and 1,1'-carbonyldiimidazole afforded 95% the urea II.


IT 640765-59-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolyl aryl ureas as glucokinase activators)

RN 640765-59-9 HCAPLUS

CN Urea, N-[5-(di-2-pyridinylamino)-2-(2-fluoro-6-methoxyphenoxy)phenyl]-N'-2-thiazolyl- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 14 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:855655 HCAPLUS

DN 139:350636

TI Preparation of amino heteroaryl amides for use in pharmaceutical compositions for the treatment of angiogenesis mediated diseases such as cancer

IN Patel, Vinod F.; Askew, Benny; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Germain, Julie; Habgood, Gregory J.; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Riahi, Babak; Yuan, Chester Chenguang; Elbaum, Daniel

PA Amgen Inc., USA

SO U.S. Pat. Appl. Publ., 148 pp., Cont.-in-part of U.S. Ser. No. 46,622.  
CODEN: USXXCO

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2003203922	A1	20031030	2002US-0197918	20020717 <--
	US2003195230	A1	20031016	2002US-0046622	20020110 <--
	CN---1538836	A	20041020	2002CN-0806467	20020111 <--
	ZA2003005198	A	20040630	2003ZA-0005198	20030704 <--
	CA---2492045	AA	20040122	2003CA-2492045	20030715 <--
	WO2004007481	A2	20040122	2003WO-US22275	20030715 <--
	WO2004007481	A3	20040219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2003263784	A1	20040202	2003AU-0263784	20030715 <--
	EP---1562933	A2	20050817	2003EP-0764755	20030715 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2006502118	T2	20060119	2004JP-0521922	20030715 <--
PRAI	2001US-261882P	P	20010112	<--	
	2001US-323808P	P	20010919	<--	
	2002US-0046622	A2	20020110	<--	
	2002US-0197918	A	20020717	<--	

OS 2003WO-US22275  
GI MARPAT 139:350636

W 20030715 <--



AB Amino substituted heteroaryl amides, such as I [R = nitrogen containing heteroaryl, such as quinolinyl, isoquinolinyl, indazolyl; R1 = aryl, cycloalkyl, heteroaryl, heterocyclyl], were prepared for therapeutic use. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of cancer, angiogenesis related disorders, KDR-related disorders, cell proliferation related disorders, inflammation, reducing blood flow in tumors, reducing tumor size and diabetic retinopathy. Thus, amide II was prepared via an amination reaction of 2-chloronicotinic acid with 6-aminoquinoline followed by an amidation reaction of the aminonicotinic acid derivative thus formed with 4-chloroaniline. Biol. evaluations included HUVEC proliferation assay, inhibition of angiogenesis in the rat corneal neovascularization micropocket model, and antitumor activity using A431 rat tumor cells.


IT 454481-07-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyridinecarboxamides for therapeutic use in treatment of angiogenesis mediated diseases such as cancer)

RN 454481-07-3 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-[2-(dimethylamino)ethoxy]-1H-indazol-6-yl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




L39 ANSWER 15 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:544805 HCAPLUS

DN 139:373643

TI Coordination compounds from 1,3,5-triazine-derived multi-directional ligands: application in oxidation catalysis

AU Gamez, Patrick; de Hoog, Paul; Lutz, Martin; Spek, Anthony L.; Reedijk, Jan  
 CS Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, Leiden, 2300 RA, Neth.  
 SO Inorganica Chimica Acta (2003), 351, 319-325  
 CODEN: ICHAA3; ISSN: 0020-1693  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 OS CASREACT 139:373643  
 AB 1,3,5-Triazine- and 2,2'-dipyridylamine-based ligands were prepared and the crystal structure from one of them, N,N',N'',N'''-tetrakis(2,4-bis(di-2-pyridylamino)-1,3,5-triazin-6-yl)-1,4,8,11-tetraazacyclotetradecane (2e), was solved. The coordination of these dendritic multi-directional ligands with various metal salts led to attractive supramol. architectures. In particular, an unprecedented 1-dimensional ladder coordination polymer resulted from the reaction of copper(II) nitrate and tris(di-2-pyridylamino)-1,3,5-triazine (2b). Reaction of nickel(II) perchlorate with 2b gave a new dinuclear nickel complex, [Ni<sub>2</sub>(2b)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>(MeOH)<sub>2</sub>](ClO<sub>4</sub>)<sub>4</sub>(MeOH)<sub>6</sub>, for which the crystal structure is discussed. Finally, several polynucleating ligands were used with copper(II) nitrate to catalyze the oxidation of 3,5-di-tert-butylcatechol. The best catalytic system was obtained when the 1st-generation dendrimer 2e was employed as a ligand for Cu(II), showing that the stability of the catalyst could be improved by incorporating 2,2'-dipyridylamine into a dendritic material.  
 IT 498568-60-8  
 RL: CAT (Catalyst use); USES (Uses)  
 (catecholase activity of triazine- and dipyridylamine-based ligands and copper for oxidation of di-tert-butylcatechol)  
 RN 498568-60-8 HCAPLUS  
 CN 1,3,5-Triazine-2,4,6-triamine, N,N',N'',N'''-1,2-ethanediylbis[N',N',N'',N'''-tetra-2-pyridinyl- (9CI) (CA INDEX NAME)




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 16 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:535048 HCAPLUS  
 DN 139:304399  
 TI Pyrimidinone antibiotics - heterocyclic analogues with improved antibacterial spectrum  
 AU Brands, Michael; Cancho Grande, Yolanda; Endermann, Rainer; Gahlmann, Reinhold; Kruger, Jochen; Raddatz, Siegfried  
 CS Business Group Pharma, Research, BAYER AG, Wuppertal, D-42096, Germany  
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(16), 2641-2645  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science B.V.  
 DT Journal


LA English  
 AB We report the synthesis and pharmacol. evaluation of new derivs. of the natural dipeptide antibiotic TAN 1057 A,B containing heterocycles either in the  $\beta$ -amino acid side chain or as mimics of the urea function. In the course of this program, we identified novel analogs that display activity towards a broader panel of Gram-pos. bacteria.  
 IT 437754-68-2 610796-46-8 610796-74-2  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (heterocyclic pyrimidinone antibiotic analogs with improved antibacterial spectrum)  
 RN 437754-68-2 HCAPLUS  
 CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)-, diacetate (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 437754-67-1  
 CMF C17 H27 N7 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2  
 CRN 64-19-7  
 CMF C2 H4 O2



RN 610796-46-8 HCAPLUS  
 CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)-, triacetate (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 437754-67-1  
 CMF C17 H27 N7 O2


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 64-19-7  
CMF C2 H4 O2




RN 610796-74-2 HCAPLUS  
CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-2-(methyl-2-pyridinylamino)-4-oxo-5-pyrimidinyl]-, (3S)-, diacetate (9CI) (CA INDEX NAME)

CM 1


CRN 610796-73-1  
CMF C18 H29 N7 O2

Absolute stereochemistry.



CM 2

CRN 64-19-7  
CMF C2 H4 O2



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 17 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:491188 HCAPLUS  
DN 139:69057  
TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders  
IN Ebdrup, Soren; Hansen, Holger Claus; Vedso, Per; Cornelis De Jong, Johannes; Jacobsen, Poul  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 390 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003051842	A2	20030626	2002WO-DK00853	20021213 <--
	WO2003051842	A3	20040603		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,


CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU2002351732 A1 20030630 2002AU-0351732 20021213 <--  
 US2003166690 A1 20030904 2002US-0319212 20021213 <--  
 US---7067517 B2 20060627  
 US2003166644 A1 20030904 2002US-0319885 20021213 <--  
 EP---1458375 A2 20040922 2002EP-0787449 20021213 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

CN---1602191 A 20050330 2002CN-0828075 20021213 <--  
 JP2005518377 T2 20050623 2003JP-0552729 20021213 <--  
 ZA2004004324 A 20050721 2004ZA-0004324 20040602 <--

PRAI 2001DK-0001879 A 20011214 <--  
 2002DK-0000645 A 20020430 <--  
 2002DK-0001000 A 20020627 <--  
 2002DK-0001562 A 20021011 <--  
 2002US-346909P P 20020103 <--  
 2002US-384253P P 20020510 <--  
 2002US-393068P P 20020628 <--  
 2002US-418481P P 20021015 <--  
 2002WO-DK00853 W 20021213 <--

OS MARPAT 139:69057  
 GI




AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10  $\mu$ M. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).

IT 548763-95-7P, N-Methyl-N-phenylcarbamic acid 4-(5-trifluoromethylpyridin-2-ylamino)phenyl ester  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548763-95-7 HCAPLUS  
 CN Carbamic acid, methylphenyl-, 4-[[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl ester (9CI). (CA INDEX NAME)





L39 ANSWER 18 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:491187 HCAPLUS

DN 139:69056

TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders

IN Ebdrup, Soren; Cornelis De Jong, Johannes; Jacobsen, Poul; Hansen, Holger Claus; Vedso, Per

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 519 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003051841	A2	20030626	2002WO-DK00852	20021213 <--
	WO2003051841	A3	20040624		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA---2468413	AA	20030626	2002CA-2468413	20021213 <--
	AU2002351731	A1	20030630	2002AU-0351731	20021213 <--
	US2003166690	A1	20030904	2002US-0319212	20021213 <--
	US---7067517	B2	20060627		
	US2003166644	A1	20030904	2002US-0319885	20021213 <--
	EP---1458374	A2	20040922	2002EP-0787448	20021213 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	CN---1602191	A	20050330	2002CN-0828075	20021213 <--
	BR2002014967	A	20050510	2002BR-0014967	20021213 <--
	JP2005518376	T2	20050623	2003JP-0552728	20021213 <--
	ZA2004004324	A	20050721	2004ZA-0004324	20040602 <--
	NO2004002962	A	20040908	2004NO-0002962	20040713 <--
PRAI	2001DK-0001879	A	20011214	<--	
	2002DK-0000645	A	20020430	<--	
	2002DK-0001000	A	20020627	<--	
	2002DK-0001562	A	20021011	<--	
	2002US-346909P	P	20020103	<--	
	2002US-384253P	P	20020510	<--	
	2002US-393068P	P	20020628	<--	
	2002US-418481P	P	20021015	<--	
	2002WO-DK00852	W	20021213	<--	
OS	MARPAT 139:69056				
GI					



AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10  $\mu$ M. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).


IT 548763-95-7P 549511-30-0P, Piperidine-1-carboxylic acid 4-[(5-trifluoromethylpyridin-2-yl)amino]phenyl ester 549512-68-7P, Morpholine-4-carboxylic acid 4-[(5-trifluoromethylpyridin-2-yl)amino]phenyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)


RN 548763-95-7 HCAPLUS

CN Carbamic acid, methylphenyl-, 4-[[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl ester (9CI) (CA INDEX NAME)




RN 549511-30-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 549512-68-7 HCAPLUS

CN 4-Morpholinecarboxylic acid, 4-[[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl ester (9CI) (CA INDEX NAME)



L39 ANSWER 19 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:56007 HCAPLUS

DN 138:90075

TI Synthesis of  $\beta$ -alanine derivatives for use as anti-bacterial medicaments in humans and animals

IN Kruger, Joachim; Brands, Michael; Endermann, Rainer; Gahlmann, Reinhold; Geschke, Frank-Ulrich; Kroll, Hein-Peter; Raddatz, Siegfried; Stoltefuss, Jurgen

PA Bayer AG, Germany

SO Ger. Offen., naples fl24 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE--10133277	A1	20030123	2001DE-1033277	20010709 <--
PRAI	2001DE-1033277		20010709	<--	
OS	MARPAT 138:90075				
GI					



AB Synthesis of title compds. (e.g., I), including enantiomers and diastereomers, using solid-phase peptide synthesis techniques, is given. Thus, 3-amino-1-propanol was protected as the diphenyl-tert-butylsilyloxy derivative, coupled with benzyl acrylate, and the resulting  $\beta$ -alanine derivative affixed to Rapp-chlorotriylpolystyrene resin. The resin-bound  $\beta$ -alanine was then O-deprotected and reprotected as the tosyloxy derivative, which was aminated using N-methyl-N-(3-pyridylmethyl)amine. This intermediate was then coupled with 5-(methylamino)-2-(2-pyridinylamino)-5,6-dihydro-4(1H)-pyrimidinone, and the product cleaved from the resin support to give the desired product as the bis-TFA salt. In a similar fashion, I was prepared. In in vitro tests against *S. aureus*, I had a min. blood concentration of 6.3  $\mu\text{g/mL}$ .

IT 436098-06-5P 436098-07-6P 436098-08-7P  
 436098-09-8P 436098-13-4P 436098-14-5P  
 436098-15-6P 436098-16-7P 436098-17-8P  
 436098-18-9P 436098-19-0P 436098-20-3P  
 436098-21-4P 436098-22-5P 436098-23-6P  
 436098-24-7P 436098-25-8P 436098-26-9P  
 436098-27-0P 436098-28-1P 436098-29-2P  
 436098-30-5P 436098-31-6P 436098-32-7P  
 436098-36-1P 436098-37-2P 436098-38-3P  
 436098-39-4P 436098-40-7P 436098-41-8P  
 436098-42-9P 436098-43-0P 436098-44-1P  
 436098-45-2P 436098-46-3P 436098-47-4P  
 436098-48-5P 436098-49-6P 436098-64-5P


## 485384-72-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\beta$ -alanine derivs. for use in treating bacterial infections in human or veterinary medicine)

RN 436098-06-5 HCAPLUS

CN Propanamide, N-methyl-3-[[3-[methyl(3-pyridinylmethyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-07-6 HCAPLUS

CN Propanamide, N-methyl-3-[[3-[methyl(3-pyridinylmethyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-06-5

CMF C23 H32 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-08-7 HCAPLUS

CN Propanamide, 3-[[3-[[2-(dimethylamino)ethyl]methylamino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-09-8 HCAPLUS

CN Propanamide, 3-[[3-[[2-(dimethylamino)ethyl]methylamino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-08-7

CMF C21 H36 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-13-4 HCAPLUS

CN Propanamide, 3-[[3-[[4-ethoxyphenyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-14-5 HCAPLUS

CN Propanamide, 3-[[3-[[4-ethoxyphenyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-13-4  
CMF C24 H33 N7 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-15-6 HCAPLUS  
CN Propanamide, N-methyl-3-[[3-[(3-pyridinylmethyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-16-7 HCAPLUS  
CN Propanamide, N-methyl-3-[[3-[(3-pyridinylmethyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-15-6  
CMF C22 H30 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-17-8 HCAPLUS  
CN Propanamide, N-methyl-3-[[3-[[2-(1-piperidinyl)ethyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-18-9 HCAPLUS  
CN Propanamide, N-methyl-3-[[3-[[2-(1-piperidinyl)ethyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-17-8  
CMF C23 H38 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-19-0 HCAPLUS  
CN Propanamide, N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-3-[[3-[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]amino]-

(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-20-3 HCAPLUS

CN Propanamide, N-methyl-N-[[3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-19-0

CMF C24 H30 F3 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 436098-21-4 HCAPLUS


CN Propanamide, N-methyl-3-[[3-[[3-(4-methyl-1-piperazinyl)propyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-22-5 HCAPLUS


CN Propanamide, N-methyl-3-[[3-[[3-(4-methyl-1-piperazinyl)propyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-21-4

CMF C24 H41 N9 O2

PAGE 1-A



PAGE 1-B




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-23-6 HCAPLUS

CN Propanamide, 3-[[3-[[4-(dimethylamino)phenyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-24-7 HCAPLUS

CN Propanamide, 3-[[3-[[4-(dimethylamino)phenyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-23-6

CMF C24 H34 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-25-8 HCAPLUS

CN Propanamide, N-methyl-3-[[3-(phenylamino)propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-26-9 HCAPLUS

CN Propanamide, N-methyl-3-[[3-(phenylamino)propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-25-8  
CMF C22 H29 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-27-0 HCAPLUS  
CN Propanamide, 3-[[3-[[2-(diethylamino)ethyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-28-1 HCAPLUS  
CN Propanamide, 3-[[3-[[2-(diethylamino)ethyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-27-0  
CMF C22 H38 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-29-2 HCAPLUS

CN Propanamide, 3-[[3-[(cyclohexylmethyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-30-5 HCAPLUS

CN Propanamide, 3-[[3-[(cyclohexylmethyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-29-2

CMF C23 H37 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-31-6 HCAPLUS

CN Propanamide, N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-3-[[3-[[4-(trifluoromethoxy)phenyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-32-7 HCAPLUS  
 CN Propanamide, N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-3-[[3-[[4-(trifluoromethoxy)phenyl]amino]propyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-31-6  
 CMF C23 H28 F3 N7 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 436098-36-1 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-[(3-phenoxyphenyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-37-2 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-[(3-phenoxyphenyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-36-1  
CMF C28 H33 N7 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-38-3 HCAPLUS  
CN Propanamide, 3-[[3-[(3,4-dichlorophenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-39-4 HCAPLUS  
CN Propanamide, 3-[[3-[(3,4-dichlorophenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 436098-38-3  
CMF C22 H27 Cl2 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 436098-40-7 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-[[3-[(methylphenylamino)sulfonyl]phenyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-41-8 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-[[3-[(methylphenylamino)sulfonyl]phenyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-40-7  
CMF C29 H36 N8 O4 S


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

RN 436098-42-9 HCAPLUS  
 CN Propanamide, 3-[[3-[(6-chloro-3-pyridinyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA

INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-43-0 HCAPLUS

CN Propanamide, 3-[[3-[(6-chloro-3-pyridinyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-42-9

CMF C21 H27 Cl N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-44-1 HCAPLUS

CN Propanamide, 3-[[3-[(5-chloro-2-pyridinyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 436098-45-2 HCAPLUS

CN Propanamide, 3-[[3-[(5-chloro-2-pyridinyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-,




bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-44-1

CMF C21 H27 Cl N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-46-3 HCAPLUS

CN Propanamide, 3-[[3-[(3-cyanophenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-47-4 HCAPLUS

CN Propanamide, 3-[[3-[(3-cyanophenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-46-3

CMF C23 H28 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-48-5 HCAPLUS

CN Propanamide, N-methyl-3-[[3-(2-naphthalenylamino)propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 436098-49-6 HCAPLUS

CN Propanamide, N-methyl-3-[[3-(2-naphthalenylamino)propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-48-5

CMF C26 H31 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-64-5 HCAPLUS


CN Propanamide, 3-[(3-aminopropyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 485384-72-3 HCAPLUS

CN Propanamide, 3-[(3-aminopropyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrobromide (9CI) (CA INDEX NAME)



●2 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 20 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:22341 HCAPLUS

DN 139:16521

TI Novel zigzag 1D coordination polymer from copper(II) chloride and N,N'-bis{2,4-di[(di-pyridin-2-yl)amine]-1,3,5-triazine}ethylenediamine exhibiting ferromagnetic interactions

AU de Hoog, Paul; Gamez, Patrick; Roubeau, Olivier; Lutz, Martin; Driessen, Willem L.; Spek, Anthony L.; Reedijk, Jan

CS Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Leiden, 2300 RA, Neth.

SO New Journal of Chemistry (2003), 27(1), 18-21

CODEN: NJCHE5; ISSN: 1144-0546

PB Royal Society of Chemistry

DT Journal

LA English

OS CASREACT 139:16521


AB Copper(II) chloride reacts with the polydentate 1,3,5-triazine-containing ligand N,N'-bis[4,6-bis{(dipyridin-2-yl)amino}-1,3,5-triazin-2-yl]ethylenediamine (opytrizediam) in MeOH-THF to form a unique infinite zigzag coordination polymer, [Cu3Cl5(opytrizediam)(MeOH)](Cl)·6.1Me OH·THF, as found by an x-ray crystallog. study, in which trinuclear Cu complexes are bridged by chloride anions, giving rise to five-coordinated ferromagnetically coupled Cu pseudo-dimers.

IT 498568-60-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(complexation with copper(II) chloride)

RN 498568-60-8 HCAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'''-1,2-ethanediylbis[N',N',N'',N'''-tetra-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 21 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:676007 HCAPLUS

DN 137:216945

TI Preparation of substituted 2-(1H-indazol-6-ylamino)nicotinamides for  
treating KDR-related diseases

IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Croghan, Michael; Dipietro,  
Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim,  
Joseph L.; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Tasker,  
Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang; Kim, Tae-Seong

PA Amgen Inc., USA

SO PCT Int. Appl., 395 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002068406	A2	20020906	2002WO-US03064	20020111 <--
	WO2002068406	A3	20030424		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US2003195230	A1	20031016	2002US-0046622	20020110 <--
	CA---2434178	AA	20020906	2002CA-2434178	20020111 <--
	EE-200300325	A	20031215	2003EE-0000325	20020111 <--
	JP2004527499	T2	20040909	2002JP-0567920	20020111 <--
	CN---1538836	A	20041020	2002CN-0806467	20020111 <--
	EP---1467721	A2	20041020	2002EP-0723086	20020111 <--
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	ZA2003005198	A	20040630	2003ZA-0005198	20030704 <--
	BG---108013	A	20040430	2003BG-0108013	20030721 <--
PRAI	2001US-261882P	P	20010112	<--	
	2001US-323808P	P	20010919	<--	
	2002US-0046622	A	20020110	<--	
	2002WO-US03064	W	20020111	<--	
OS	MARPAT 137:216945				
GI					



AB The title compds. [I; each of A1 and A2 = C, CH, N; A = 5-6 membered partially saturated heterocyclyl, 5-6 membered heteroaryl, 9-11 membered fused partially saturated heterocyclyl, etc.; X = C(:Z)N(R5a)R4; Z = O, S; R = (un)substituted 4-6 membered heterocyclyl, aryl, fused 9-14 membered bicyclic or tricyclic heterocyclyl; R1 = (un)substituted 6-10 membered aryl, 4-6 membered heterocyclyl, cycloalkyl, etc.; R2 = H, halo, cycloalkyl, etc.; R4 = a bond, alkylene, alkenylene, etc.; R5 = H, alkyl, (un)substituted Ph, aralkyl; R5a is not defined] which are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases, were prepared. Thus, heating N-(4-chlorophenyl)-2-chloro-3-pyridinecarboxamide with 6-aminoindazole at 150° for 2 h afforded II which inhibited VEGF-stimulated HUVEC proliferation at level below 50 nM. Compds. I showed inhibition of KDR at doses less than 50  $\mu$ M.


IT 454481-07-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases)

RN 454481-07-3 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-[2-(dimethylamino)ethoxy]-1H-indazol-6-ylamino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



L39 ANSWER 22 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:675054 HCAPLUS


DN 138:187745

TI New polydentate and polynucleating N-donor ligands from amines and 2,4,6-trichloro-1,3,5-triazine

AU de Hoog, Paul; Gamez, Patrick; Driessen, Willem L.; Reedijk, Jan

CS Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, Leiden, 2300 RA, Neth.

SO Tetrahedron Letters (2002), 43(38), 6783-6786  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 138:187745  
 AB An efficient synthesis of a novel class of multidentate polynucleating ligands has been developed based on high-yielding chloride substitutions of 2,4,6-trichloro-1,3,5-triazine by primary and secondary amines. The polydentate, polynucleating ligands include a first-generation dendrimer of a N,N'-(2-pyridinyl)-1,3,5-triazine-2,4,6-triamine derivative  
 IT 498568-60-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of N,N'-(2-pyridinyl)-1,3,5-triazine-2,4,6-triamine derivs. as polydentate and polynucleating N-donor ligands)  
 RN 498568-60-8 HCAPLUS  
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'''-1,2-ethanediylbis[N',N',N'',N'''-tetra-2-pyridinyl- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L39 ANSWER 23 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:615603 HCAPLUS  
 DN 137:169514  
 TI Preparation of pyrazoles as TGF- $\beta$  inhibitors  
 IN Gellibert, Francoise Jeanne  
 PA Glaxo Group Limited, UK  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2002062787	A1	20020815	2002WO-GB00424	20020131 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP---1363904	A1	20031126	2002EP-0710136	20020131 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

	JP2004521901	T2	20040722	2002JP-0563140	20020131 <--
	US2004097502	A1	20040520	2003US-0470862	20030731 <--
PRAI	2001GB-0002670	A	20010202	<--	
	2001GB-0019399	A	20010809	<--	
	2002WO-GB00424	W	20020131	<--	
OS	MARPAT 137:169514				
GI					



AB The title compds. [I; R1 = H, alkyl, CH<sub>2</sub>CONR<sub>4</sub>R<sub>5</sub> (wherein R<sub>4</sub> = H, alkyl; R<sub>5</sub> = alkyl); R2 = (un)substituted (CH<sub>2</sub>)<sub>n</sub>Ph, (CH<sub>2</sub>)<sub>n</sub>heterocyclyl, (CH<sub>2</sub>)<sub>n</sub>heteroaryl; R3 = H, halo, CN, etc.; n = 0-5; X, X1 = CH, N, provided that X and X1 are not both N], useful in therapy, particularly in the treatment of prophylaxis of disorders characterized by overexpression of transforming growth factor β (TGF-β), were prepared Thus reacting 4-{4-[3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]-(pyridin-2-yl)amino}phenol (preparation given) with 1-(2-chloroethyl)piperidine.HCl in the presence of Cs<sub>2</sub>CO<sub>3</sub> in Me<sub>2</sub>CO followed by trityl group removal afforded 49% I [R1, R3 = H; R2 = 4-(2-piperidinoethoxy)phenyl]. All 28 exemplified compds. I showed IC<sub>50</sub> of 5 μM or below in TGF-β assay, and IC<sub>50</sub> of 1 μM or below against kinase Alk5.


IT 446880-58-6P 446880-59-7P 446880-63-3P  
446880-78-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazoles as TGF-β inhibitors)


RN 446880-58-6 HCAPLUS

CN 2-Pyridinamine, N-[3-[2-(1-piperidinyl)ethoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-59-7 HCAPLUS

CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 446880-63-3 HCAPLUS

CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 446880-78-0 HCAPLUS

CN 2-Pyridinamine, N-[4-[2-(1-piperidinyl)ethoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 24 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:615572 HCAPLUS

DN 137:169409

TI Preparation of aminated diones as potassium channel openers

IN Kort, Michael E.; Carroll, William A.; Perez, Medrano Arturo; Dinges, Jurgen; Gregg, Robert J.; Basha, Fatima Z.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 180 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002062761	A1	20020815	2002WO-US02949	20020131 <--
	W: CA, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				




$$\begin{array}{c}
 \text{R}^2 \quad \text{R}^3 \quad \text{R}^4 \\
 | \quad | \quad | \\
 \text{R}^1 - \text{N} - \text{A} - \text{N} - \text{C} - \text{N} - \text{C} - \text{R}^5 \\
 \quad \quad \quad | \quad | \quad | \\
 \quad \quad \quad \text{R}^6 \quad \text{R}^7 \quad \text{O}
 \end{array}$$


IT 446861-47-8P, 4-Chloro-N-[1-[[3,4-dioxo-2-(4-pyridinylamino)cyclobuten-1-yl]amino]-2,2-dimethylpropyl]benzamide  
446861-50-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL. (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of aminated diones as potassium channel openers)


RN 446861-47-8 HCAPLUS

CN Benzamide, 4-chloro-N-[1-[[3,4-dioxo-2-(4-pyridinylamino)-1-cyclobuten-1-yl]amino]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)



RN 446861-50-3 HCAPLUS

CN Benzamide, 4-chloro-N-[1-[[3,4-dioxo-2-(2-pyridinylamino)-1-cyclobuten-1-yl]amino]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 25 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:575044 HCAPLUS

DN 137:124993

TI Trisubstituted carbocyclic cyclophilin binding compounds and their use

IN Wu, Yong-Qian; Belyakov, Sergei; Hamilton, Gregory; Limburg, David;

Steiner, Joseph; Vaal, Mark; Wei, Ling; Wilkinson, Douglas

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 120 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2002059080	A2	20020801	2002WO-US02538	20020125 <--
WO2002059080	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2435829	AA	20020801	2002CA-2435829	20020125 <--
US2002165275	A1	20021107	2002US-0057203	20020125 <--
US---6656971	B2	20031202		
EP---1360173	A2	20031112	2002EP-0706049	20020125 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP2004532187 T2 20041021 2002JP-0559382 20020125 <--  
 US2004157919 A1 20040812 2003US-0713566 20031114 <--  
 PRAI 2001US-263703P P 20010125 <--  
 2001US-291965P P 20010521 <--  
 2001US-291365P P 20010517 <--  
 2002US-0057203 A3 20020125 <--  
 2002WO-US02538 W 20020125 <--  
 OS MARPAT 137:124993  
 AB Novel, non-peptidic small organic compds. having an affinity for cyclophilin (CyP)-type immunophilin proteins are reported. These compds. are used for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity. Thus, 5-HOC6H3(CO2Me)2-1,3 was O-benzylated, hydrolyzed to the acid and treated with 3,4-Cl2C6H3NH2 to give 5-PhCH2OC6H3(CONHC6H3Cl2-3,4)2-1,3. This compound gave complete protection against cell death in L-threo-3-hydroxyaspartic acid treated spinal cord slices.  
 IT 444342-90-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (trisubstituted carbocyclic cyclophilin binding compds.)  
 RN 444342-90-9 HCAPLUS  
 CN Thiourea, N,N''-[5-(2-pyridinylamino)-1,3-phenylene]bis[N'-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)]



L39 ANSWER 26 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:462351 HCAPLUS  
 DN 137:33314  
 TI Preparation of arylaminodihydropyrimidinones as antibacterials.  
 IN Raddatz, Siegfried; Brands, Michael; Endermann, Rainer; Gahlmann, Reinhold; Geschke, Frank-Ulrich; Kroll, Hein-Peter; Krueger, Joachim; Stoltefuss, Juergen  
 PA Bayer AG, Germany  
 SO Ger. Offen., 32 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE--10061541	A1	20020620	2000DE-1061541	20001211 <--
PRAI 2000DE-1061541		20001211		
OS MARPAT 137:33314				
GI				



AB Title compds. [I; A = R4R5N, R6R7NC(:Q)NR5, R6C(:NR9)NR5; R4-R7, R9 = H, alkyl, alkanoyl, PhCH2, pyridylmethyl; R8 = H, alkyl; Q = O, S, NR9; D = (substituted) alkylene; E = bond, CH2; R2 = H, alkyl; R3 = (substituted) aryl, (unsatd.) heterocyclyl], were prepared Thus, title compound (II) (general preparation given) showed a min. inhibitory concentration of 0.06 against *S. aureus* 133.

IT 437754-58-0P 437754-66-0P 437754-67-1P  
 437754-68-2P 437754-69-3P 437754-70-6P  
 437754-71-7P 437754-72-8P 437754-73-9P  
 437754-74-0P 437754-75-1P 437754-76-2P  
 437754-90-0P 437754-91-1P 437754-96-6P  
 437755-00-5P 437755-02-7P 437755-04-9P  
 437755-14-1P 437755-15-2P 437755-17-4P  
 437755-18-5P 437755-19-6P 437755-20-9P  
 437755-21-0P 437755-22-1P 437755-42-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylaminodihydropyrimidinones as antibacterials)

RN 437754-58-0 HCAPLUS

CN Hexanamide, 3-amino-6-[(1-iminoethyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-66-0 HCAPLUS


CN Hexanamide, 3,6-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)-, diacetate (9CI) (CA INDEX NAME)

CM 1

CRN 437754-65-9

CMF C16 H25 N7 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 437754-67-1 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-68-2 HCAPLUS


CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)-, diacetate (9CI) (CA INDEX NAME)

CM 1

CRN 437754-67-1

CMF C17 H27 N7 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 437754-69-3 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-70-6 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-71-7 HCAPLUS

CN Octanamide, 3,8-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-72-8 HCAPLUS


CN Octanamide, 3,8-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, diacetate (9CI) (CA INDEX NAME)

CRN 437754-71-7  
CMF C18 H29 N7 O2




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN	437754-73-9	HCAPLUS
CN	Octanamide, 3,8-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)	




●<sub>2</sub> HCl

RN 437754-74-0 HCAPLUS

CN Hexanamide, 3-amino-6-[(aminoiminomethyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 437754-75-1 HCAPLUS

CN Hexanamide, 3-amino-6-[(aminoiminomethyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, (3S)-, triacetate (9CI) (CA INDEX NAME)

CM 1


CRN 437754-74-0  
CMF C17 H27 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 64-19-7  
CMF C2 H4 O2RN 437754-76-2 HCAPLUS  
CN Hexanamide, 3-amino-6-[(aminoiminomethyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, trihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-90-0 HCAPLUS  
CN Hexanamide, 3-amino-6-[(aminoiminomethyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-[[5-(trifluoromethyl)-2-pyridinyl]amino]-5-pyrimidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-91-1 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-[[5-(trifluoromethyl)-2-pyridinyl]amino]-5-pyrimidinyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437754-96-6 HCAPLUS


CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-2-[(6-methyl-2-pyridinyl)amino]-4-oxo-5-pyrimidinyl]-, (3S)-, diacetate (9CI) (CA INDEX NAME)

CM 1

CRN 437754-95-5

CMF C18 H29 N7 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 437755-00-5 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-2-[(6-methyl-5-phenyl-2-pyridinyl)amino]-4-oxo-5-pyrimidinyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-02-7 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-[(6-phenyl-2-pyridinyl)amino]-5-pyrimidinyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-04-9 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-[(4-phenyl-2-pyridinyl)amino]-5-pyrimidinyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-14-1 HCAPLUS

CN Heptanamide, 3-amino-7-[[imino(methylamino)methyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, trihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-15-2 HCAPLUS

CN Hexanamide, 3-amino-6-[[imino(methylamino)methyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, trihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-17-4 HCAPLUS

CN Hexanamide, 3-amino-6-[[imino(methylamino)methyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, trihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-18-5 HCAPLUS

CN Heptanamide, 3,6-diamino-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-19-6 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-5-oxo-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-20-9 HCAPLUS

CN Heptanamide, 3,7-diamino-N-methyl-5-oxo-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-21-0 HCAPLUS

CN Heptanamide, 3,7-diamino-5-hydroxy-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-22-1 HCAPLUS

CN Heptanamide, 3,7-diamino-5-hydroxy-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, dihydrochloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-42-5 HCAPLUS

CN Hexanamide, 3-amino-6-[(aminocarbonyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, monohydrobromide, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 437755-29-8P 437755-30-1P 437755-31-2P

437755-39-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylaminodihydropyrimidinones as antibacterials)

RN 437755-29-8 HCAPLUS

CN Carbamic acid, [(1S)-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[2-[methyl[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]-2-oxoethyl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-30-1 HCAPLUS

CN Carbamic acid, [(1S)-4-amino-1-[2-[methyl[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]-2-oxoethyl]butyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-31-2 HCAPLUS

CN Carbamic acid, [(1S)-4-[(1-iminoethyl)amino]-1-[2-[methyl[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]-2-oxoethyl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 437755-39-0 HCAPLUS

CN Carbamic acid, [(1S)-1-[2-[methyl[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]-2-oxoethyl]-3-oxo-1,5-pentanedyl]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 27 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:462349 HCAPLUS

DN 137:33536

TI Synthesis of tetrahydropyridinone  $\beta$ -alanine compounds for use as antibacterial agents in human and veterinary medicine

IN Kruger, Joachim; Brands, Michael; Endermann, Rainer; Gahlmann, Reinhold; Geschke, Fank-Ulrich; Kroll, Hein-Peter; Raddatz, Siegfried; Stoltefuss, Jurgen

PA Bayer AG, Germany

SO Ger. Offen., 20 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE--10061537	A1	20020620	2000DE-1061537	20001211 <--
PRAI	2000DE-1061537		20001211	<--	
OS	MARPAT 137:33536				
GI					



AB Title compds., e.g. (I), were prepared and tested as antibacterial agents for use in treatment of humans and animals. Thus, 3-aminopropanol was O-protected and reacted with benzyl acrylate, and then attached to a polystyrol resin for further reaction. Deprotection and tosylation of the O-group, followed by reaction with an amine, (e.g., H<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>NHC(O)OCH<sub>2</sub>Ph), was followed by amidation with a second amine, (e.g., (5RS)-3,4,5,6-tetrahydro-5-methylamino-2-ureidopyrimidin-4-one) gave I (60%) as the dihydrochloride salt. In in vitro Minimal Inhibition Concentration tests using Staphylococcus aureus, I had MIH 6.3  $\mu$ g/mL.

IT 436098-07-6P 436098-18-9P 436098-22-5P

436098-24-7P 436098-43-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\beta$ -alanine derivs. for use in treating bacterial infections in human and veterinary medicine)

RN 436098-07-6 HCAPLUS


CN Propanamide, N-methyl-3-[[3-[methyl(3-pyridinylmethyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-,

bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-06-5

CMF C23 H32 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 436098-18-9 HCAPLUS

CN Propanamide, N-methyl-3-[[3-[[2-(1-piperidinyl)ethyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-17-8

CMF C23 H38 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 436098-22-5 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-[[3-(4-methyl-1-piperazinyl)propyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 436098-21-4  
 CMF C24 H41 N9 O2

PAGE 1-A




PAGE 1-B



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 436098-24-7 HCAPLUS  
 CN Propanamide, 3-[[3-[[4-(dimethylamino)phenyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-23-6  
 CMF C24 H34 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-43-0 HCAPLUS  
CN Propanamide, 3-[[3-[(6-chloro-3-pyridinyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-42-9  
CMF C21 H27 Cl N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



IT 436098-09-8P 436098-14-5P 436098-16-7P  
436098-20-3P 436098-26-9P 436098-28-1P  
436098-30-5P 436098-32-7P 436098-37-2P  
436098-39-4P 436098-41-8P 436098-45-2P  
436098-47-4P 436098-49-6P 436098-64-5P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of  $\beta$ -alanine derivs. for use in treating bacterial infections in human and veterinary medicine)  
RN 436098-09-8 HCAPLUS  
CN Propanamide, 3-[[3-[[2-(dimethylamino)ethyl]methylamino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-08-7  
CMF C21 H36 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-14-5 HCAPLUS  
CN Propanamide, 3-[[3-[(4-ethoxyphenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-13-4  
CMF C24 H33 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 436098-16-7 HCAPLUS  
CN Propanamide, N-methyl-3-[[3-[(3-pyridinylmethyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-15-6

CMF C22 H30 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 436098-20-3 HCAPLUS

CN Propanamide, N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-3-[[3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-19-0

CMF C24 H30 F3 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 436098-26-9 HCAPLUS

CN Propanamide, N-methyl-3-[[3-(phenylamino)propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-25-8  
CMF C22 H29 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-28-1 HCAPLUS  
CN Propanamide, 3-[[3-[[2-(diethylamino)ethyl]amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-27-0  
CMF C22 H38 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-30-5 HCAPLUS  
CN Propanamide, 3-[[3-[(cyclohexylmethyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-29-2  
CMF C23 H37 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-32-7 HCAPLUS  
CN Propanamide, N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-3-[[3-[[4-(trifluoromethoxy)phenyl]amino]propyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-31-6  
CMF C23 H28 F3 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-37-2 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-[(3-phenoxyphenyl)amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-36-1  
 CMF C28 H33 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 436098-39-4 HCAPLUS  
 CN Propanamide, 3-[[3-[(3,4-dichlorophenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-38-3  
 CMF C22 H27 Cl2 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-41-8 HCAPLUS  
CN Propanamide, N-methyl-3-[[3-[[3-[(methylphenylamino)sulfonyl]phenyl]amino]propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-40-7  
CMF C29 H36 N8 O4 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 436098-45-2 HCAPLUS  
CN Propanamide, 3-[[3-[(5-chloro-2-pyridinyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-44-1  
CMF C21 H27 Cl N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 436098-47-4 HCAPLUS  
 CN Propanamide, 3-[[3-[(3-cyanophenyl)amino]propyl]amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 436098-46-3  
 CMF C23 H28 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 436098-49-6 HCAPLUS  
 CN Propanamide, N-methyl-3-[[3-(2-naphthalenylamino)propyl]amino]-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436098-48-5  
 CMF C26 H31 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 436098-64-5 HCAPLUS

CN Propanamide, 3-[(3-aminopropyl)amino]-N-methyl-N-[1,4,5,6-tetrahydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 28 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:407968 HCAPLUS

DN 138:49372

TI Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor

AU Dumas, Jacques; Hatoum-Mokdad, Holia; Sibley, Robert N.; Smith, Roger A.; Scott, William J.; Khire, Uday; Lee, Wendy; Wood, Jill; Wolanin, Donald; Cooley, Jeffrey; Bankston, Donald; Redman, Aniko M.; Schoenleber, Robert; Caringal, Yolanda; Gunn, David; Romero, Romulo; Osterhout, Martin; Paulsen, Holger; Housley, Timothy J.; Wilhelm, Scott M.; Pirro, John; Chien, Du-Shieng; Ranges, Gerald E.; Shrikhande, Alka; Muzsi, Andrew; Bortolon, Elizabeth; Wakefield, Jean; Gianpaolo Ostravage, Cynthia; Bhargava, Ajay; Chau, Thuy

CS Department of Chemistry Research, Bayer Research Center, West Haven, CT, 06516, USA

SO Bioorganic & Medicinal Chemistry Letters (2002), 12(12), 1559-1562

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

AB Inhibitors of the MAP kinase p38 provide a novel approach for the treatment of osteoporosis, inflammatory disorders, and cancer. We have identified N-(3-tert-butyl-1-methyl-5-pyrazolyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea as a potent and selective p38 kinase inhibitor in biochem. and cellular assays. This compound is orally active in two acute models of cytokine release (TNF-induced IL-6 and LPS-induced TNF)

and a chronic model of arthritis (20-day murine collagen-induced arthritis).


IT 229155-53-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationship, synthesis and pharmacol. characterization of a potent, orally active p38 kinase inhibitors)

RN 229155-53-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 29 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:174790 HCAPLUS

DN 137:352864

TI Synthesis of carbon-14 labeled 1-(4-pyridinylamino)-1H-indol-5-ol-methylcarbamate, (Z)-2-butenedioate ([14C]HMR 2420)

AU Gill, Harpal S.

CS Radiochemistry Section, Aventis Pharmaceuticals Chemical Development, Cincinnati, OH, 45215, USA


SO Synthesis and Applications of Isotopically Labelled Compounds, Proceedings of the International Symposium, 7th, Dresden, Germany, June 18-22, 2000 (2001), Meeting Date 2000, 280-282. Editor(s): Pleiss, Ulrich; Voges, Rolf. Publisher: John Wiley & Sons Ltd., Chichester, UK. CODEN: 69CIJC; ISBN: 0-471-49501-8

DT Conference

LA English

OS CASREACT 137:352864


GI



I

AB A diazonium chemical route was developed to accomplish the synthesis of 1-(4-pyridinylamino)-1H-[2-14C]indol-5-ol-methylcarbamate, (Z)-2-butenedioate (I, [14C]MDL 106276G-02, [14C]HMR 2420) which is under development for treatment of Alzheimer's disease. The synthetic sequence provided I in seven steps from [14C]methyl iodide in an overall radiochem. yield of 7.2%, specific activity of 52.4  $\mu$ Ci/mg (20.9 mCi/mmol, 1938.8


MBq/g), radiochem. purity of 99.9% and chemical purity of 99.7%.  
 IT 474380-68-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of <sup>14</sup>C-labeled (pyridinylamino)indole via diazotization of  
<sup>14</sup>C-labeled hydroxystyrene with pyridinediazonium salt followed by  
 carbamate formation and salt formation with maleic acid)  
 RN 474380-68-2 HCAPLUS  
 CN 1H-Indol-5-ol-2-<sup>14</sup>C, 1-(4-pyridinylamino)-, methylcarbamate (ester) (9CI)  
 (CA INDEX NAME)



IT 474380-69-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of <sup>14</sup>C-labeled (pyridinylamino)indole via diazotization of  
<sup>14</sup>C-labeled hydroxystyrene with pyridinediazonium salt followed by  
 carbamate formation and salt formation with maleic acid)  
 RN 474380-69-3 HCAPLUS  
 CN 1H-Indol-5-ol-2-<sup>14</sup>C, 1-(4-pyridinylamino)-, methylcarbamate (ester),  
 (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 474380-68-2  
 CMF C15 H14 N4 O2



CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 30 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:122980 HCAPLUS  
 DN 136:183708  
 TI Preparation of non-imidazole aryloxyalkylamines as histamine H3 receptor

antagonists

IN Apodaca, Richard; Carruthers, Nicholas I.; Dvorak, Curt A.; Rudolph, Dale A.; Shah, Chandravadan R.; Xiao, Wei

PA Ortho McNeil Pharmaceutical Inc., USA

SO PCT Int. Appl., 155 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002012214	A2	20020214	2001WO-US24655	20010806 <--
	WO2002012214	A3	20020620		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2418369	AA	20020214	2001CA-2418369	20010806 <--
	AU2001084733	A5	20020218	2001AU-0084733	20010806 <--
	US2002065278	A1	20020530	2001US-0922631	20010806 <--
	EP---1313721	A2	20030528	2001EP-0963813	20010806 <--
	EP---1313721	B1	20060308		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004505960	T2	20040226	2002JP-0518191	20010806 <--
	BR2001013162	A	20040406	2001BR-0013162	20010806 <--
	AT---319696	E	20060315	2001AT-0963813	20010806 <--
	ZA2003001853	A	20040621	2003ZA-0001853	20030306 <--
	ZA2003001854	A	20040621	2003ZA-0001854	20030306 <--
PRAI	2000US-223768P	P	20000808	<--	
	2001US-0922631	A	20010806	<--	
	2001WO-US24655	W	20010806	<--	
OS	MARPAT 136:183708				
GI					



I




II

AB Title compds. I [Ra-b = alk(en/yn)yl, cycloalkyl; n = 0-4; one of R1-3 = G and the remaining two are H or halo; G = N-containing heterocycle, e.g., piperidinyl, etc.] were prepared For instance, 4-(2-(piperidin-1-yl)ethoxy)benzaldehyde was used to alkylate 1,2,3,4-tetrahydroisoquinoline (ClCH<sub>2</sub>CH<sub>2</sub>Cl, HOAc, NaBH(OAc)<sub>3</sub>, 15 h) to give II. II had K<sub>i</sub> = 37 nM for the histamine H<sub>3</sub> receptor. I are useful for treating histamine-mediated conditions.

IT 398473-94-4P, (2-(Morpholin-4-yl)ethyl) [4-(3-(piperidin-1-yl)propoxy)phenyl] (pyridin-2-yl)amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug; preparation of non-imidazole aryloxyalkylamines as histamine-H<sub>3</sub> receptor antagonists)

RN 398473-94-4 HCAPLUS

CN 4-Morpholineethanamine, N-[4-[3-(1-piperidinyl)propoxy]phenyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



L39 ANSWER 31 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:122964 HCAPLUS

DN 136:167384

TI Preparation of 4-pyrimidinamines as neuroprotectants.

IN Grant, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael; Zhong, Zhong; Scott, Malcolm; Reitz, Allen B.; Ross, Tina Morgan

PA Ortho-McNeil Pharmaceutical, Inc., USA

SO PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002012198	A2	20020214	2001WO-US24659	20010806 <--
	WO2002012198	A3	20020606		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---	2419030	AA	20020214	2001CA-2419030	20010806 <--
AU2001081120		A5	20020218	2001AU-0081120	20010806 <--
EP---	1313713	A2	20030528	2001EP-0959581	20010806 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR2001013165		A	20030715	2001BR-0013165	20010806 <--
JP2004505952		T2	20040226	2002JP-0518176	20010806 <--
NZ----	524100	A	20050128	2001NZ-0524100	20010806 <--
ZA2003001868		A	20040625	2003ZA-0001868	20030306 <--
PRAI	2000US-223791P	P	20000808	<--	

2001WO-US24659  
OS MARPAT 136:167384  
GI

W 20010806 <--




AB Pharmaceutical compns. comprising a pharmaceutically acceptable carrier [I; R9 = H, thienyl, furanyl, pyrrolyl, (substituted) Ph, pyridinyl, pyridinyl, naphthyl, benzo[b]thien-2-yl, 2-benzofuranyl, pyrimidinyl, 2,4-bis(methoxyphenyl)-5-pyrimidinyl; R10 = cyanoalkyl, alkylamino, dialkylamino, hydroxyalkylamino, hydroxydialkylamino; R11 = H, alkyl], are claimed. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbamoyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07  $\mu$ M to >1  $\mu$ M.

IT 397850-40-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-40-7 HCAPLUS

CN 1,4-Benzenediamine, N-(2-aminoethyl)-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)



IT 397850-34-9P 397850-35-0P 397850-36-1P  
397850-37-2P 397850-38-3P 397850-41-8P  
397850-42-9P 397850-43-0P 397850-44-1P  
397850-45-2P 397850-46-3P 397850-47-4P  
397850-48-5P 397850-49-6P 397850-50-9P  
397850-51-0P 397850-52-1P 397850-53-2P  
397850-54-3P 397850-55-4P 397850-56-5P  
397850-57-6P 397850-58-7P 397850-59-8P  
397850-60-1P 397850-61-2P 397850-62-3P  
397850-63-4P 397850-64-5P 397850-65-6P  
397850-66-7P 397850-67-8P 397850-68-9P  
397850-69-0P 397850-70-3P 397850-71-4P  
397850-72-5P 397850-73-6P 397850-74-7P  
397850-75-8P 397850-76-9P 397850-77-0P  
397850-78-1P 397850-79-2P 397850-80-5P  
397850-81-6P 397850-82-7P 397850-83-8P  
397850-84-9P 397850-85-0P 397850-86-1P  
397850-87-2P 397850-88-3P 397850-89-4P  
397850-90-7P 397850-92-9P 397850-94-1P  
397850-97-4P 397850-98-5P 397850-99-6P  
397851-00-2P 397851-01-3P 397851-02-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-34-9 HCAPLUS

CN Benzamide, N-[2-[[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]amino]-1-methyl-2-oxoethyl]-  
(9CI) (CA INDEX NAME)




RN 397850-35-0 HCAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]hexahydro-2-oxo-,  
(3aS,4S,6aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 397850-36-1 HCAPLUS

CN Hexadecanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)







RN 397850-37-2 HCAPLUS  
 CN Butanamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(1-oxobutyl)amino]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 397850-38-3 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(cyclohexylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-41-8 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-42-9 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxypropyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-43-0 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[(3-chlorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-44-1 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-45-2 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-46-3 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(propylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-47-4 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2,5-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-48-5 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [[[1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-  
 methylethyl)-1-phenanthrenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




RN 397850-49-6 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-50-9 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[3,4-  
 dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-51-0 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[3-  
 (diethylamino)propyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-52-1 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(4-bromo-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-53-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-54-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[butyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME).




RN 397850-55-4 HCAPLUS

CN 1,4-Benzenediamine, N'-[2-([1,1'-biphenyl]-4-ylamino)ethyl]-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-56-5 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-furanylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-57-6 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-iodophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-58-7 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-59-8 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-60-1 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-thienyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-61-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,5-dimethyl-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-62-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-63-4 HCAPLUS

CN Acetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-2-ethoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 397850-64-5 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-65-6 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-bromophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-66-7 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-67-8 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(3-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 397850-68-9 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-69-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 397850-70-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(1H-imidazol-4-yl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-71-4 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-72-5 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-73-6 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-methoxyphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-74-7 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-methylphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-75-8 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,5-dimethoxyphenyl]methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)





RN 397850-76-9 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-77-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(4-bromophenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br

RN 397850-78-1 HCAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(4-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-79-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(1-naphthalenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 397850-80-5 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [(2-phenoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-81-6 HCAPLUS  
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-  
 [[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-82-7 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(butylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-83-8 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-bis(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-84-9 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(3-pyridinylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-85-0 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-86-1 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-87-2 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-88-3 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[ethyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-89-4 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-90-7 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-92-9 HCAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-94-1 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 397850-97-4 HCAPLUS  
 CN Benzeneacetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-α-chloro- (9CI) (CA INDEX NAME)




RN 397850-98-5 HCAPLUS  
 CN 3-Pyridinecarboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-6-nitro- (9CI) (CA INDEX NAME)



RN 397850-99-6 HCAPLUS  
 CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)




RN 397851-00-2 HCAPLUS  
 CN Benzamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-4-butoxy- (9CI) (CA INDEX NAME)




RN 397851-01-3 HCAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(4-(trifluoromethyl)benzoyl)amino]ethyl]amino]phenyl]-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 397851-02-4 HCAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(3-fluorobenzoyl)amino]ethyl]amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



L39 ANSWER 32 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:565040 HCAPLUS

DN 135:152817

TI Preparation of pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors for treatment of proliferative disorders

IN Booth, Richard John; Dobrusin, Ellen Myra; Josyula, Vara Prasad Venkata Nagendra; McNamara, Dennis Joseph; Toogood, Peter Laurence

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001055147	A1	20010802	2001WO-IB00069	20010123 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA---2397961	AA	20010802	2001CA-2397961	20010123 <--
EP---1254137	A1	20021106	2001EP-0900591	20010123 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR2001007751	A	20021112	2001BR-0007751	20010123 <--
JP2003523357	T2	20030805	2001JP-0561006	20010123 <--
EE-200200405	A	20031215	2002EE-0000405	20010123 <--

BG----	106850	A	20030228	2002BG-0106850	20020620 <--
ZA2002005879		A	20030929	2002ZA-0005879	20020723 <--
NO2002003527		A	20020910	2002NO-0003527	20020724 <--
US2003073668		A1	20030417	2002US-0182178	20020724 <--
US---	7053070	B2	20060530		
PRAI	2000US-178261P	P	20000125	<--	
	2001WO-IB00069	W	20010123	<--	
OS	MARPAT 135:152817				
GI					




AB Title compds. (I) [wherein R2, R7, R13, R14, and R15 = independently H, or (un)substituted alkyl, alkenyl, alkynyl, or (CH2)nR12; R5 = halo, CN, NO2, R9, NR9R10, or OR9; R6 = halo, CN, NO2, R9, NR9R10, OR9, CO2R9, COR9, CONR9R10, NR9COR10, or (un)substituted alkenyl or alkynyl; R8 = CO2R13, COR13, CONR13R14, CSNR13R14, C(NR13)NR14R15, SO3R13, SO2R13, SO2NR13R14, PO3R13R14, POR13R14, or PO(NR13R14)2; R9 and R10 = independently H or (un)substituted alkyl; R11 = heteroaryl or heterocyclic group; R12 = cycloalkyl, heterocyclic, or (hetero)aryl group; n = 0-3; and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] were prepared and formulated as cyclin dependent kinase (cdk) and growth factor-mediated tyrosine kinase inhibitors. For example, the 2-methylsulfinyl group of 2-methanesulfinylpyrido[2,3-d]pyrimidin-7-ylamine was displaced by 4-(4-aminophenyl)piperazine-1-carboxylic acid tert-Bu ester (multi-step preparation of starting materials given) by refluxing in DMSO (36%). The pyrido[2,3-d]pyrimidin-7-amine was converted to the urea by reaction with tert-Bu isocyanate (67.9%) and the piperazine deprotected using HCl/dioxane (93.4%) to afford II•2.1HCl. The latter inhibited the cyclin dependent kinases cdk1/B, cdk2/A, cdk2/E, and cdk4D with IC50 values of 0.219 μM, 0.060 μM, 0.130 μM, and 0.006 μM, resp. In addition, II•2.1HCl inhibited the growth factor receptor tyrosine kinases PDGF-β and FGF-1 by 94.4% and 93.7%, resp., at 50 μM. I are useful for treating cell proliferative disorders, such as cancer and restenosis (no data).

IT 352329-42-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (formulation component; preparation of pyrido[2,3-d]pyrimidine-2,7-diamines  
 kinase inhibitors by cyclization of 3-[2-(methylsulfinyl)-4-  
 aminopyrimidin-5-yl]acrylates or [2,4-diaminopyrimidine-5-yl]ketones)

RN 352329-42-1 HCAPLUS

CN Urea, N-[6-bromo-2-[(3-ethyl-4-pyridinyl)amino]-5-methylpyrido[2,3-d]pyrimidin-7-yl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 352328-17-7P 352328-18-8P 352328-19-9P  
 352328-21-3P 352328-22-4P 352328-23-5P  
 352328-24-6P 352328-25-7P 352328-26-8P  
 352338-85-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrido[2,3-d]pyrimidine-2,7-diamines kinase inhibitors by cyclization of 3-[2-(methylsulfinyl)-4-aminopyrimidin-5-yl]acrylates or [2,4-diaminopyrimidine-5-yl]ketones)


RN 352328-17-7 HCAPLUS

CN Urea, N-(1,1-dimethylethyl)-N'-[2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 352328-18-8 HCAPLUS

CN Urea, N-cyclohexyl-N'-[2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 352328-19-9 HCAPLUS


CN Urea, N-ethyl-N'-[2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 352328-21-3 HCAPLUS


CN Urea, N-(2-hydroxyethyl)-N'-[2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)






RN 352328-22-4 HCAPLUS

CN Urea, N-(1,1-dimethylethyl)-N'-[6-fluoro-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 352328-23-5 HCAPLUS

CN Urea, N-cyclohexyl-N'-[6-fluoro-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 352328-24-6 HCAPLUS

CN Urea, N-ethyl-N'-[6-fluoro-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 352328-25-7 HCAPLUS

CN Urea, N-[6-fluoro-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 352328-26-8 HCAPLUS

CN Urea, N-(1,1-dimethylethyl)-N'-[5-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 352338-85-3 HCAPLUS  
 CN Urea, N-cyclohexyl-N'-[5-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 33 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:343384 HCAPLUS  
 DN 135:92847  
 TI Triazine conjugates for multiple site-specific labeling of peptides  
 AU Zerkowski, Jonathan A.; Scheftner, Douglas A.  
 CS Department of Chemistry, Loyola University Chicago, Chicago, IL, 60626, USA  
 SO Protein and Peptide Letters (2001), 8(2), 123-129  
 CODEN: PPELEN; ISSN: 0929-8665  
 PB Bentham Science Publishers  
 DT Journal  
 LA English  
 AB Mono- and di-substituted triazines were appended to the side chain of lysine or ornithine, which was then used in the synthesis of peptides. In this way, environment-sensitive "reporter" groups can be included in a sequence-specific manner in a peptide. The triazine adducts are stable to standard conditions employed in peptide synthesis. Several model peptides showing the utility of these conjugates were prepared  
 IT 348603-44-1P 348603-49-6P 348603-53-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (triazine conjugates for multiple site-specific labeling of peptides)  
 RN 348603-44-1 HCAPLUS  
 CN L-Threonine, N6-[4-chloro-6-(di-2-pyridinylamino)-1,3,5-triazin-2-yl]-N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348603-49-6 HCAPLUS

CN L-Alanine, N-[ (9H-fluoren-9-ylmethoxy)carbonyl]-L-tyrosyl-N6-[4-(di-2-pyridinylamino)-6-(1-methylethyl)-1,3,5-triazin-2-yl]-L-lysyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348603-53-2 HCAPLUS

CN L-Leucinamide, L-leucyl-L-lysyl-N6-[4-[bis(2-methoxyethyl)amino]-6-(2-naphthalenylamino)-1,3,5-triazin-2-yl]-L-lysyl-L-alanyl-L-arginyl-L-asparaginy-L-threonyl-L-α-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-arginyl-L-seryl-L-arginyl-L-alanyl-N5-[4-(di-2-pyridinylamino)-6-[4-(2-pyridinyl)-1-piperazinyl]-1,3,5-triazin-2-yl]-L-ornithyl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

COCCN(CCCOC)C1=NC2=C(N1)N=CN=C2Nc3ccc4ccccc43


PAGE 1-B



PAGE 1-C




PAGE 1-D



PAGE 2-B




PAGE 2-C



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 34 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:161507 HCAPLUS  
DN 134:207720  
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or  
sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix  
metalloproteinase inhibitors  
IN Venkatesan, Aranapakam Mudumbai; Grosu, George Theodore; Davis, Jamie  
Marie; Baker, Jannie Lea; Levin, Jeremy Ian  
PA American Cyanamid Company, USA  
SO U.S., 72 pp., Cont.-in-part of U.S. Ser. No. 26,372, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---6197791	B1	20010306	1998US-0140504	19980826 <--
	US---6331563	B1	20011218	2000US-0587560	20000605 <--
	US---6288086	B1	20010911	2000US-0593918	20000614 <--
	US2002032186	A1	20020314	2001US-0898604	20010703 <--
	US---6441023	B2	20020827		
	US2002006922	A1	20020117	2001US-0899641	20010705 <--
	US---6462073	B2	20021008		
	US2002188120	A1	20021212	2002US-0185080	20020628 <--
PRAI	1997US-038899P	P	19970227	<--	
	1998US-0026372	B2	19980219	<--	
	1998US-0140504	A3	19980826	<--	
	2000US-0587457	A1	20000605	<--	
	2000US-0587560	XX	20000605	<--	
	2000US-0593918	A3	20000614	<--	
OS	MARPAT 134:207720				
GI					



AB The invention provides low-mol.-weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF- $\alpha$  converting enzyme (TACE), useful for the treatment of a wide variety of related conditions, including arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance), and HIV infection. The compds. have formula R1AC(R2R3)CON(OH)R4 [wherein R1 = (un)substituted alk(en/yn)yl, aryl, cycloalkyl, heterocyclyl, heteroaryl, or heteroarylalkyl; A = S, SO, or SO<sub>2</sub>; R2 and R3 form a 6-membered heterocyclic ring containing substituted N; R4 = H, (un)substituted alk(en/yn)yl, Ph, naphthyl, (bi)cycloalkyl, or heterocyclyl; or salts]. For example, (2-naphthylmethyl)bis(2-chloroethyl)amine (prepared in 2 steps) was cyclized with 4-MeOC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et to give a piperidine derivative (52%), followed by saponification of the ester to the acid (36%) and amidation with NH<sub>2</sub>OH.HCl (31%), to give title compound I. This compound gave the following inhibitions (IC<sub>50</sub>, nM): MMP-1 368, MMP-9 5.0, MMP-13 1.6, and TACE 170.7 (in vitro).


IT 212768-33-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of organic sulfanyl/sulfinyl/sulfonyl-substituted N-hydroxyamides  
as matrix metalloproteinase inhibitors)

RN 212768-33-7 HCAPLUS

CN Octanamide, N-hydroxy-2-[[4-(4-pyridinylamino)phenyl]thio]- (9CI) (CA  
INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 35 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:27435 HCAPLUS

DN 134:100760

TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or  
sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix  
metalloproteinase inhibitors

IN Venkatesan, Aranapakam Mudumbai; Grosu, George Theodore; Davis, Jamie  
Marie; Hu, Baihua; Cole, Derek Cecil; Baker, Jannie Lea; Jacobson, Marcy  
Pamela; O'dell, Matthew Robin

PA American Cyanamid Company, USA

SO U.S., 58 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---6172057	B1	20010109	1998US-0026371	19980219 <--
	US---6342508	B1	20020129	2000US-0640532	20000817 <--
	US---6444704	B1	20020903	2000US-0640531	20000817 <--
	US2002032186	A1	20020314	2001US-0898604	20010703 <--
	US---6441023	B2	20020827		
PRAI	1997US-038899P	P	19970227	<--	
	1998US-0026371	A3	19980219	<--	
	2000US-0587560	XX	20000605	<--	
OS	MARPAT 134:100760				
GI					



I

AB The invention provides low-mol.-weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF- $\alpha$  converting enzyme (TACE), useful for the treatment of a wide variety of related conditions, including arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes, diabetes (insulin resistance), and HIV infection. The compds. have formula R1AC(R2R3)CON(OH)R4 [wherein R1 = (un)substituted alk(en/yn)yl, aryl, cycloalkyl, heterocyclyl, heteroaryl, or heteroarylalkyl; A = S, SO, or SO2; R2 and R3 = (un)substituted alkyl, alk(en/yn)yl, arylalkyl, biphenylalkyl, (bi)cycloalkylalkyl, or form 5- to


7-membered heterocyclic ring containing O, S, or (un)substituted NH; R4 = H, (un)substituted alk(en/yn)yl, Ph, naphthyl, (bi)cycloalkyl, or heterocyclyl; or salts]. For example, (2-naphthylmethyl)bis(2-chloroethyl)amine (prepared in 2 steps) was cyclized with 4-MeOC6H4SO2CH2CO2Et to give a piperidine derivative (52%), followed by saponification of the ester to the acid (36%) and amidation with NH2OH.HCl (31%), to give title compound I. This compound gave the following inhibitions (IC50, nM): MMP-1 368, MMP-9 5.0, MMP-13 1.6, and TACE 170.7 (in vitro).

IT 212768-33-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of organic sulfanyl/sulfinyl/sulfonyl-substituted N-hydroxyamides as matrix metalloproteinase inhibitors)

RN 212768-33-7 HCAPLUS

CN Octanamide, N-hydroxy-2-[[4-(4-pyridinylamino)phenyl]thio]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 36 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:646004 HCAPLUS

DN 133:238016

TI Preparation of pyrimidinamines as anti-cancer agents

IN Breault, Gloria Anne; James, Stewart Russell; Pease, Jane Elizabeth

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2000053595	A1	20000914	2000WO-GB00737	20000302 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2366668	AA	20000914	2000CA-2366668	20000302 <--
AU2000028187	A5	20000928	2000AU-0028187	20000302 <--
AU---754967	B2	20021128		
EP---1161428	A1	20011212	2000EP-0906531	20000302 <--
EP---1161428	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR2000008770	A	20020108	2000BR-0008770	20000302 <--
JP2002539120	T2	20021119	2000JP-0604033	20000302 <--
AT---241617	E	20030615	2000AT-0906531	20000302 <--
PT---1161428	T	20031031	2000PT-0906531	20000302 <--
ES---2200824	T3	20040316	2000ES-0906531	20000302 <--
NZ---513893	A	20040326	2000NZ-0513893	20000302 <--
ZA2001007252	A	20021202	2001ZA-0007252	20010831 <--
NO2001004317	A	20011101	2001NO-0004317	20010905 <--




NO----	320909	B1	20060213		
US----	6716831	B1	20040406	2001US-0914788	20011115 <--
PRAI	1999GB-0005075	A	19990306	<--	
	2000WO-GB00737	W	20000302	<--	
OS	MARPAT 133:238016				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The title compds. [I or II; R1 = H, halo, OH, etc.; Q1 = (un)substituted Ph; Q1 bears X(CH<sub>2</sub>)nCYLY2(CH<sub>2</sub>)mZ (wherein X = CH<sub>2</sub>, O, NH, etc.; Y1 = H, alkyl, Z; Y2 = H, alkyl; Z = RaO, RbRcN, RdS, etc.; Ra-Rd = H, alkyl, alkenyl, etc.; n, m = 1-3); NQ2 = (un)substituted heterocyclic moiety containing one N atom and optionally containing a further heteroatom] and their pharmaceutically acceptable salts, useful as anti-cancer agents, were prepared. E.g., a multi-step synthesis of the pyrimidinamine III was given. CDK4 and FAK inhibitory activity of compds. I and II was tested.

IT 293292-21-4P 293292-22-5P 293292-37-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidinamines as anti-cancer agents)


RN 293292-21-4 HCAPLUS  
 CN 2-Propanol, 1-[4-[[6-(2,3-dihydro-1H-indol-1-yl)-4-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 293292-22-5 HCAPLUS  
 CN 2-Propanol, 1-[4-[[6-(2,3-dihydro-2-methyl-1H-indol-1-yl)-4-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 293292-37-2 HCAPLUS  
 CN 2-Propanol, 1-[4-[[6-(2,3-dihydro-2,3-dimethyl-1H-indol-1-yl)-4-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 37 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:191055 HCAPLUS  
 DN 132:222544  
 TI Preparation of malonic diester derivatives as cell adhesion inhibitors and  
 process for producing the same  
 IN Kono, Yasushi; Nomura, Masahiro; Sawada, Takayuki; Ando, Naoki; Takahashi,  
 Yukie; Kuriyama, Kazuhiko  
 PA Kyorin Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2000015604	A1	20000323	1999WO-JP04914	19990910 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU---9956486	A1	20000403	1999AU-0056486	19990910 <--
PRAI	1998JP-0258840	A	19980911	<--	
	1999WO-JP04914	W	19990910	<--	
OS	MARPAT 132:222544				
GI					




AB Described are malonic diesters derivs. represented by general formula [I;  
 W = (un)substituted benzene, pyridine, quinoline, benzothiazole,  
 pyrimidine, quinazoline, thienopyrimidine, or benzimidazole; X = NH, CONH;  
 Y = (un)substituted benzene, naphthalene, pyridine, chroman, or  
 1,3-thiazole; Z = CH:CH, OCH<sub>2</sub>, OCM<sub>2</sub>, NHCOCH<sub>2</sub>CH<sub>2</sub>, or (CH<sub>2</sub>)<sub>n</sub>; wherein n =  
 03; R<sub>1</sub> = C1-4 lower alkyl; R<sub>2</sub> = H, C1-4 lower alkyl or alkoxycarbonyl] and  
 pharmacol. acceptable salts thereof being capable of preventing ICAM-1 and  
 VCAM-1, which play the major roles among cell adhesion mols., from binding  
 to leukocytes; and cell adhesion inhibitors containing as the active  
 ingredient at least one of the above compds. and serving as excellent  
 immunosuppressants, anti-inflammatory agents, antiallergic agents and  
 tumor metastasis inhibitors. Thus, 2-[[4-(benzothiazol-2-ylamino)benzoyl]amino]acetic acid di-Et ester was condensed with  
 aminomalonic acid di-Et ester using 1-ethyl-3-(3-  
 dimethylaminopropyl)carbodiimide hydrochloride in the  
 presence of 4-dimethylaminopyridine and Et<sub>3</sub>N in DMF at room temperature for 18 h  
 to give 2-{2-[[4-(benzothiazol-2-ylamino)benzoyl]amino]acetamido}malonic  
 acid di-Et ester. 2-[2-[4-(Benzothiazol-2-ylamino)-2-  
 methoxyphenoxy]acetamido]malonic acid di-Et ester inhibited by 100% the  
 binding of U937 cells to human umbilical vein endothelial cells (HUVEC)  
 which was treated with human interleukin 1β to induce the expression  
 of ICAM-1.

IT 261348-66-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of malonic diester derivs. as cell adhesion inhibitors)

RN 261348-66-7 HCAPLUS

CN Propanedioic acid, [[[4-(2-pyridinylamino)phenoxy]acetyl]amino]-, diethyl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 38 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:764041 HCAPLUS

DN 132:22971

TI Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors

IN Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard;  
Schroeder, Mel Conrad; Showalter, Howard Daniel Hollis; Toogood, Peter;  
Trump-Kallmeyer, Susanne A.

PA Warner-Lambert Co., USA

SO PCT Int. Appl., 133 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO---9961444	A2	19991202	1999WO-US10187	19990510 <--
WO---9961444	A3	20000203		
W:			AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA---2329703	AA	19991202	1999CA-2329703	19990510 <--
CA---2329703	C	20051220		
AU---9940734	A1	19991213	1999AU-0040734	19990510 <--
AU---763839	B2	20030731		
BR---9911590	A	20010213	1999BR-0011590	19990510 <--
EP---1080092	A2	20010307	1999EP-0924165	19990510 <--
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
TR-200003429	T2	20010723	TR 2000-200003429	19990510 <--
JP2002516327	T2	20020604	2000JP-0550849	19990510 <--
EE-200000706	A	20020617	2000EE-0000706	19990510 <--
NZ---508268	A	20040227	1999NZ-0508268	19990510 <--
ZA2000006536	A	20020211	2000ZA-0006536	20001110 <--
BG---104960	A	20011031	2000BG-0104960	20001117 <--
HR2000000799	A1	20010630	2000HR-0000799	20001120 <--
NO2000005928	A	20001123	2000NO-0005928	20001123 <--
HK---1039483	A1	20040618	2001HK-0107828	20011108 <--
US2004044012	A1	20040304	2003US-0638848	20030811 <--
PRAI 1998US-086708P	P	19980526	<--	
1999US-126158P	P	19990325	<--	
1999WO-US10187	W	19990510	<--	
2000US-0623737	A3	20000907	<--	
OS MARPAT 132:22971				
GI				



AB Title compds. [I; G = NR<sub>2</sub> or CHR<sub>2</sub>; R = NHR<sub>1</sub> or SOO-2R<sub>1</sub>; R<sub>1</sub>, R<sub>2</sub> = H, (cyclo)alkyl, (un)substituted PH, -pyridyl, etc.; R<sub>3</sub> = groups cited for R<sub>1</sub>, OH, alkoxy(carbonyl), etc.; R<sub>4</sub> = H; R<sub>3</sub>R<sub>4</sub> = bond; R<sub>8</sub>, R<sub>9</sub> = H, halo, NH<sub>2</sub>, alkoxy-carbonyl, etc.; X = O, S, (alkyl)imino, etc.; Z = N or CH] were prepared as cyclin-dependant and tyrosine kinase inhibitors. Thus, 5-aminomethyl-4-cyclopentylamino-2-methylthiopyrimidine (preparation given) was cyclocondensed with 1,1'-carbonyldiimidazole and the oxidized product aminated by 4-(MeO)C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> to give I [G = cyclopentylimino, R = 4-(MeO)C<sub>6</sub>H<sub>4</sub>NH, R<sub>3</sub> = R<sub>4</sub> = R<sub>8</sub> = R<sub>9</sub> = H, X = O]. Data for biol. activity of I were given.

IT 251370-45-3P 251370-46-4P 251370-47-5P

251370-48-6P 251370-62-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation)


RN 251370-45-3 HCAPLUS

CN Urea, N-[3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-2-yl]-N'-(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)




RN 251370-46-4 HCAPLUS

CN Urea, N-[3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-2-yl]-N'-ethyl-(9CI) (CA INDEX NAME)




RN 251370-47-5 HCAPLUS


CN Urea, N-[3-(2-chloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-2-yl]-N'-(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



RN 251370-48-6 HCAPLUS  
 CN Urea, N-[3-(2-chloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 251370-62-4 HCAPLUS  
 CN Urea, N-(1-methylethyl)-N'-[7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



L39 ANSWER 39 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:549247 HCAPLUS  
 DN 131:184865  
 TI Preparation of N-hydroxycarboxamides as matrix metalloproteinase inhibitors  
 IN Venkatesan, Aranapakam Mudumbai; Grosu, George Theodore; Davis, Jamie Marie; Baker, Jannie Lea; Levin, Jeremy Ian  
 PA American Cyanamid Company, USA  
 SO PCT Int. Appl., 200 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO---9942436	A1	19990826	1998WO-US17633	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA---2320469	AA	19990826	1998CA-2320469	19980826 <--
AU---9891201	A1	19990906	1998AU-0091201	19980826 <--
AU---757719	B2	20030306		
BR---9815781	A	20001107	1998BR-0015781	19980826 <--
EP---1054858	A1	20001129	1998EP-0943392	19980826 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

TR-200002423	T2	20010122	TR 2000-200002423	19980826 <--
JP2002503717	T2	20020205	2000JP-0532389	19980826 <--
EE-200000471	A	20020215	2000EE-0000471	19980826 <--
NZ---506184	A	20030530	1998NZ-0506184	19980826 <--
ZA---9905455	A	20010226	1999ZA-0005455	19990825 <--
NO2000004093	A	20001003	2000NO-0004093	20000816 <--
HR2000000543	A1	20010831	2000HR-0000543	20000818 <--
BG---104782	A	20010831	2000BG-0104782	20000919 <--
US2002032186	A1	20020314	2001US-0898604	20010703 <--
US---6441023	B2	20020827		

PRAI 1998US-0026372 A 19980219 <--  
 1998WO-US17633 W 19980826 <--  
 2000US-0587560 XX 20000605 <--


OS MARPAT 131:184865

AB R1ZCR2R3CONR4OH [I; R1 = alk(en)yl, aryl, heteroaryl(alkyl), etc.; R2R3 = atoms to complete an (un)substituted heterocyclic ring; R4 = H, alkyl, Ph, etc.; Z = SO0-2] were prepared Thus, PhCH2N(CH2CH2Cl)2 was cyclocondensed with 4-(MeO)C6H4CH2CO2Et (preparation each given) and the saponified product amidated by NH2OH to give 1-benzyl-N-hydroxy-4-(4-methoxyphenylsulfonyl)piperidine-4-carboxamide. Data for biol. activity of I were given.

IT 212768-33-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-hydroxycarboxamides as matrix metalloproteinase inhibitors)

RN 212768-33-7 HCAPLUS

CN Octanamide, N-hydroxy-2-[[4-(4-pyridinylamino)phenyl]thio]- (9CI) (CA INDEX NAME)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 40 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:425745 HCAPLUS  
 DN 131:87909  
 TI Inhibition of p38 kinase activity using substituted heterocyclic ureas  
 IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko  
 PA Bayer Corporation, USA  
 SO PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9932111	A1	19990701	1998WO-US26080	19981222 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA---2315720 AA 19990701 1998CA-2315720 19981222 <--  
 AU---9919971 A1 19990712 1999AU-0019971 19981222 <--  
 AU---739642 B2 20011018  
 EP---1041982 A1 20001011 1998EP-0964709 19981222 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO  
 JP2001526223 T2 20011218 2000JP-0525102 19981222 <--  
 PRAI 1997US-0995750 A 19971222 <--  
 1998WO-US26080 W 19981222 <--  
 OS MARPAT 131:87909  
 GI




AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing  $\geq 1$  5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compound II. In an in vitro p38 kinase assay, I displayed IC<sub>50</sub> values of 1-10  $\mu$ M.

IT 229155-53-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 229155-53-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 41 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN


AN 1999:425740 HCAPLUS

DN 131:73648

TI Inhibition of raf kinase using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger;  
 Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.;  
 Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko  
 PA Bayer Corporation, USA  
 SO PCT Int. Appl., 163 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9932106	A1	19990701	1998WO-US26078	19981222 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA---2315717	AA	19990701	1998CA-2315717	19981222 <--
	AU---9921989	A1	19990712	1999AU-0021989	19981222 <--
	EP---1047418	A1	20001102	1998EP-0965981	19981222 <--
	EP---1047418	B1	20050727		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR-200002618	T2	20010420	TR 2000-200002618	19981222 <--
	JP2001526220	T2	20011218	2000JP-0525097	19981222 <--
	BR---9814374	A	20020514	1998BR-0014374	19981222 <--
	RU---2232015	C2	20040710	2000RU-0120184	19981222 <--
	CN---1544420	A	20041110	CN 2004-10028655	19981222 <--
	AT---300299	E	20050815	1998AT-0965981	19981222 <--
	ES---2153340	T3	20060201	1998ES-0965981	19981222 <--
	NO2000003232	A	20000821	2000NO-0003232	20000621 <--
	IN---193672	A	20040731	2000IN-MN00153	20000704 <--
	BG---104597	A	20010228	2000BG-0104597	20000712 <--
	HK---1029052	A1	20051118	2000HK-0107684	20001130 <--
PRAI	1997US-0996343	A	19971222	<--	
	1998WO-US26078	W	19981222	<--	
OS	MARPAT 131:73648				
GI					




AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing  $\geq 1$  5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave title compound II. In an in vitro raf kinase assay, I displayed IC<sub>50</sub> values of 1-10  $\mu$ M.


IT 229000-35-5P 229001-43-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)



RN 229000-35-5 HCAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-(methyl-4-pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-43-8 HCAPLUS  
 CN Urea, N-[3-(1,1-dimethylpropyl)-5-isoxazolyl]-N'-[4-(4-pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 42 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:608598 HCAPLUS  
 DN 129:230641  
 TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors  
 IN Venkatesan, Mudumbai Aranapakam; Grosu, George Theodore; Davis, Jamie Marie; Hu, Baihua; O'Dell, Mathew James; Cole, Derek Cecil; Baker, Jannie Lea; Jacobson, Marcy Pamela  
 PA American Cyanamid Co., USA  
 SO PCT Int. Appl., 181 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9838163	A1	19980903	1998WO-US03291	19980217 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,  
 VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG


CA---2282656	AA	19980903	1998CA-2282656	19980217 <--
AU---9864368	A1	19980918	1998AU-0064368	19980217 <--
AU---748998	B2	20020613		
EP---970046	A1	20000112	1998EP-0910022	19980217 <--
EP---970046	B1	20031210		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

BR---9807803	A	20000222	1998BR-0007803	19980217 <--
EE---9900369	A	20000417	1999EE-0000369	19980217 <--
EE-----4150	B1	20031015		
JP2001513771	T2	20010904	1998JP-0537724	19980217 <--
NZ---337298	A	20021126	1998NZ-0337298	19980217 <--
AT---256107	E	20031215	1998AT-0910022	19980217 <--
PT---970046	T	20040430	1998PT-0910022	19980217 <--
ES---2212274	T3	20040716	1998ES-0910022	19980217 <--
PT---973512	T	20040730	1998PT-0906468	19980217 <--
ES---2217540	T3	20041101	1998ES-0906468	19980217 <--
ZA---9801625	A	19990826	1998ZA-0001625	19980226 <--
ZA---9801628	A	20000228	1998ZA-0001628	19980226 <--
TW---568900	B	20040101	TW 1998-87102853	19980317 <--
MX---9907862	A	20000630	1999MX-0007862	19990825 <--
NO---9904124	A	19991026	1999NO-0004124	19990826 <--
NO---314258	B1	20030224		

PRAI 1997US-0806728 A 19970227 <--  
 1998WO-US03291 W 19980217 <--

OS MARPAT 129:230641  
 GI




AB The invention provides low-mol.-weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF- $\alpha$  converting enzyme (TACE), useful for the treatment of a wide variety of related conditions, including arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance), and HIV infection. The compds. have formula R1AC(R2R3)CON(OH)R4 [wherein R1 = (un)substituted alk(en/yn)yl, aryl, cycloalkyl, heterocyclyl, heteroaryl, or heteroarylalkyl; A = S, SO, or SO<sub>2</sub>; R2, R3 = H, (un)substituted alk(en/yn)yl, aralkyl, biphenylalkyl, arylalkenyl, (bi)cycloalkylalkyl, heterocyclyl, alkoxyaralkyl, heteroaryl, heteroaralkyl, etc.; R4 = H, (un)substituted alk(en/yn)yl, Ph, naphthyl, (bi)cycloalkyl, or heterocyclyl; or salts]. For instance,  $\alpha$ -alkylation of 4-MeOC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>CH(Me)CO<sub>2</sub>Et by 3-(Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Cl (93%), followed by saponification of the ester to the acid (88%) and amidation with NH<sub>2</sub>OH.HCl (21%), gave compound I as the HCl salt. This compound gave the following inhibitions (IC<sub>50</sub>, nM): MMP-1 297, MMP-9 4.3, and MMP-13 3.6, and 41% inhibition of TACE at 1  $\mu$ M.

IT 212768-33-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of organic sulfanyl/sulfinyl/sulfonyl-substituted N-hydroxyamides as matrix metalloproteinase inhibitors)

RN 212768-33-7 HCAPLUS

CN Octanamide, N-hydroxy-2-[[4-(4-pyridinylamino)phenyl]thio]- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 43 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:603237 HCAPLUS

DN 129:230639

TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors

IN Venkatesan, Aranapakam Mudumbai; Grosu, George Theodore; Davis, Jamie Marie; Baker, Jannie Lea

PA American Cyanamid Co., USA

SO PCT Int. Appl., 176 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9837877	A1	19980903	1998WO-US02987	19980217 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA---2282655	AA	19980903	1998CA-2282655	19980217 <--
	AU---9861686	A1	19980918	1998AU-0061686	19980217 <--
	AU---726204	B2	20001102		
	EP---973512	A1	20000126	1998EP-0906468	19980217 <--
	EP---973512	B1	20040407		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR---9807802	A	20000321	1998BR-0007802	19980217 <--
	EE---9900371	A	20000417	1999EE-0000371	19980217 <--
	EE-----4295	B1	20040615		
	JP2001519777	T2	20011023	1998JP-0537706	19980217 <--
	AT---263554	E	20040415	1998AT-0906468	19980217 <--
	PT---970046	T	20040430	1998PT-0910022	19980217 <--
	ES---2212274	T3	20040716	1998ES-0910022	19980217 <--
	PT---973512	T	20040730	1998PT-0906468	19980217 <--
	ES---2217540	T3	20041101	1998ES-0906468	19980217 <--
	ZA---9801625	A	19990826	1998ZA-0001625	19980226 <--
	ZA---9801628	A	20000228	1998ZA-0001628	19980226 <--
	TW---568900	B	20040101	TW 1998-87102853	19980317 <--
	MX---9907868	A	20000630	1999MX-0007868	19990825 <--
	NO---9904125	A	19991026	1999NO-0004125	19990826 <--

NO---314302 B1 20030303  
 HK---1024875 A1 20040924 2000HK-0104181 20000707 <--  
 PRAI 1997US-0806728 A 19970227 <--  
 1998WO-US02987 W 19980217 <--  
 OS MARPAT 129:230639  
 GI




AB The invention provides low-mol.-weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF- $\alpha$  converting enzyme (TACE), useful for the treatment of a wide variety of related conditions, including arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance), and HIV infection. The compds. have formula R<sub>1</sub>AC(R<sub>2</sub>R<sub>3</sub>)CON(OH)R<sub>4</sub> [wherein R<sub>1</sub> = (un)substituted alk(en/yn)yl, aryl, cycloalkyl, heterocyclyl, heteroaryl, or heteroarylalkyl; A = S, SO, or SO<sub>2</sub>; R<sub>2</sub> and R<sub>3</sub> form 5- to 7-membered heterocyclic ring containing O, S, or (un)substituted NH; R<sub>4</sub> = H, (un)substituted alk(en/yn)yl, Ph, naphthyl, (bi)cycloalkyl, or heterocyclyl; or salts]. For example, (2-naphthylmethyl)bis(2-chloroethyl)amine (prepared in 2 steps) was cyclized with 4-MeOC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et to give a piperidine derivative (52%), followed by saponification of the ester to the acid (36%) and amidation with NH<sub>2</sub>OH.HCl (31%), to give title compound I. This compound gave the following inhibitions (IC<sub>50</sub>, nM): MMP-1 368, MMP-9 5.0, MMP-13 1.6, and TACE 170.7 (in vitro).

IT 212768-33-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of organic sulfanyl/sulfinyl/sulfonyl-substituted N-hydroxyamides as matrix metalloproteinase inhibitors)

RN 212768-33-7 HCAPLUS

CN Octanamide, N-hydroxy-2-[[4-(4-pyridinylamino)phenyl]thio]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 44 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:485052 HCAPLUS

DN 129:122575

TI Preparation of N-(pyridinylamino)isoindolines and related compounds for treatment of memory dysfunction and depression.

IN Kurys, Barbara E.; Fink, David M.; Freed, Brian S.; Merriman, Gregory H.

PA Hoechst Marion Roussel, Inc., USA

SO PCT Int. Appl., 99 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9829407	A2	19980709	1997WO-US20591	19971113 <--
	WO---9829407	A3	19981022		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US---6004977	A	19991221	1997US-0959789	19971029 <--
	AU---9854349	A1	19980731	1998AU-0054349	19971113 <--
	AU---720466	B2	20000601		
	EP---950056	A2	19991020	1997EP-0948250	19971113 <--
	EP---950056	B1	20020918		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN---1242012	A	20000119	1997CN-0181021	19971113 <--
	BR---9714189	A	20000229	1997BR-0014189	19971113 <--
	JP2001511119	T2	20010807	1998JP-0529990	19971113 <--
	AT---224387	E	20021015	1997AT-0948250	19971113 <--
	PT---950056	T	20021231	1997PT-0948250	19971113 <--
	ES---2179377	T3	20030116	1997ES-0948250	19971113 <--
	CA---2276203	C	20030722	1997CA-2276203	19971113 <--
	CA---2276203	AA	19980709		
	ZA---9711520	A	19980629	1997ZA-0011520	19971222 <--
	NO---9903180	A	19990826	1999NO-0003180	19990625 <--
PRAI	1996US-0774308	A	19961227	<--	
	1997US-0959789	A	19971029	<--	
	1997WO-US20591	W	19971113	<--	
OS	MARPAT 129:122575				
GI					



AB Title compds. [I; Q = (CH<sub>2</sub>)<sub>n</sub>; R = H, R<sub>2</sub>O, (R<sub>3</sub>)<sub>3</sub>Si, R<sub>4</sub>R<sub>5</sub>NCO; R<sub>2</sub> = H, alkyl, PhCH<sub>2</sub>; R<sub>3</sub> = alkyl; R<sub>4</sub>, R<sub>5</sub> = H, alkyl, PhCH<sub>2</sub>; R<sub>4</sub>R<sub>5</sub> = tetrahydroisoquinolinyl, pyridinylpiperazinyl; R<sub>1</sub> = H, alkyl; X, Y = H, alkyl, halo, OH, alkoxy, CF<sub>3</sub>; m, p = 1, 2; n = 1-3], were prepared. Thus, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl dimethylcarbamate (preparation given) inhibited acetylcholinesterase with IC<sub>50</sub> = 0.029 mM.


IT 210171-86-1P 210171-95-2P 210172-20-6P  
 210172-34-2P 210172-35-3P 210172-47-7P  
 210172-49-9P 210172-57-9P 210172-61-5P  
 210172-62-6P 210172-66-0P 210172-73-9P  
 210172-75-1P 210172-77-3P 210172-82-0P  
 210172-87-5P 210172-97-7P 210173-03-8P  
 210173-04-9P 210173-05-0P 210173-06-1P  
 210173-08-3P 210173-09-4P 210173-11-8P  
 210173-13-0P 210173-15-2P 210173-21-0P  
 210173-22-1P 210173-23-2P 210173-24-3P  
 210173-97-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-(pyridinylamino)isoindolines and related compds. for  
 treatment of memory dysfunction and depression)


RN 210171-86-1 HCAPLUS

CN 1H-Isoindol-5-ol, 2,3-dihydro-2-(2-pyridinylamino)-, methylcarbamate  
 (ester) (9CI) (CA INDEX NAME)




RN 210171-95-2 HCAPLUS

CN 1H-Isoindol-4-ol, 2,3-dihydro-2-(2-pyridinylamino)-, methylcarbamate  
 (ester) (9CI) (CA INDEX NAME)




RN 210172-20-6 HCAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester (9CI) (CA INDEX NAME)




RN 210172-34-2 HCAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-6-methoxy-2-(4-pyridinylamino)-7-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 210172-35-3 HCAPLUS


CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-(4-pyridinylamino)-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 210172-47-7 HCAPLUS  
 CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-(4-pyridinylamino)-7-isoquinolinyl ester (9CI) (CA INDEX NAME)



RN 210172-49-9 HCAPLUS  
 CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-7-methoxy-2-(4-pyridinylamino)-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 210172-57-9 HCAPLUS  
 CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-2-(4-pyridinylamino)-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 210172-61-5 HCAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 210172-62-6 HCAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester (9CI) (CA INDEX NAME)




RN 210172-66-0 HCAPLUS  
 CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 210172-73-9 HCAPLUS  
 CN Carbamic acid, dimethyl-, 6-fluoro-1,2,3,4-tetrahydro-2-(4-pyridinylamino)-7-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 210172-75-1 HCAPLUS  
 CN Carbamic acid, dimethyl-, 8-chloro-1,2,3,4-tetrahydro-2-(4-pyridinylamino)-4-isoquinolinyl ester (9CI) (CA INDEX NAME)





RN 210172-77-3 HCAPLUS

CN Carbamic acid, dimethyl-, 5-bromo-1,2,3,4-tetrahydro-2-(4-pyridinylamino)-8-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 210172-82-0 HCAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-(4-pyridinylamino)-8-isoquinolinyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 210172-81-9

CMF C17 H20 N4 O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 210172-87-5 HCAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-5-yl ester (9CI) (CA INDEX NAME)




RN 210172-97-7 HCAPLUS  
 CN Carbamic acid, methyl(phenylmethyl)-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 210173-03-8 HCAPLUS  
 CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-7-methoxy-2-(4-pyridinylamino)-8-isoquinolinyl ester (9CI) (CA INDEX NAME)



RN 210173-04-9 HCAPLUS  
 CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-7-methoxy-2-(4-pyridinylamino)-8-isoquinolinyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 210173-03-8  
 CMF C18 H22 N4 O3




CM 2


CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 210173-05-0 HCAPLUS  
 CN Carbamic acid, diethyl-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 210173-06-1 HCAPLUS  
 CN Carbamic acid, dimethyl-, 4-fluoro-2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 210173-08-3 HCAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 4-fluoro-2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 210173-09-4 HCAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 4-fluoro-2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-5-yl ester (9CI) (CA INDEX NAME)



RN 210173-11-8 HCAPLUS


CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 210173-13-0 HCAPLUS


CN Carbamic acid, dimethyl-, 7-chloro-2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 210173-15-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-pyridinyl)-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester (9CI) (CA INDEX NAME)




RN 210173-21-0 HCAPLUS

CN Carbamic acid, methyl(phenylmethyl)-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester (9CI) (CA INDEX NAME)




RN 210173-22-1 HCAPLUS

CN Carbamic acid, diethyl-, 2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester (9CI) (CA INDEX NAME)




RN 210173-23-2 HCAPLUS


CN Carbamic acid, dimethyl-, 4-fluoro-2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-5-yl ester (9CI) (CA INDEX NAME)



RN 210173-24-3 HCAPLUS  
 CN Carbamic acid, dimethyl-, 7-chloro-2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl ester (9CI) (CA INDEX NAME)




RN 210173-97-0 HCAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-1H-2-benzazepin-8-yl ester (9CI) (CA INDEX NAME)



L39 ANSWER 45 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:537574 HCAPLUS  
 DN 127:161697  
 TI 2-Amino heterocycles and their therapeutic uses as leukotriene biosynthesis inhibitors  
 IN Es-Sayed, Mazen; Yamamoto, Masaru; Frobels, Klaus; Poll, Chris; Grix, Suzanna; Tudhope, Stephen  
 PA Bayer Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 275 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9724328	A1	19970710	1996WO-EP05643	19961216 <--
	W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, IS, JP, KE, KP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU---9713728	A1	19970728	1997AU-0013728	19961216 <--
PRAI	1995GB-0026560	A	19951227	<--	
	1996WO-EP05643	W	19961216	<--	
OS	MARPAT 127:161697				
GI					





AB 2-Amino heterocycles R1R2NCOR3 [I; R1 = H, Me, (un)substituted 6-membered aromatic heterocycle containing ≤2 N atoms and optionally benzo-fused; R2 = (un)substituted adamantyl, cycloalkyl, pyridyl, Ph, CH2Ph, tetralin-5-yl, 2-norbornyl, 1-azabicyclo[2.2.2]oct-3-yl; or NR1R2 forms α-carboline residue; R3 = (un)substituted or cyclic amino groups linked via a bond, carbonyl, or alkylene group] are disclosed. I can be used for the production of medicaments which inhibit leukotriene synthesis (in particular LTB4), and are especially useful for the treatment and control of respiratory diseases and inflammatory processes (no data). For instance, condensation of 2-chloropyridine with 4-MeOC6H4NH2 at 150° gave 2-(4-methoxyanilino)pyridine, which reacted with ClCO2CCl3 and then HN(CH2Ph)2 in dioxane at 60° to give title compound II plus a byproduct.

IT 193556-83-1P 193556-84-2P 193556-85-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2-amino heterocycles as leukotriene biosynthesis inhibitors)


RN 193556-83-1 HCAPLUS

CN Ethanediameide, N-[5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl](3-nitro-2-pyridinyl)amino]-2-methoxyphenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 193556-84-2 HCAPLUS

CN Ethanediameide, N-[2-methoxy-5-[[[3-methyl-4-(3-methylphenyl)-1-piperazinyl]carbonyl](3-nitro-2-pyridinyl)amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 193556-85-3 HCAPLUS  
 CN Ethanediameide, N-[5-[[[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]carbonyl](3-nitro-2-pyridinyl)amino]-2-methoxyphenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




L39 ANSWER 46 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:281669 HCAPLUS  
 DN 127:13310  
 TI Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease  
 AU Smith, Craig P.; Bores, Gina M.; Petko, Wayne; Li, Mary; Selk, David E.; Rush, Douglas K.; Camacho, Fernando; Winslow, James T.; Fishkin, Rod; Cunningham, Dana M.; Brooks, Karen M.; Roehr, Joachim; Hartman, Harold B.; Davis, Larry; Vargas, Hugo M.  
 CS Neuroscience Therapeutic Domain, Hoechst Marion Roussel, Inc., Bridgewater, NJ, USA  
 SO Journal of Pharmacology and Experimental Therapeutics (1997), 280(2), 710-720  
 CODEN: JPETAB; ISSN: 0022-3565  
 PB Williams & Wilkins  
 DT Journal  
 LA English  
 AB P10358 [1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1(H)-indol-5-yl Me carbamate] is a potent, reversible acetylcholinesterase inhibitor that produces central cholinergic stimulation after oral and parental administration in rats and mice. P10358 is a 2.5 times more potent acetylcholinesterase inhibitor than THA in vitro ( $IC_{50} = 0.10 \pm 0.02 \mu M$  vs.  $IC_{50} = 0.25 \pm 0.03 \mu M$ ). It also inhibits butyrylcholinesterase activity as potently as THA ( $IC_{50} = 0.08 \pm 0.05 \mu M$  vs.  $IC_{50} = 0.07 \pm 0.01 \mu M$ ). Ex vivo, P10358 (0.2-20 mg/kg, p.o.) produced dose-dependent inhibition of brain acetylcholinesterase activity. At 10 and 20 mg/kg, it produced profound and long-lasting hypothermia in mice. P10358 enhanced performance in rats in a step-down passive avoidance task (0.62 and 1.25 mg/kg) and in a social recognition paradigm (0.32, 0.64 and 1.25 mg/kg) in mice. It reversed scopolamine-induced deficits in the Morris Water maze in rats (1.256 and 2.5 mg/kg) and a higher dose elevated striatal homovanillic acid levels. These behavioral and biochem. effects are consistent with central




cholinergic stimulation. Hemodynamic studies in the rat demonstrated a 16-fold separation between behaviorally active doses (1.25 mg/kg) and those that elevated arterial pressure (20 mg/kg). Lethality in rats occurred at an oral dose of 80 mg/kg, but not at lower doses. Chemical, P10358 is an N-aminoindole and may not have the hepatotoxic liability associated with aminoacridine structure of tacrine. P10358 had weak affinity (>10  $\mu$ M) at a variety of aminergic and peptidergic receptors and uptake carriers. These properties suggest that P10358 may be a safe and promising symptomatic treatment of Alzheimer's disease.

IT 188240-59-7, P 10358  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmacol. activity and safety of N-aminoindole P-10358 as orally active acetylcholinesterase inhibitor for Alzheimer's disease)  
 RN 188240-59-7 HCAPLUS  
 CN 1H-Indol-5-yl, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 47 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:123307 HCAPLUS  
 DN 126:220296  
 TI Synthesis and preliminary structure-activity relationships of 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl methyl carbamate (P10358), a novel acetylcholinesterase inhibitor  
 AU Martin, Lawrence L.; Davis, Larry; Klein, Joseph T.; Nemoto, Peter; Olsen, Gordon E.; Bores, Gina M.; Camacho, Fernando; Petko, Wayne W.; Rush, Douglas K.; et al.  
 CS Hoechst Marion Roussel Inc., Neuroscience Therapeutic Area, Bridgewater, NJ, 08807-0800, USA  
 SO Bioorganic & Medicinal Chemistry Letters (1997), 7(2), 157-162  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier  
 DT Journal  
 LA English  
 AB A series of carbamate analogs of besipirdine (HP 749) was synthesized as potential agents with enhanced cholinomimetic properties for the treatment of Alzheimer's disease. P10358, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl Me carbamate, emerged as a potent, reversible acetylcholinesterase inhibitor that significantly enhanced performance on oral or parenteral administration in learning and memory paradigms.  
 IT 141287-42-5P 141287-43-6P 141287-44-7P  
 141287-45-8P 188240-59-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis and structure-activity relationships of besipirdine carbamate analogs as acetylcholinesterase inhibitors)  
 RN 141287-42-5 HCAPLUS  
 CN 1H-Indol-5-yl, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-43-6 HCAPLUS

CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-44-7 HCAPLUS

CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-45-8 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 188240-59-7 HCAPLUS  
 CN 1H-Indol-5-yl, 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-, methylcarbamate  
 (ester) (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 48 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:51439 HCAPLUS

DN 126:89269

TI Preparation of heterocyclic compounds as cholesterol acyltransferase inhibitors

IN Natsukari, Hideaki; Ishimaru, Takenori; Doi, Takayuki; Sugiyama, Yasuo; Morimoto, Shinji

PA Takeda Chemical Industries Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--08295667	A2	19961112	1995JP-0129433	19950427 <--
PRAI	1995JP-0129433		19950427 <--		
OS	MARPAT 126:89269				

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A, B = (un)substituted (hetero)cycle; X = N, CR1; R, R1 = H, (un)substituted hydrocarbyl; Y = (oxo)alkylene; Z = bond, alkylene; W = (un)substituted (hetero)cycle; when A, B = benzene ring, X = CR1, Y = CO, W = substituted cycle or (un)substituted heterocycle] are prepared I having a potent antagonism on tachykinin receptor (substance P receptor special) are useful as cholesterol acyltransferase (ACAT) inhibitors. Thus, N-[3,5-bis(trifluoromethyl)benzyl]-N'-(4-chloro-2-phenylaminophenyl)-N-methyloxamide (preparation given) was treated with HCl and reacted with AcONa in the presence of Pd/C under H atmospheric to give the title compound (II). II showed IC50 of 0.36 nM against tachykinin receptors.


IT 185332-30-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heterocyclic compds. as cholesterol acyltransferase inhibitors)

RN 185332-30-3 HCAPLUS

CN Propanediamide, N-[2,6-bis(1-methylethyl)phenyl]-N'-[4-chloro-2-(2-

pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)



L39 ANSWER 49 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:340214 HCAPLUS

DN 125:10857

TI Preparation of pyrido[2,3-b]pyrazin-4-one inhibitors of phosphodiesterase IV and tumor necrosis factor

IN Shimazaki, Norihiko; Watanabe, Shinya; Sawada, Akihiko; Hemmi, Keiji

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Brit. UK Pat. Appl., 29 pp.


CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB---2291422	A1	19960124	1994GB-0014453	19940718 <--
PRAI	1994GB-0014453		19940718 <--		
OS	MARPAT 125:10857				
GI					



AB The title compds. [I; R1 = lower alkyl, (un) protected CO<sub>2</sub>H; R2 = aryl which may have protected amino groups], which are inhibitors of phosphodiesterase IV and tumor necrosis factor (TNF), are prepared by the cyclization of 2,3-pyridinediamines (II) with  $\alpha$ -ketocarboxylic acids.HO<sub>2</sub>CCOR1. Thus, 2-isobutyl-3-oxo-4-[3-[3-(2-methoxyphenyl)ureido]phenyl]-3,4-dihydropyrido[2,3-b]pyrazine, m.p. 211-213°, was prepared and demonstrated a IC<sub>50</sub> of 3.1 x 10<sup>-8</sup> M against  $\alpha$ -TNF.


IT 177343-39-4P 177343-40-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrido[2,3-b]pyrazin-4-one inhibitors of phosphodiesterase IV and tumor necrosis factor)

RN 177343-39-4 HCAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[3-[(3-nitro-2-pyridinyl)amino]phenyl]- (9CI) (CA INDEX NAME)





RN 177343-40-7 HCAPLUS  
 CN Urea, N-[3-[(3-amino-2-pyridinyl)amino]phenyl]-N'-(2-methoxyphenyl)- (9CI)  
 (CA INDEX NAME)



L39 ANSWER 50 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1995:998135 HCAPLUS  
 DN 124:176160  
 TI Preparation of CCK or gastrin modulating 5-heterocyclyl-1,5-benzodiazepinediones  
 IN Aquino, Christopher Joseph; Sugg, Elizabeth Ellen; Szewczyk, Jerzy Ryszard  
 PA Glaxo Wellcome Inc., USA  
 SO PCT Int. Appl., 71 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9528419	A1	19951026	1995WO-US04163	19950412 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA---2186900	AA	19951026	1995CA-2186900	19950412 <--
	AU---9522390	A1	19951110	1995AU-0022390	19950412 <--
	AU---697349	B2	19981001		
	ZA---9503005	A	19960320	1995ZA-0003005	19950412 <--
	EP---756602	A1	19970205	1995EP-0915540	19950412 <--
	EP---756602	B1	19990630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU-----76135	A2	19970630	1996HU-0002835	19950412 <--
	BR---9507381	A	19970923	1995BR-0007381	19950412 <--
	JP--09511223	T2	19971111	1995JP-0516406	19950412 <--
	CN---1176646	A	19980318	1995CN-0193582	19950412 <--
	AT---181737	E	19990715	1995AT-0915540	19950412 <--
	ES---2135722	T3	19991101	1995ES-0915540	19950412 <--
	CZ---286764	B6	20000614	1996CZ-0002972	19950412 <--
	RU---2152939	C1	20000720	1996RU-0121555	19950412 <--
	PL---180026	B1	20001229	1995PL-0316870	19950412 <--
	SK---281433	B6	20010312	1996SK-0001300	19950412 <--
	IL---113365	A1	19991130	1995IL-0113365	19950413 <--
	FI---9604045	A	19961009	1996FI-0004045	19961009 <--
	NO---9604348	A	19961202	1996NO-0004348	19961011 <--
	US---5739129	A	19980414	1996US-0722191	19961011 <--
PRAI	1994GB-0007433	A	19940414	<--	
	1994GB-0020783	A	19941014	<--	
	1995WO-US04163	W	19950412	<--	
OS	MARPAT 124:176160				
GI					




AB The title compds. [I; X = H, CF<sub>3</sub>, alkyl, alkylthio, alkoxy, halo; R<sub>1</sub> = Q, disubstituted NH<sub>2</sub>; R<sub>6</sub> = H, Me; R<sub>7</sub> = H, OH, F, dimethylamino, alkoxy, benzyloxy; R<sub>2</sub> = (un)substituted 2-heterocyclyl, Ph, or pyridyl, 7-indazolylamino, PhNH optionally substituted on Ph; R<sub>3</sub> = (un)substituted heterocyclyl] and physiol. salts thereof, which exhibit agonist activity for CCK-A receptors and thereby enable them to modulate the hormones gastrin and CCK in mammals, are prepared. Thus, a solution of 84 mg 2-(3-amino-7-fluoro-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxyphenyl)acetamide in 4 mL MeCN was combined with 59 mg tert-Bu 3-[(4-nitrophenyl)oxycarbonyl]aminobenzoate and heated under reflux for 3 h to give the title compound tert-Bu ester (II; R = tert-butyl), which was stirred with CF<sub>3</sub>CO<sub>2</sub>H for 1.5 h to give II.CF<sub>3</sub>CO<sub>2</sub>H (R = H). In guinea pig gall bladder contraction assay, the title compds. I at 1 μM gave 32-96% sulfated CCK-8 maximal response.

IT 173944-70-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of CCK- or gastrin-modulating heterocyclylbenzodiazepinediones as CCK-A receptor agonists)



RN 173944-70-2 HCAPLUS

CN Acetamide, N-(4-methoxyphenyl)-N-(1-methylethyl)-2-[[2-(2-pyridinylamino)phenyl]amino]- (9CI) (CA INDEX NAME)



DN 116:255492  
 TI Preparation of N-[(2-arylamino)aryl]benzenesulfonamides as antitumor agents  
 IN Yoshino, Hiroshi; Ueda, Norihiro; Sugumi, Hiroyuki; Niijima, Jun; Kotake, Yoshihiko; Okada, Toshimi; Koyanagi, Nozomu; Watanabe, Tatsuo; Asada, Makoto; et al.  
 PA Eisai Co., Ltd., Japan  
 SO Eur. Pat. Appl., 85 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP----472053	A2	19920226	1991EP-0113256	19910807 <--
	EP----472053	A3	19940810		
	EP----472053	B1	19980617		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	AT----167473	E	19980715	1991AT-0113256	19910807 <--
	US---5250549	A	19931005	1991US-0742618	19910808 <--
	JP--05039256	A2	19930219	1991JP-0199687	19910809 <--
	JP---2790926	B2	19980827		
	FI---9103815	A	19920221	1991FI-0003815	19910812 <--
	HU-----59663	A2	19920629	1991HU-0002676	19910812 <--
	NO---9103207	A	19920221	1991NO-0003207	19910816 <--
	NO----178695	B	19960205		
	NO----178695	C	19960515		
	AU---9182493	A1	19920227	1991AU-0082493	19910816 <--
	AU----636239	B2	19930422		
	CA---2049496	AA	19920221	1991CA-2049496	19910819 <--
	CA---2049496	C	19970204		
	CN---1059519	A	19920318	1991CN-0105827	19910819 <--
	CN---1036650	B	19971210		
	RU---2059615	C1	19960510	1991RU-5001370	19910820 <--
	US---5292758	A	19940308	1992US-0923345	19920731 <--
	US---5332751	A	19940726	1993US-0085962	19930630 <--
	US---5434172	A	19950718	1994US-0231272	19940422 <--
	CN---1136036	A	19961120	1995CN-0103522	19950317 <--
	US---5610320	A	19970311	1995US-0450138	19950526 <--
	US---5610304	A	19970311	1995US-0453058	19950526 <--
PRAI	1990JP-0218710	A	19900820	<--	
	1991JP-0038509	A	19910305	<--	
	1991JP-0121041	A	19910527	<--	
	1991US-0742618	A3	19910808	<--	
	1992US-0923345	A3	19920731	<--	
	1993US-0085962	A3	19930630	<--	
	1994US-0231272	A3	19940422	<--	
OS	MARPAT 116:255492				
GI					



AB Title compds. [I; A = N, CH; B = N, CR10; R = (substituted) Ph; R4, R7, R10 = H, alkyl; R5, R6 = H, halo, alkoxy, (substituted) amino; R8 = C(:X)R11, (substituted) Ph, pyridyl; R11 = H, alkyl, NH2, alkoxy, etc.; X = O, S] were prepared Thus, 2-chloro-3-nitropyridine was condensed with PhNH2 and the reduced product condensed with 4-MeC6H4SO2Cl to give title

compound II (R1 = Me, R9 = H). II (R1, R9 = MeO) gave 99% inhibition of colon 38 tumors in mice at 100 mg/kg/day orally for 21 days.


IT 141450-44-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of antitumor agents)

RN 141450-44-4 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[(3-amino-2-pyridinyl)amino]phenyl ester (9CI) (CA INDEX NAME)




IT 141431-18-7P 141449-92-5P 141449-93-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as antitumor agent)


RN 141431-18-7 HCAPLUS

CN Glycine, N-(2,2-dimethyl-1-oxopropyl)-, 4-[[3-[[4-methoxyphenyl)sulfonyl]amino]-2-pyridinyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 141449-92-5 HCAPLUS


CN Carbamic acid, dimethyl-, 4-[[3-[[4-methoxyphenyl)sulfonyl]amino]-2-pyridinyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 141449-93-6 HCAPLUS

CN Glycine, 4-[[3-[[4-methoxyphenyl)sulfonyl]amino]-2-pyridinyl]amino]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

L39 ANSWER 52 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:235443 HCAPLUS

DN 116:235443

TI Preparation of acetylcholinesterase-inhibiting 1-(substituted pyridinylamino)-1H-(indol-5-yl)carbamates as drugs for treatment of memory dysfunctions

IN Effland, Richard Charles; Davis, Larry; Olsen, Gordon Edward; Klein, Joseph Thomas; Wettlaufer, David Gordon; Nemoto, Peter Allen

PA Hoechst-Roussel Pharmaceuticals, Inc., USA

SO Eur. Pat. Appl., 44 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP----468401	A2	19920129	1991EP-0112237	19910722 <--
	EP----468401	A3	19920729		
	EP----468401	B1	19980916		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US---5102891	A	19920407	1990US-0555890	19900723 <--
	FI---9103502	A	19920124	1991FI-0003502	19910719 <--
	FI---102067	B1	19981015		
	CA---2047531	AA	19920124	1991CA-2047531	19910722 <--
	CA---2047531	C	20030107		
	NO---9102866	A	19920124	1991NO-0002866	19910722 <--
	NO---300132	B1	19970414		
	AU---9181216	A1	19920130	1991AU-0081216	19910722 <--
	AU---639581	B2	19930729		
	HU---58317	A2	19920228	1991HU-0002450	19910722 <--
	ZA---9105723	A	19920429	1991ZA-0005723	19910722 <--
	JP--04243878	A2	19920831	1991JP-0181210	19910722 <--
	JP--2564714	B2	19961218		
	IL---98920	A1	19950831	1991IL-0098920	19910722 <--
	CZ---283253	B6	19980218	1991CZ-0002281	19910722 <--
	AT---171176	E	19981015	1991AT-0112237	19910722 <--
	ES---2121761	T3	19981216	1991ES-0112237	19910722 <--
	KR---201515	B1	19990615	1991KR-0012579	19910723 <--
PRAI	1990US-0555890	A	19900723	<--	
OS	MARPAT 116:235443				
GI					



AB The title compds. [I; R1 = H, (aryl)alkyl, alkenyl, alkynyl, (aryl)alkanoyl, heteroarylalkyl, heteroarylalkanoyl; R2 = H, alkyl, CHO, cyano; R3 = H, alkyl; R4 = (cyclo)alkyl, aralkyl, heteroaryl; NR3R4 = pyrrolidino, piperidino, morpholino, etc.; X, Y = H, halo, NO2, amino, CF3, alkyl, alkoxy; n = 0, 1], their optical and geometrical stereoisomers and racemates and pharmaceutically acceptable salts, useful for the treatment of memory dysfunctions such as Alzheimer's disease, were prepared, e.g. by addition reaction of isocyanates with the appropriate indoles. Thus, 1-(N-propyl-4-pyridinylamino)-1H-indol-5-ol (preparation from 5-phenylmethoxyindole given) in THF was stirred with K2CO3 and MeNCO to give title compound II. II inhibited brain acetylcholinesterase with IC50 = 0.0023  $\mu$ M.


IT 141287-56-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of acetylcholinesterase inhibitors)

RN 141287-56-1 HCAPLUS

CN Carbamic acid, cyclohexyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




IT 141287-16-3P 141287-17-4P 141287-18-5P  
 141287-19-6P 141287-20-9P 141287-21-0P  
 141287-22-1P 141287-23-2P 141287-24-3P  
 141287-25-4P 141287-26-5P 141287-27-6P  
 141287-28-7P 141287-29-8P 141287-30-1P  
 141287-31-2P 141287-32-3P 141287-33-4P  
 141287-34-5P 141287-35-6P 141287-36-7P  
 141287-37-8P 141287-38-9P 141287-39-0P  
 141287-40-3P 141287-41-4P 141287-42-5P  
 141287-43-6P 141287-44-7P 141287-45-8P  
 141287-46-9P 141303-08-4P 141303-09-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as acetylcholinesterase inhibitor)

RN 141287-16-3 HCAPLUS


CN 1H-Indol-5-ol, 1-(methyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI)

(CA INDEX NAME)



RN 141287-17-4 HCAPLUS


CN Carbamic acid, butyl-, 1-(methyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 141287-18-5 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-(methyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-19-6 HCAPLUS

CN 1H-Indol-5-ol, 1-(propyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-20-9 HCAPLUS  
 CN Carbamic acid, ethyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester,  
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 141287-21-0 HCAPLUS  
 CN Carbamic acid, propyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester  
 (9CI) (CA INDEX NAME)



RN 141287-22-1 HCAPLUS  
 CN Carbamic acid, (1-methylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl  
 ester (9CI) (CA INDEX NAME)




RN 141287-23-2 HCAPLUS  
 CN Carbamic acid, butyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester,  
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-24-3 HCAPLUS  
 CN Carbamic acid, heptyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester  
 (9CI) (CA INDEX NAME)




RN 141287-25-4 HCAPLUS  
 CN Carbamic acid, cyclohexyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl  
 ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-26-5 HCAPLUS  
 CN Carbamic acid, (2-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-27-6 HCAPLUS  
 CN Carbamic acid, (2-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-28-7 HCAPLUS  
 CN Carbamic acid, (1-phenylethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 141287-29-8 HCAPLUS  
 CN Carbamic acid, dimethyl-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester  
 (9CI) (CA INDEX NAME)




RN 141287-30-1 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl  
 ester (9CI) (CA INDEX NAME)




RN 141287-31-2 HCAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1-(propyl-4-  
 pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-32-3 HCAPLUS  
CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-33-4 HCAPLUS  
CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141287-34-5 HCAPLUS  
CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-35-6 HCAPLUS  
CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester, monohydrochloride (9CI) (CA INDEX NAME)






● HCl


RN 141287-36-7 HCAPLUS  
 CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-37-8 HCAPLUS  
 CN 1H-Indol-5-ol, 3-methyl-1-(propyl-4-pyridinylamino)-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-38-9 HCAPLUS  
 CN Carbamic acid, butyl-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-39-0 HCAPLUS  
 CN Carbamic acid, heptyl-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 141287-40-3 HCAPLUS  
 CN Carbamic acid, (phenylmethyl)-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-41-4 HCAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 3-methyl-1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-42-5 HCAPLUS

CN 1H-Indol-5-ol, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-, methylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 141287-43-6 HCAPLUS

CN Carbamic acid, butyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-44-7 HCAPLUS

CN Carbamic acid, heptyl-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-45-8 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141287-46-9 HCAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1-[(3-fluoro-4-pyridinyl)propylamino]-3-methyl-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141303-08-4 HCAPLUS

CN Carbamic acid, (phenylmethyl)-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)




RN 141303-09-5 HCAPLUS  
 CN Carbamic acid, [(4-chlorophenyl)methyl]-, 1-(propyl-4-pyridinylamino)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



L39 ANSWER 53 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1990:7380 HCAPLUS  
 DN 112:7380  
 TI Preparation and testing of 3-aminobenzoyl phenylurea as insecticides and parasiticides  
 IN Maiefisch, Peter; Gehret, Jean Claude; Frei, Bruno  
 PA Ciba-Geigy A.-G., Switz.  
 SO Eur. Pat. Appl., 26 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP----320448	A2	19890614	1988EP-0810818	19881129 <--
	EP----320448	A3	19901010		
	EP----320448	B1	19941228		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US---4946854	A	19900807	1988US-0280061	19881205 <--
	CA---1329610	A1	19940517	1988CA-0585005	19881205 <--
	AU---8826612	A1	19890608	1988AU-0026612	19881206 <--
	AU---619228	B2	19920123		
	ZA---8809122	A	19890830	1988ZA-0009122	19881206 <--
	JP--02000252	A2	19900105	1988JP-0307062	19881206 <--
PRAI	1987CH-0004756	A	19871207	<--	
OS	MARPAT 112:7380				
GI					




AB The title compds. [I; R1, R2, R3, R7, R8, R9 = H, halo; R4 = H, R10CO, R11NHCO; R5, R6 = H, halo, (halo)alkyl; R10 = (substituted) C1-4 alkyl; R11 = (halo)alkyl, Ph; X = O, S, SO, SO2], useful as insecticides and parasiticides, were prepared. Thus, 2,6-dichloro-3-nitrobenzamide (preparation given) in CH2Cl2 was treated with (COCl)2 at room temperature and the mixture was refluxed 18 h to give 2,6-dichloro-3-nitrobenzoylisocyanate. The latter in CH2Cl2 was treated with 3-(3-chloro-5-trifluoromethylpyridyl-2-oxy)-4-chloroaniline and the mixture was stirred 18 h to give the corresponding urea, which was reduced with H/Rh/C in THF to give N-[3-(3-chloro-5-trifluoromethylpyridyl-2-oxy)-4-chlorophenyl]-N'-[2,6-dichloro-3-aminobenzoyl]urea. I were effective against *Fasciola hepatica* eggs at 7.5-750 ppm.

IT 124169-33-1P 124169-60-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as insecticide and parasiticide)


RN 124169-33-1 HCAPLUS

CN Benzamide, 3-amino-N-[[[4-chloro-3-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 124169-60-4 HCAPLUS

CN Benzamide, 3-amino-N-[[[3-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-4-methylphenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




IT 124169-66-0P 124169-67-1P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for insecticide and parasiticide)

RN 124169-66-0 HCAPLUS

CN Benzamide, N-[[[3-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-4-methylphenyl]amino]carbonyl]-2,6-difluoro-3-nitro- (9CI) (CA INDEX NAME)





RN 124169-67-1 HCAPLUS  
 CN Benzamide, N-[[[4-chloro-3-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]-2,6-difluoro-3-nitro- (9CI) (CA INDEX NAME)



L39 ANSWER 54 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1989:496975 HCAPLUS  
 Correction of: 1984:209516  
 DN 111:96975  
 Correction of: 100:209516  
 TI Cephalosporin derivatives  
 IN Wetzel, Bernd; Woitun, Eberhard; Reuter, Wolfgang; Maier, Roland; Lechner, Uwe; Goeth, Hanns  
 PA Boehringer Ingelheim International G.m.b.H., Fed. Rep. Ger.  
 SO U.S., 48 pp. Cont.-in-part of U.S. Ser. No. 163,194, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---4415566	A	19831115	1980US-0191423	19800926 <--
PRAI	1979DE-2938344	A	19790713	<--	
	1980US-0163194	A2	19800626	<--	
OS	MARPAT 111:96975				
GI					




AB Cephalosporins I [R = heterocyclyl; R1 = cyclohexyl, cyclohexenyl, cyclohexadienyl, thienyl, furyl, (un)substituted Ph; R2 = heterocyclylthio; R3 = H, protective group; n = 0, 1] were prepared Thus II was obtained by treating the aminocephem with the ureidoacetic acid obtained by reaction of 4-HOC6H4CH(NH2)CO2H, COCl2, and 3-pyridinemethanamine. II had a min. inhibitory concentration of 0.12 µg/mL against Escherichia coli ATCC 11775. Penicillin analogs of I were similarly prepared

IT 90061-19-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and acylation of, aminocephem by)

RN 90061-19-1 HCAPLUS

CN Benzeneacetic acid, α-[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 77962-43-7P 77962-51-7P 90129-84-3P

90129-85-4P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77962-43-7 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[1,4-dihydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]carbonyl]amino] (4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2α,5α,6β(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 77962-51-7 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S\*)]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 90129-84-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, monosodium salt, [6R-(6 $\alpha$ ,7 $\beta$ )]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 90129-85-4 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-7-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-8-oxo-, monosodium salt, [6R-(6 $\alpha$ ,7 $\beta$ )]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 55 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:510042 HCAPLUS

DN 109:110042

TI Benzoylureas, a process for their production, and pesticidal formulations containing them

IN Haga, Takahiro; Toki, Tadaaki; Koyanagi, Toru; Fujii, Yasuhiro; Yoshida, Kiyomitsu; Imai, Osamu

PA Ishihara Sangyo Kaisha, Ltd., Japan

SO Eur. Pat. Appl., 52 pp.


CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP----263438	A2	19880413	1987EP-0114341	19871001 <--
	EP----263438	A3	19890315		
	EP----263438	B1	19920715		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP--63099055	A2	19880430	1987JP-0240142	19870925 <--
	JP--63222154	A2	19880916	1987JP-0240143	19870925 <--
	JP--63307852	A2	19881215	1987JP-0240144	19870925 <--
	CN--87106674	A	19880817	1987CN-0106674	19870929 <--
	CN--1023006	B	19931208		
	AU--8779234	A1	19880414	1987AU-0079234	19870930 <--
	AU--594199	B2	19900301		
	JP--01085966	A2	19890330	1987JP-0244162	19870930 <--
	JP--08019081	B4	19960228		
	US--4861799	A	19890829	1987US-0102855	19870930 <--
	DD--281378	A5	19900808	1987DD-0307508	19871001 <--
	ES--2051719	T3	19940701	1987ES-0114341	19871001 <--
	DK--8705189	A	19880404	1987DK-0005189	19871002 <--
	DK--169151	B1	19940829		
	BR--8705244	A	19880524	1987BR-0005244	19871002 <--
	ZA--8707421	A	19880629	1987ZA-0007421	19871002 <--
	PL--153343	B1	19910430	1987PL-0268033	19871002 <--
	RU--2032343	C1	19950410	1987RU-4203447	19871002 <--
	CA--1340938	A1	20000328	1987CA-0548485	19871002 <--
	US--4985449	A	19910115	1989US-0365607	19890613 <--
PRAI	1986JP-0235857	A	19861003	<--	
	1987JP-0056006	A	19870311	<--	
	1987JP-0141214	A	19870605	<--	
	1987US-0102855	A3	19870930	<--	
OS	CASREACT 109:110042; MARPAT 109:110042				
GI					



I



III


AB Pesticidal benzoylureas I [X1, X2 = H, halo, Me; both X1 and X2 ≠ H; Y = H, halo, (halo)alkyl, CO2R1, OR1 (R1 = H, cation, alkyl); A1 = N, CY; W = O, S, NR1; k = 1-3; p = 0, 1; Z = H, halo, (halo)alkyl, (halo)alkoxy, NO2, cyano, S(O)nR2 [n = 0-2; R2 = (halo)alkyl]; A2 = S, N:CZ, ZC:CZ; m = 1-3] are prepared 4-Amino-4'-bromobiphenyl was acylated with AcCl, N-methylated using NaH and MeI in Me2SO, and deacetylated with concentrated HCl in MeOH, to give 4-bromo-4'-(methylamino)biphenyl (II). Reaction of II with 2,6-F2C6H3NCO in dioxane at room temperature gave (bromobiphenyl)(difluorobenzoyl)methylurea III. At 0.04 ppm III gave ≥90% kill of Spodoptera litura; the demethylated analog required 0.6 ppm for the same effect. An emulsifiable concentrate contained III 5, DMF 5, polyoxyethylene alkylaryl ether 10, and xylene 80 parts by weight

IT 115704-74-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pesticide)

RN 115704-74-0 HCAPLUS

CN Benzamide, N-[[[4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methylamino]phenyl]methylamino]carbonyl]-2,6-difluoro- (9CI)  
(CA INDEX NAME)



L39 ANSWER 56 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1985:487832 HCAPLUS

DN 103:87832

TI Reactions of ethyl 4-chloro-5-pyrimidinecarboxylates with 2-aminopyridine. Synthesis of 5H-pyrido[1,2-a]pyrimido[5,4-e]pyrimidin-5-ones and 5H-pyrido[1,2-a]pyrimido[4,5-d]pyrimidin-5-ones and rearrangement of the former to the latter

AU Kim, Dong Han

CS Res. Div., Wyeth Lab., Inc., Philadelphia, PA, 19101, USA

SO Journal of Heterocyclic Chemistry (1985), 22(1), 173-6


CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

OS CASREACT 103:87832

GI



AB Title compds. I and II (R = MeS, Ph) were synthesized from pyrimidinecarboxylates III and 2-aminopyridine. I were obtained directly upon heating the reactants in ethanol, and the latter were prepared by the fusion of Et 4-(2-pyridylamino)-5-pyrimidinecarboxylates obtained as minor products from the above reaction. Heating II (R = MeS) with morpholine gave II (R = morpholino).

IT 115927-82-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 115927-82-7 HCAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(diethylamino)ethyl]-2-[[2-(diethylamino)ethyl]amino]-4-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



AN 1984:209516 HCAPLUS

DN 100:209516

TI Cephalosporin derivatives

IN Wetzell, Bernd; Woitun, Eberhard; Reuter, Wolfgang; Maier, Roland; Lechner, Uwe; Goeth, Hanns

PA Boehringer Ingelheim International G.m.b.H., Fed. Rep. Ger.

SO U.S., 48 pp. Cont.-in-part of U.S. Ser. No. 163,194, abandoned.

CODEN: USXXAM

DT Patent

LA English

PATENT NO.

KIND

DATE \_\_\_\_\_

APPLICATION NO.

DATE \_\_\_\_\_

PI US---4415566 A



198311151980US-0191423

19800926

PRAI 1979DE-2938344 19790713

1980US-0163194 19800626

GI




AB Cephalosporins I (R = heterocyclic; R1 = Ph, substituted Ph, cyclohexyl, cyclohexenyl, cyclohexadienyl, thienyl, furyl, R2 = heterocyclylthio; R3 = H, protective group; n = 0, 1) were prepared. Thus II was obtained by treating the aminocephem with the ureidoacetic acid obtained from 4-HOC6H4CH(NH2)CO2H, COCl2, and 3-pyridylmethylamine. II had a min. inhibitory concentration against *Escherichia coli* ATCC 11775 of 0.12 µg/mL. Penicillin analogs of I were similarly prepared.

IT 90061-19-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and acylation of aminocephem by)

RN 90061-19-1 HCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 77962-43-7P 77962-51-7P 90129-84-3P


90129-85-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77962-43-7 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[1,4-dihydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 77962-51-7 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 90129-84-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, monosodium salt, [6R-(6 $\alpha$ ,7 $\beta$ )]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 90129-85-4 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-7-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-8-oxo-, monosodium salt, [6R-(6 $\alpha$ ,7 $\beta$ )]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 58 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:120899 HCAPLUS

DN 100:120899

TI N-benzoyl-N'-phenylurea compounds

PA Ishihara Sangyo Kaisha, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 5 pp.



CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--58185563	A2	19831029	1982JP-0068242	19820423 <--
PRAI	1982JP-0068242		19820423	<--	
GI					



AB Fifteen N-benzoyl-N'-phenylurea compds. I (R = H, alkyl, alkenyl, acyl; R1, R2 = halo, alkyl, alkoxy, CF3, alkenyl, cyano, CO2H, alkoxy carbonyl; R3 = halo, CF3; l, m, n = 0-2) were prepared by reaction of R1lC6H5-lCONCO (II) with III. Insecticidal test data of I were shown against *Plutella maculipennis*, *Prodenia litura*, and *Culex pipiens*. Thus, reaction of 0.6 g II (R1l = 2-Cl) with 1.3 g III (R = Me3CCO, R2m = 3-Cl, R3n = 5-F3C) in dioxane 4 h at room temperature gave 1.1 g I (R = Me3CCO, R1l = 2-Cl, R2m = 3-Cl, R3n = 5-F3C).

IT 89245-43-2P 89245-44-3P 89245-45-4P  
 89245-46-5P 89245-47-6P 89245-48-7P  
 89245-49-8P 89245-50-1P 89245-51-2P




89245-55-6P 89245-56-7P 89245-57-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and insecticidal activity of)


RN 89245-43-2 HCAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[(2,2-dimethyl-1-oxopropyl)[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 89245-44-3 HCAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 89245-45-4 HCAPLUS

CN Benzamide, N-[[[3-chloro-4-[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 89245-46-5 HCAPLUS


CN Benzamide, 2-chloro-N-[[[3-chloro-4-[ethyl[5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 89245-47-6 HCAPLUS


CN Benzamide, N-[[[3-chloro-4-[(2,2-dimethyl-1-oxopropyl)[5-(trifluoromethyl)-

2-pyridinyl]amino]phenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 89245-48-7 HCAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[(1-oxohexadecyl) [5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 89245-49-8 HCAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[(2-methyl-2-propenyl) [5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 89245-50-1 HCAPLUS


CN Benzamide, 2-chloro-N-[[[3-chloro-4-[(1-oxopropyl) [5-(trifluoromethyl)-2-pyridinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 89245-51-2 HCAPLUS


CN Benzamide, N-[[[3-chloro-4-[[3-chloro-5-(trifluoromethyl)-2-

pyridinyl]amino]phenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 89245-55-6 HCAPLUS

CN Benzamide, N-[[[4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-2-methylphenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 89245-56-7 HCAPLUS

CN Benzamide, N-[[[5-chloro-4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-2-methylphenyl]amino]carbonyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 89245-57-8 HCAPLUS

CN Benzoic acid, 2-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-5-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L39 ANSWER 59 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:79557 HCAPLUS

DN 100:79557

TI Induction of petite mutants in yeast by nonintercalative DNA-binding antitumor agents

AU Ferguson, Lynnette R.; Baguley, Bruce C.

CS Med. Sch., Univ. Auckland, Auckland, N. Z.

SO European Journal of Cancer & Clinical Oncology (1983), 19(11), 1575-83

CODEN: EJCODS; ISSN: 0277-5379

DT Journal

LA English

AB A series of 17 bis-charged nonintercalative DNA-binding antitumor agents and 7 related inactive compds. have been tested for the induction of respiratory deficient (petite) mutants in *Saccharomyces cerevisiae* D5. Many compds. were strong inducers of petite mutants at concns. which were not toxic to the growth of the yeast cells. Mutagenicity is only weakly correlated with in vitro inhibition of L1210 cell growth; however, mutagenicity, yeast toxicity and in vitro and in vivo antitumor activity are all correlated with selective binding to polydeoxy(adenylic-thymidylic) acid [26966-61-0] rather than polydeoxy(guanylic-cytidylic) acid [36786-90-0]. Thus, A-T-rich DNA may be a target for all the biol. effects measured in this study. Furthermore, the possibility that the target for antitumor action may be tumor cell mitochondrial DNA is supported by these results.

IT 81944-20-9


RL: BIOL (Biological study)

(petite mutants in *Saccharomyces cerevisiae* induction by, DNA binding and antitumor activity in relation to)


RN 81944-20-9 HCAPLUS

CN Quinolinium, 1-methyl-4-[[4-[[5-[[4-[[1-methylpyridinium-4-yl)amino]phenyl]amino]-1,5-dioxopentyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L39 ANSWER 60 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:400302 HCAPLUS

DN 97:302

TI A comparison of the requirements for antitumor activity and antibacteriophage lambda activity for a series of nonintercalative DNA-binding agents

AU Robertson, Iain G. C.; Baguley, Bruce C.

CS Dep. Cell Biol., Univ. Auckland, Auckland, N. Z.

SO European Journal of Cancer & Clinical Oncology (1982), 18(3), 271-9

CODEN: EJCODS; ISSN: 0277-5379

DT Journal

LA English

AB A series of nonintercalative DNA-binding agents, comprising mainly bisquaternary ammonium heterocyclic compds., inhibit strongly the production of bacteriophage lambda following its induction in Escherichia coli. The inhibition is much greater than that found with a number of DNA intercalating agents, including 9-aminoacridine, ethidium, and Daunorubicin. The inhibition correlated with antitumor effect, as measured in a life extension assay with L1210 leukemia. Activity in both biol. systems demanded the presence of strongly charged groups and a rigid coplanar aromatic skeleton, these requirements being almost identical to those needed to displace ethidium efficiently from DNA in a simple assay system. Biol. activity may be associated with the ability of these agents to bind in the minor groove of the DNA double helix. Previous data on the antibacteriophage action of one of these agents suggests possible models for antitumor activity.

IT 81944-21-0

RL: BIOL (Biological study)

(bacteriophage  $\lambda$  and neoplasm inhibition by, structure in relation to)

RN 81944-21-0 HCAPLUS


CN Quinolinium, 1-methyl-4-[[4-[[5-[[4-[(1-methylpyridinium-4-yl)amino]phenyl]amino]-1,5-dioxopentyl]amino]phenyl]amino]-, salt with 4-methylbenzenesulfonic acid (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 81944-20-9

CMF C33 H34 N6 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 16722-51-3


CMF C7 H7 O3 S



L39 ANSWER 61 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 1982:181110 HCAPLUS  
DN 96:181110  
TI Metal-chelating 1,3-bis(2-pyridylimino)isoindolines  
AU Siegl, Walter O.

noble jarrell 16/08/2006

CS Ford Motor Co., Dearborn, MI, 48121, USA  
 SO Journal of Heterocyclic Chemistry (1981), 18(8), 1613-18  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 96:181110  
 GI




AB A variety of novel chelating 1,3-bis(2-pyridylimino)isoindoline ligands, e.g. I, were prepared by reaction of phthalonitriles or 1,3-diiminoisoindolines with 2-aminopyridines and characterized including ligands substituted on both the pyridyl and isoindoline ring systems. Noteworthy are the 1st isoindoline ligands with solubility in aqueous media. A convenient preparation of 4-alkoxyphthalonitriles is reported; these compds. are readily obtained from 4-nitrophthalonitrile and are suitable starting materials for alkoxy-substituted ligands.

IT 81560-28-3P 81560-29-4P 81560-30-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 81560-28-3 HCAPLUS


CN 1H-Isoindol-3-amine, 5-[2-(dimethylamino)ethoxy]-N-(4-methyl-2-pyridinyl)-1-[(4-methyl-2-pyridinyl)imino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 81560-29-4 HCAPLUS


CN Ethanaminium, N-ethyl-N,N-dimethyl-2-[[3-[(4-methyl-2-pyridinyl)amino]-1-[(4-methyl-2-pyridinyl)imino]-1H-isoindol-5-yl]oxy]-, iodide (9CI) (CA INDEX NAME)

● I<sup>-</sup>

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 81560-30-7 HCAPLUS

CN Ethanaminium, N,N,N-trimethyl-2-[[3-[(4-methyl-2-pyridinyl)amino]-1-[(4-methyl-2-pyridinyl)imino]-1H-isoindol-5-yl]oxy]-, chloride (9CI) (CA INDEX NAME)

● Cl<sup>-</sup>

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 62 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:516041 HCAPLUS

DN 95:116041

TI Polymeric chelating ligands derived from 1,3-bis(2'-pyridylimino)isoindolines

AU Siegl, Walter O.

CS Eng. Res. Staff, Ford Motor Co., Dearborn, MI, 48121, USA

SO Chemistry &amp; Industry (London, United Kingdom) (1981), (8), 291-2


CODEN: CHINAG; ISSN: 0009-3068

DT Journal


LA English

GI





- AB 4-Nitrophthalonitrile [31643-49-9] underwent  $\text{CaCl}_2$ -facilitated condensation with 2-amino-4-methylpyridine [695-34-1] to give 79% of the isoindoline derivative I ( $\text{R} = \text{NO}_2$ ) [78696-54-5], which on reduction with  $\text{H}$  (60 psi  $\text{H}$ ,  $\text{EtOH}$ , 10%  $\text{Pd/C}$ ,  $25^\circ$ ) gave 90% I ( $\text{R} = \text{NH}_2$ ) (II) [78696-55-6]. Treatment of II with a chlorosulfonated styrene-divinylbenzene copolymer led to a maximum loading of 15% based on the N:S ratio. II with  $\text{CH}_2:\text{CMeCOCl}$  [920-46-7] and  $\text{CH}_2:\text{CMeCO}_2(\text{CH}_2)_2\text{NCO}$  [30674-80-7] gave 68% I ( $\text{R} = \text{NHCOCMe:CH}_2$ ) (III) [78696-56-7] and 67% I [ $\text{R} = \text{NHCONH}(\text{CH}_2)_2\text{O}_2\text{CCMe:CH}_2$ ] (IV) [78696-57-8], resp. III and IV polymerized in DMF at  $60\text{--}70^\circ$  to give 65% III homopolymer [78705-29-0] and 86% IV homopolymer [78705-30-3], resp. The 2 homopolymers reacted with  $\text{Cu}^{2+}$  to give complexes in which 94 and 77% of the chelating sites, resp., were occupied by  $\text{Cu}^{2+}$ .
- IT 78696-57-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and polymerization of)
- RN 78696-57-8 HCAPLUS
- CN 2-Propenoic acid, 2-methyl-, 2-[[[3-[(4-methyl-2-pyridinyl)amino]-1-[(4-methyl-2-pyridinyl)imino]-1H-isoindol-5-yl]amino]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

- IT 78705-30-3DP, copper complexes 78705-30-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)
- RN 78705-30-3 HCAPLUS
- CN 2-Propenoic acid, 2-methyl-, 2-[[[3-[(4-methyl-2-pyridinyl)amino]-1-[(4-methyl-2-pyridinyl)imino]-1H-isoindol-5-yl]amino]carbonyl]amino]ethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 78696-57-8

CMF C27 H27 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 78705-30-3 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[[3-[(4-methyl-2-pyridinyl)amino]-1-[(4-methyl-2-pyridinyl)imino]-1H-isoindol-5-yl]amino]carbonyl]amino]ethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 78696-57-8

CMF C27 H27 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 63 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:425097 HCAPLUS

DN 95:25097

TI Beta-lactam compounds and therapeutic agents containing them

IN Wetzels, Bernd; Woitun, Eberhard; Reuter, Wolfgang; Maier, Roland; Lechner, Uwe; Goeth, Hanns

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 61 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

PATENT NO.




KIND

DATE

APPLICATION NO.

DATE

PI	EP----	22494	A1	19810121	1980EP-0103612	19800626 <--
	EP----	22494	B1	19830223		
	R:	AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	DE---	2928344	A1	19810205	1979DE-2928344	19790713 <--
	AT-----	2621	E	19830315	1980AT-0103612	19800626 <--
	DD----	151941	C	19811111	1980DD-0222305	19800701 <--
	DK---	8003025	A	19810114	1980DK-0003025	19800711 <--
	FI---	8002227	A	19810114	1980FI-0002227	19800711 <--
	NO---	8002086	A	19810114	1980NO-0002086	19800711 <--
	AU---	8060361	A1	19810115	1980AU-0060361	19800711 <--
	AU----	539009	B2	19840906		
	JP---	56015292	A2	19810214	1980JP-0094949	19800711 <--
	ES----	493307	A1	19811001	1980ES-0493307	19800711 <--
	ZA---	8004203	A	19820331	1980ZA-0004203	19800711 <--
	CA---	1146542	A1	19830517	1980CA-0355988	19800711 <--
	HU----	25572	O	19830728	1980HU-0001749	19800711 <--
	HU----	183177	B	19840428		
	IL-----	60547	A1	19831130	1980IL-0060547	19800711 <--
	ES----	502528	A1	19820401	1981ES-0502528	19810527 <--
	ES----	502529	A1	19820401	1981ES-0502529	19810527 <--
PRAI	1979DE-	2928344	A	19790713	<--	
	1980EP-	0103612	A	19800626	<--	
GI						



AB Lactams I and II (R = optionally substituted heterocyclic; R1 = optionally substituted Ph, thienyl, furyl, optionally unsatd. cyclohexyl; R2 = H, protective group; R3 = H, OH, OAc, O2CNH2, pyridinium, 4-carbamoylpyridinium, heterocyclylthio; n = 0, 1) were prepared. Thus amoxycillin was treated with COCl2 and the aminopyrimidine III to give 79% I (R = 3-pyridyl, R1 = 4-HOC6H4, R2 = Na, n = 1) which had a min. inhibitory concentration against Escherichia coli ATCC 9637 of 0.5 µg/mL.


IT **77962-13-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and acylation of aminocephem and aminopenam by)

RN 77962-13-1 HCAPLUS

CN Benzeneacetic acid, α-[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino]-4'-hydroxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 77962-43-7P 77962-45-9P 77962-51-7P


77968-92-4P 77968-93-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77962-43-7 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[1,4-dihydro-4-oxo-2-(2-pyridinylamino)-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 77962-45-9 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[2-[(1,6-dihydro-6-oxo-2-pyridinyl)amino]-1,4-dihydro-4-oxo-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 77962-51-7 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 77968-92-4 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, monosodium salt, [6R-[6 $\alpha$ ,7 $\beta$ (R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 77968-93-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-7-[[[[[1,4-dihydro-4-oxo-2-[(1,2,3,6-tetrahydro-2,6-  
dioxo-4-pyrimidinyl)amino]-5-pyrimidinyl]amino]carbonyl]amino](4-  
hydroxyphenyl)acetyl]amino]-8-oxo-, monosodium salt, [6R-  
[6 $\alpha$ ,7 $\beta$ (R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L39 ANSWER 64 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:57955 HCAPLUS

DN 94:57955

TI Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]-  
and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinodiamines

AU Elslager, Edward F.; Hess, Carolyn; Johnson, Judith; Ortwine, Daniel; Chu,  
Vera; Werbel, Leslie M.


CS Pharm. Res. Div., Warner-Lambert/Parke Davis, Ann Arbor, MI, 48106, USA

SO Journal of Medicinal Chemistry (1981), 24(2), 127-40

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English  
OS CASREACT 94:57955  
GI




AB The title compds. I (R = H, Cl, NH<sub>2</sub>, NO<sub>2</sub>, etc.; R<sub>1</sub> = substituted Ph, heterocyclic, or dialkylaminoalkyl; R<sub>2</sub> = dialkylaminoalkyl, substituted heterocyclic, or substituted Ph) were prepared by stepwise reactions from either 2,4-dichloroquinazoline [607-68-1] or 2-chloro-4-quinazolinol [607-69-2], and tested in mice for antimalarial activity. N2-(3,4-Dichlorophenyl)-N4-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2,4-quinazolinediamine-2HCl [76004-48-3] was among the more active compds. Structure-activity relations are discussed.

IT **76005-07-7P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and antimalarial activity of)

RN 76005-07-7 HCAPLUS

CN 2,4-Quinazolinediamine, N2-4-pyridinyl-N4-[3-(1-pyrrolidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L39 ANSWER 65 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1979:66509 HCAPLUS

DN 90:66509

TI Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles

AU Denny, William A.; Atwell, Graham J.; Baguley, Bruce C.; Cain, Bruce F.

CS Exp. Chemother. Res. Lab., New Zealand Cancer Soc., Auckland, N. Z.

SO Journal of Medicinal Chemistry (1979), 22(2), 134-50  
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB Quant. relations between physicochem. drug properties and antileukemic (L1210) efficacy were examined for a series of bisquaternary ammonium heterocycles employing multiple variable regression anal. The synthesis of these compds. is described. The drug dose necessary to provide a 40%

increase in life span and the chemotherapeutic index were independent of toxicity. There was a parabolic relation between agent lipophilic-hydrophilic balance and the percentage increase in mean life span of leukemic animals at the LD10 dose. Relative levels of drug-DNA interaction were obtained by spectrofluorimetric quantitation of drug displacement of DNA-bound ethidium. Extensive quant. structure-activity relations are discussed.

IT 50309-29-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(antileukemic activity of)

RN 50309-29-0 HCAPLUS


CN Quinolinium, 6-amino-1-methyl-4-[[[4-[[[4-[(1-methylpyridinium-4-yl)amino]phenyl]amino]carbonyl]amino]phenyl]amino]-, salt with 4-methylbenzenesulfonic acid (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 50576-42-6

CMF C29 H29 N7 O

PAGE 1-A



PAGE 2-A






CM 2

CRN 16722-51-3

CMF C7 H7 O3 S



L39 ANSWER 66 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:542784 HCAPLUS

DN 85:142784

TI Substituted N-arylanilines

IN Schulenberg, John W.

PA Sterling Drug Inc., USA

SO U.S., 14 pp. Division of U.S. 3,625,972.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---3960886	A	19760601	1970US-0091515	19701120 <--
	US---3625972	A	19711207	1968US-0742161	19680703 <--
PRAI	1968US-0742161	A3	19680703		<--

AB PhNR1R2 [R1, R2 = e.g., Ph, 4-(2-morpholinoethoxy)phenyl, 4-MeOC6H4, 4-[Me2N(CH2)3O]C6H4, 2-MeC6H4CO, 2,4-(MeO)2C6H3CO, R3C6H4CO, R3 = 4-Me2N(CH2)2O, 4-[2-(1-pyrrolidinyl)ethoxy]] (.apprx.70 compds.), with hypocholesteremic activity in doses of 100 mg/kg/day, were prepared via alkylation, acylation, and reduction reactions. Thus, 4-(Me2NCH2CH2)C6H4NPhCOC6H4Cl-4, prepared by acylation of 4-(Me2NCH2CH2)C6H4NPh with 4-ClC6H4COX (X = Cl or Br), was reduced with diborane in THF to give PhN(CH2C6H4Cl-4)C6H4(OCH2CH2NMe2)-4.

IT 60709-37-7P 60709-75-3P 60710-27-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 60709-37-7 HCAPLUS

CN 2-Pyridinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 60709-75-3 HCAPLUS

CN Benzamide, N-[4-[2-(dimethylamino)ethoxy]phenyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 60710-27-2 HCAPLUS  
 CN 2-Pyridinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-N-(phenylmethyl)-  
 (9CI) (CA INDEX NAME)



L39 ANSWER 67 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1975:443373 HCAPLUS  
 DN 83:43373  
 TI (Phenylamino)pyrimidine pharmaceuticals  
 IN Fauran, Claude; Bourgerie, Guy; Raynaud, Guy; Gouret, Claude  
 PA Delalande S. A., Fr.  
 SO Ger. Offen., 49 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE---2444426	A1	19750327	1974DE-2444426	19740917 <--
	FR---2244459	A1	19750418	1973FR-0033831	19730920 <--
	FR---2265386	A2	19751024	1974FR-0010327	19740326 <--
	FR---2265386	B2	19780929		
	BE---819057	A1	19750221	1974BE-0147794	19740821 <--
	CH---593266	A	19771130	1974CH-0011401	19740821 <--
	GB---1430729	A	19760407	1974GB-0037550	19740828 <--
	US---3978055	A	19760831	1974US-0502285	19740903 <--
	ES---429869	A1	19761001	1974ES-0429869	19740907 <--
	ZA---7405741	A	19751029	1974ZA-0005741	19740910 <--
	JP--50088079	A2	19750715	1974JP-0105900	19740913 <--
	AU---7473441	A1	19760325	1974AU-0073441	19740918 <--
	CA---1008074	A1	19770405	1974CA-0209631	19740918 <--
	SE---7411806	A	19750321	1974SE-0011806	19740919 <--
	SE---410600	B	19791022		
	NL---7412494	A	19750324	1974NL-0012494	19740920 <--
	US---4025514	A	19770524	1976US-0714472	19760816 <--
	US---4041030	A	19770809	1976US-0714473	19760816 <--
	SU---698531	D	19791115	1977SU-2558803	19771228 <--
PRAI	1973FR-0033831	A	19730920	<--	
	1974FR-0010327	A	19740326	<--	
	1974US-0502285	A2	19740903	<--	
	1976FR-0020775	A	19760707	<--	

GI For diagram(s), see printed CA Issue.


AB Pyrimidines I (R = Ph, 4-ClC6H4, 3-FC6H4, 3-F3CC6H4, 3,4-methylenedioxypheyl, 3,4,5-(MeO)3C6H2; R1 = 4-CONH2, 4-substituted carbamoyl, 2-carboxylic ester, 2-CONH2, 4-CO2Et, 4-aminoethoxy) (77 compds.) were prepared. Thus, I [R = 3,4,5-(MeO)3C6H2, R1 = 4-pyrrolidinylcarbonyl] was obtained by treating the 4-chloropyrimidine with 4-pyrrolidinocarbonylaniline. Various I demonstrated sedative, antihypotensive, antiulcer, vasodilator, bronchodilator, diuretic, antihypertensive, pos. inotropic, analgesic, muscle relaxant, and antiinflammatory activities.

IT 56302-92-2P 56303-02-7P 56303-03-8P  
 56303-05-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and analgesic activity of)


RN 56302-92-2 HCAPLUS

CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-phenyl-  
(9CI) (CA INDEX NAME)




RN 56303-02-7 HCAPLUS

CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(3-fluorophenyl)-  
6-methyl- (9CI) (CA INDEX NAME)




RN 56303-03-8 HCAPLUS

CN 4-Pyrimidinamine, 2-(3-chlorophenyl)-N-[4-[2-(dimethylamino)ethoxy]phenyl]-  
6-methyl- (9CI) (CA INDEX NAME)



RN 56303-05-0 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 56303-01-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and antiinflammatory activity of)

RN 56303-01-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT	56302-93-3P 56302-94-4P 56302-96-6P 56302-97-7P 56302-99-9P 56303-06-1P 56303-07-2P 56303-08-3P 56328-03-1P
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and pharmacological activity of)
RN	56302-93-3 HCAPLUS
CN	4-Pyrimidinamine, N- [4- [2- (dipropylamino)ethoxy]phenyl] -6-methyl-2-phenyl- monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 56302-94-4 HCAPLUS  
CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-  
(9CI) (CA INDEX NAME)



RN 56302-96-6 HCAPLUS  
CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 56302-97-7 HCAPLUS  
CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl-  
(9CI) (CA INDEX NAME)




RN 56302-99-9 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 56303-06-1 HCAPLUS

CN 4-Pyrimidinamine, 2-(3-chlorophenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 56303-07-2 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 56303-08-3 HCAPLUS

CN 4-Pyrimidinamine, 2-(1,3-benzodioxol-5-yl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 56328-03-1 HCAPLUS

CN 4-Pyrimidinamine, 2-(3-fluorophenyl)-6-methyl-N-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 56302-95-5P 56302-96-6P 56303-00-5P  
 56303-04-9P 56303-09-4P 56303-10-7P  
 56303-11-8P 56303-12-9P 56303-13-0P  
 56303-14-1P 56303-15-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 56302-95-5 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-[4-[2-(1-piperidinyl)ethoxy]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 56302-96-6 HCAPLUS

CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-(3,4,5-  
 trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 56303-00-5 HCAPLUS

CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-[3-  
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 56303-04-9 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-(3,4,5-  
 trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 56303-09-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(3-fluorophenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 56303-10-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-methoxyphenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 56303-11-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 56303-12-9 HCAPLUS

CN 4-Pyrimidinamine, 2-[4-(dimethylamino)phenyl]-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 56303-13-0 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-[2-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 56303-14-1 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl-  
(9CI) (CA INDEX NAME)



RN 56303-15-2 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-[4-[3-(4-morpholinyl)propoxy]phenyl]-2-phenyl-  
(9CI) (CA INDEX NAME)



L39 ANSWER 68 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:542776 HCAPLUS

DN 79:142776

TI Potential antitumor agents. 13. Bisquaternary salts

AU Atwell, G. J.; Cain, B. F.

CS Cancer Chemother. Lab., Cornwall Geriatr. Hosp., Auckland, N. Z.

SO Journal of Medicinal Chemistry (1973), 16(6), 673-8

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB 4-Anilinoquinolinium compounds bearing any of a number of quaternary N substituents on the phenyl ring were active in mice against L1210 leukemia. Activity was enhanced by the electron-donor substituents such as an amino group on the quinoline nucleus, as in 6-amino-1-ethyl-4-[p-[p-[(1-ethylpyridinium-4-yl)amino]phenyl]carbamoyl]anilino]quinolinium dibromide (I) [42013-69-4], or by a 7-nitro group. I at 0.67 mg/kg/day i.p. for 5 days, given to mice inoculated i.p. with 105 L1210 cells 1 day previously, increased the life span by 40% and 2 out of 6 inoculated mice survived for 100 days when treated with 6.7 mg I/kg/day for 5 days. This survival indicated a lower toxicity of I (and of several related compds. tested) and of some bisquaternary antileukemics reported previously. I was prepared by condensation of 4-chloro-1-ethyl-6-nitroquinolinium [42013-70-7], prepared from 6-nitro-4-hydroxyquinoline [23432-42-0], with 1-ethyl-4-[4-(4-aminobenzamido)anilino]pyridinium [42013-72-9], followed by a reduction of the NO<sub>2</sub> group to NH<sub>2</sub>.

IT 50309-28-9P 50309-29-0P 50440-45-4P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and antitumor activity of)

RN 50309-28-9 HCAPLUS


CN Quinolinium, 1-methyl-4-[[4-[[[4-[(1-methylpyridinium-4-yl)amino]phenyl]amino]carbonyl]phenyl]amino]-6-nitro-, salt with 4-methylbenzenesulfonic acid (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 50576-54-0

CMF C29 H27 N7 O3

PAGE 1-A




PAGE 2-A



CM 2

CRN 16722-51-3

CMF C7 H7 O3 S



RN 50309-29-0 HCAPLUS


CN Quinolinium, 6-amino-1-methyl-4-[[4-[[[4-[(1-methylpyridinium-4-yl)amino]phenyl]amino]carbonyl]amino]phenyl]amino]-, salt with 4-methylbenzenesulfonic acid (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 50576-42-6

CMF C29 H29 N7 O

PAGE 1-A




PAGE 2-A



CM 2


CRN 16722-51-3

CMF C7 H7 O3 S




RN 50440-45-4 HCAPLUS  
 CN Urea, N-[4-[(6-nitro-4-quinolinyl)amino]phenyl]-N'-[4-(4-pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L39 ANSWER 69 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1972:443068 HCAPLUS  
 DN 77:43068  
 TI Basic ethers of 2-anilinobenzothiazoles and 2-anilinobenzoxazoles as potential antidepressants  
 AU Sharpe, C. J.; Palmer, P. J.; Evans, D. E.; Brown, G. R.; King, Gillian; Shadbolt, R. S.; Trigg, R. B.; Ward, R. J.; Ashford, A.; Ross, Janet W.  
 CS Chem. Dep., Twyford Lab. Ltd., London, UK  
 SO Journal of Medicinal Chemistry (1972), 15(5), 523-9  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 AB Some 2-[4-(β-tert-aminoethoxy)anilino]benzothiazoles and the corresponding benzoxazoles reversed reserpine [50-55-5]-induced

hypothermia in mice at low doses. The compds. were classified as antidepressants with a mild stimulant component, with properties intermediate between those of imipramine [50-49-7] and amphetamine [300-62-9]. Several of the more active compds. caused a severe stereotyped behavioral response in cats; the most active compds. not causing this response were 2-[4-[β-(1-pyrrolidinyl)ethoxyanilino]benzothiazole (I) [35189-20-9] and the corresponding benzoxazole (II). The ED50 values for antireserpine activity in mice were 3.7 and 4.3 mg/kg perorally, resp., for I and II. The compds. were prepared by reacting the 2-chlorobenzazoles with substituted anilines in refluxing DMF or Cl<sub>2</sub>CHCHCl<sub>2</sub>.


IT 38519-71-0

RL: BIOL (Biological study)

(antidepressant activity and behavior in response to)

RN 38519-71-0 HCAPLUS

CN 2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



L39 ANSWER 70 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:49453 HCAPLUS

DN 68:49453

TI N-Pyridyl-4-dialkylaminoalkoxyanilines

IN English, Jackson P.; Bach, Frederick L., Jr.; Gordon, Samuel

PA American Cyanamid Co.

SO U.S., 2 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---3330832		19670711	1966US-0597516	19661129 <--

GI For diagram(s), see printed CA Issue.


AB Reaction of halopyridines with 4-dialkylaminoalkoxyanilines yields the title compds. (I). A solution of 9.6 g. 4-BrC<sub>5</sub>H<sub>4</sub>N.HBr and excess p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub> in 100 ml. EtOH was warmed, then concentrated to a semisolid, which was triturated with H<sub>2</sub>O, dissolved in Et<sub>2</sub>O, and precipitated by adding petroleum ether to give N-(4-pyridyl)-p-(2-diethylaminoethoxy)aniline, gray-green, m. 125-7°. Also prepared were N-(3-nitro-2-pyridyl)-p-(2-diethylaminoethoxy)aniline, m. 47-8° (Et<sub>2</sub>O-petroleum ether), and N-(5-nitro-2-pyridyl)-p-(2-diethylaminoethoxy)aniline, m. 143-5° (C<sub>6</sub>H<sub>6</sub>-petroleum ether). Et<sub>2</sub>NCH<sub>2</sub>CHMeONa, from 7.2 g. NaH and 131 g. of the alc., and 72.3 g. p-FC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub> gave Et<sub>2</sub>NCH<sub>2</sub>CHMeOC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>-p, yellow oil, b<sub>0.3-0.4</sub> 130-5°, which was reduced by H and 5% Pd-C to give Et<sub>2</sub>NCH<sub>2</sub>CHMeOC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>-p (II), b<sub>1</sub> 147-9°. II (5.6 g.) and 3.8 g. 2-chloro-5-nitropyridine gave N-(5-nitro-2-pyridyl)-p-(2-diethylamino-1-methylethoxy)aniline, m. 56-61° (Et<sub>2</sub>O-petroleum ether). These products have hypocholesteremic activity.

IT 1240-59-1P 2101-60-2P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 1240-59-1 HCAPLUS


CN 2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 2101-60-2 HCAPLUS  
 CN Pyridine, 4-[β-(diethylamino)-p-phenetidino]- (7CI, 8CI) (CA INDEX NAME)



L39 ANSWER 71 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1967:499762 HCAPLUS  
 DN 67:99762  
 TI Nonsteroidal hypocholesteremic agents. I. Synthesis and serum sterol lowering properties of substituted 4-(2-dialkylaminoethoxy)diphenylamines and related compounds  
 AU Bach, Frederick L., Jr.; Barclay, John C.; Cohen, Elliott  
 CS American Cyanamid Co., Pearl River, NY, USA  
 SO Journal of Medicinal Chemistry (1967), 10(5), 802-6  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 GI For diagram(s), see printed CA Issue.  
 AB The preparation and serum sterol lowering properties of a series of 4,4'-disubstituted diphenylamines and related compds., e.g. I, are discussed. Initial screening data indicate that several of these compds., synthesized by conventional means, possess oral activity greater than most nonsteroidal hypocholesteremic agents reported to date.  
 IT 1240-59-1P 2101-60-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 1240-59-1 HCAPLUS  
 CN 2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 2101-60-2 HCAPLUS  
 CN Pyridine, 4-[β-(diethylamino)-p-phenetidino]- (7CI, 8CI) (CA INDEX NAME)



L39 ANSWER 72 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1967:443822 HCAPLUS  
 DN 67:43822


TI Aminoethoxyphenyl amine, ether, and sulfide derivatives of pyrimidine  
 IN English, Jackson P.; Bach, Frederick L., Jr.; Gordon, Samuel  
 PA American Cyanamid Co.  
 SO U.S., 4 pp.

CODEN: USXXAM


DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---3321478		19670523	1964US-0382383	19630920 <--
GI	For diagram(s), see printed CA Issue.				
AB	<p>Pyrimidine derivs. (I) where NR5R6 is pyrrolidino, piperidino, morpholino, or 4-lower alkyl-1-piperazino, are prepared. The disubstituted aminoethoxyphenyl amines, ethers, and sulfides are hypocholesteremic agents. Thus, 6.2 g. p-(2-diethylaminoethoxy)aniline and 4.4 g. 2,4-dichloropyrimidine in 75 ml. EtOH was warmed to 70°, then kept overnight. The volatile material was distilled to leave a dark brown oil which was warmed with 250 ml. water, the aqueous phase was separated and extracted twice with 50 ml. portions of ether, then neutralized with dilute NH4OH to give N-(2-chloro-4-pyrimidyl)-p-(2-diethylaminoethoxy)aniline (II), m. 75-7°. Similarly prepared were the following N-substituted II (N-substituent and m.p. given): 2,6-dichloro-4-pyrimidyl, 104-6° (C6H6); 5-chloro-2-pyrimidyl, 92-4° (ether-petroleum ether); 5-nitro-2-pyridyl, 143-5°. Alternatively, 6.3 g. p-[(2-(dimethylamino)-2,2-dimethylethoxy)aniline and 3.9 g. 2,5-dichloropyrimidine was sealed in a tube flushed with argon, heated 15 hrs., dissolved in water, decolorized with C, and made basic with dilute NaOH. The insol. material in benzene was chromatographed on Florisil and eluted with C6H6-petroleum ether. The eluant was concentrated to give N-(5-chloro-2-pyrimidyl)-p-[2-(dimethylamino)-2,2-dimethylethoxy]aniline, m. 120-1° (C6H6-petroleum ether). Similarly prepared was N-(5-chloro-2-pyrimidyl)-p-(2-pyrrolidinoethoxy)aniline. Also prepared were 4-(2-diethylaminoethoxy)-4-nitrodiphenylamine, m. 86-8° (EtOH), 4-(2-diethylaminoethoxy)-2,4-dinitrodiphenylamine, m. 70-1° (EtOH), 2-(2-diethylaminoethoxy)-2-amino-4-nitrodiphenylamine hydrochloride, m. 179-81°, N-(4-pyridyl)-p-[2-(diethylamino)ethoxy]aniline, m. 125-7° (Et2O-petroleum ether), N-(3-nitro-2-pyridyl)-p-[2-(diethylamino)ethoxy]aniline, m. 47-8° (Et2O-petroleum ether), 4'-[2-(diethylamino)ethoxy]-4-nitrodiphenyl ether, b0.2 170-5°, 4'-[2-(diethylaminoethoxy)-4-nitrodiphenyl sulfide, 2 - [p - (2-diethylaminoethoxy)anilino]benzothiazole, m. 92-4° (ether-petroleum ether), and N-(5-nitro-2-pyridyl)-p-[2-(diethylamino)-1-methylethoxy]aniline, m. 59-61° (Et2O-petroleum ether).</p>				
IT	1240-59-1P 2101-60-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	1240-59-1 HCAPLUS				
CN	2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-3-nitro- (9CI) (CA INDEX NAME)				



RN 2101-60-2 HCAPLUS  
 CN Pyridine, 4-[β-(diethylamino)-p-phenetidino]- (7CI, 8CI) (CA INDEX NAME)



L39 ANSWER 73 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:482319 HCAPLUS

DN 65:82319

OREF 65:15397a-d

TI (Disubstituted-amino) ethoxyphenylamines, ethers, and sulfides

IN English, Jackson P.; Bach, Frederick L., Jr.; Gordon, Samuel

PA American Cyanamid Co.

SO 9 pp.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB---1034538		19660629	GB	19640904 <--

AB The title compds. p-RZC6H4OCHR1CR2R3X (I) and their salts are hypocholesteremic agents. Thus a solution of p-(2-diethylaminoethoxy)aniline (II) (4.2 g.) and K 2-chloro-5-nitrobenzoate (3.6 g.) in 50 ml. H2O and 50 ml. EtOH was refluxed 15 hrs. and extracted with CHCl3 (2 + 100 ml.). The aqueous raffinate acidified precipitated crude 4'-(2-diethylaminoethoxy)-2-carboxy-4-nitrodiphenylamine, which was recovered and decarboxylated at 180°/0.1 mm. to afford III. Similarly prepared, without the latter decarboxylation stage, were the tabulated I. With the exception of IV, in which the OCHR1CR2R3X group is ortho to the RZ group, all the others are para. R, Z, R1 R2R3, X, m.p. or b.p./mm.; 4-O2NC6H4, NH, H, Et2N (III), 86-8°; 2,4(O2 N)2C6H3, NH, H, Et2N, 70-1°; 2,4-(H2N)2C6H3, NH, H, Et2N, 90-1°; 2,4-H2N(O2N) C6H3, NH, H, Et2N, 179-81°; 4-pyridyl, NH, H, Et2N, 125-7°; 3-nitro-2-pyridyl, NH, H, Et2N, 47-8°; 4-O2 NC6H4, O, H, Et2N, 170-5°/0.2; 4-O2NC6H4, S, H, Et2N (IV), oil; 2,6-dichloro-4-pyrimidinyl, NH, H, Et2N, 104-6°; 2-chloro-4-pyrimidinyl, NH, H, Et2N, 75-6°; 5-chloro-2-pyrimidinyl, NH, H, Et2N, 92-4°; 5-nitro-2-pyridyl, NH, H, Et2N, 143-5°; 2-benzothiazole, NH, H, Et2N, 92-4°; 5-nitro-2-pyridyl, NH, R1 = Me, Et2N 59-61°; , , R2 = R3 = H, , ; 5-chloro-2-pyrimidinyl, NH, R1 = H, Me2N, 120-1°; , , R2 = R3 = Me, , ; 5-chloro-2-pyrimidinyl, NH, H, 1-pyrrolidinyl, --.

IT 1240-59-1, Pyridine, 2-[β-(diethylamino)-p-phenetidino]-3-nitro- 2101-60-2, Pyridine, 4-[β-(diethylamino)-p-phenetidino]- (preparation of)


RN 1240-59-1 HCAPLUS

CN 2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 2101-60-2 HCAPLUS

CN Pyridine, 4-[β-(diethylamino)-p-phenetidino]- (7CI, 8CI) (CA INDEX NAME)



L39 ANSWER 74 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1965:82617 HCAPLUS

DN 62:82617

OREF 62:14692e-h,14693a-b

TI Preparation of disubstituted aminoethoxyphenyl derivatives

PA American Cyanamid Co.

SO 13 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL---6410914		19641125	1964NL-0010914	19640918 <--
PRAI	US		19630920 <--		

AB Disubstituted aminoethoxyphenylamines, ethers, and sulfides, useful as oral hypocholesteremic agents (active with 3-30 mg./kg./day) are prepared by standard procedures. A solution of 4.2 g. p-(2-diethylaminoethoxy)aniline (I), 3.6 g. K 2-chloro-5-nitrobenzoate, 50 ml., H<sub>2</sub>O, and 50 ml. EtOH is refluxed 15 hrs. to yield after decarboxylation at 180° and 0.1 mm. 4'-(2-diethylaminoethoxy)-4-nitrodiphenylamine, m. 86-8° (EtOH). A solution of 4.2 g. I, and 2.8 g. 2,4-dinitrofluorobenzene in 100 ml. EtOH is refluxed 3 hrs. to yield 4'-(2-diethylaminoethoxy)-2,4-dinitrodiphenylamine (II), m. 70-1° (EtOH). Similarly was prepared the 2'-isomer of II, m. 90-1°. A solution of II in EtOH was reduced at boiling temperature with (NH<sub>4</sub>)<sub>2</sub>S in EtOH to yield 4'-(2-diethylaminoethoxy)-2-amino-4-nitrodiphenylamine-2HCl, m. 179-81°. A solution of 6.3 g. 2-chloro-3-nitropyridine, and 8.3 g. I in EtOH was heated 1 hr. on a steam-bath to yield N-(3-nitro-2-pyridyl)-p-(2-diethylaminoethoxy)aniline, m. 47-8° (Et<sub>2</sub>O-petr. ether b. 30-60°). Similarly are prepared the following p-(2-diethylaminoethoxy)-anilines: N-(4-pyridyl), m. 125-7° (Et<sub>2</sub>O-petr. ether); N-(2,6-dichloro-4-pyrimidinyl), m. 104-6° (C<sub>6</sub>H<sub>6</sub>); N-(2-chloro-4-pyrimidinyl), m. 75-7°; N-(5-chloro-2-pyrimidinyl), m. 92-4° (Et<sub>2</sub>O-petr. ether); N-(5-nitro-2-pyridyl), m. 143-5° (C<sub>6</sub>H<sub>6</sub>-petr. ether); 2-benzothiazolyl, m. 92-4° (Et<sub>2</sub>O-petr. ether). A mixture of 3.3 g. p-hydroquinone, 1.2 g. NaOH, and 4.2 g. 4-nitrofluorobenzene (III) is refluxed 15 hrs. (solvent is not given) to yield 4'-hydroxy-4-nitrodiphenyl ether, which is converted with 0.7 g. NaH in toluene into the 4'-NaO analog. The latter is reacted with 4.1 g. diethylaminoethyl chloride in toluene to yield 4'-(2-diethylaminoethoxy)-4-nitrodiphenyl ether, b.p. 170-5°. From 4-nitrophenylsulfenyl chloride and phenol was similarly obtained 4'-(2-diethylaminoethoxy)-4-nitrodiphenyl sulfide. To 131 g. 1-diethylamino-2-propanol was added 7.2 g. NaH at 0-10°, followed by 72.3 g. III to yield p-(2-diethylamino-1-methylethoxy)nitrobenzene (IV), b.p. 130-5°. A solution of 12 g. IV in EtOH was reduced at room temperature with 5% Pd-C and 2.45 atmospheric H to yield p-(2-diethylamino-1-methylethoxy)aniline (V), b.p. 147-9°. A solution of 5.6 g. V and 3.8 g. 2-chloro-5-nitropyridine in 75 ml. EtOH was heated 2 hrs. at 70° to yield N-(5-nitro-2-pyridyl)-p-(2-diethylamino-1-methylethoxy)aniline, m. 59-61° (Et<sub>2</sub>O-petr. ether). A mixture of 6.3 g. p-(2-dimethylamino-2,2-dimethylethoxy)aniline and 3.9 g. 2,5-dichloropyrimidine was heated 15 hrs. under argon in a closed Pyrex glass tube to yield N-(5-chloro-2-pyrimidinyl)-p-(2-dimethylamino-2,2-dimethylethoxy)aniline, m. 120-1° (C<sub>6</sub>H<sub>6</sub>-petr. ether). Similarly was prepared N-(5-chloro-2-pyrimidinyl)-p-(2-pyrrolidinoethoxy)aniline.


IT 1240-59-1, Pyridine, 2-[β-(diethylamino)-p-phenetidino]-3-nitro- 2101-60-2, Pyridine, 4-[β-(diethylamino)-p-phenetidino]-



(preparation of)


RN 1240-59-1 HCAPLUS

CN 2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 2101-60-2 HCAPLUS

CN Pyridine, 4-[β-(diethylamino)-p-phenetidino]- (7CI, 8CI) (CA INDEX NAME)



L39 ANSWER 75 OF 75 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1948:32077 HCAPLUS

DN 42:32077

OREF 42:6830e-i,6831a

TI Synthetic antimalarials. XXVI. Pyridyl- and pyrimidylaminopyrimidines

AU Curd, F. H. S.; Graham, W.; Rose, F. L.

CS Imp. Chem. Industries Ltd., Blackley, UK

SO Journal of the Chemical Society (1948) 594-7

CODEN: JCSOA9; ISSN: 0368-1769


DT Journal

LA Unavailable

AB 4-Hydroxy-2-methylmercapto-6-methylpyrimidine (12 g.) and 14 g. 2-aminopyridine (I), heated 100 hrs. at 150-60°, give 2-(2-pyridylamino)-4-hydroxy-6-methylpyrimidine (II), m. 172-3°; after 2 recrystns. from H2O II m. 205-7° but reverts to the lower-melting form after several recrystns. from C6H6. II (11 g.) and 45 cc. POCl3, heated 4 hrs. at 115-20°, give the 4-Cl compound (III), m. 199-201°; 3 g. III and 2.8 cc. Et2NCH2CH2NH2, 10 hrs. at 130°, give 3 g. 2-(2-pyridylamino)-4-(2-diethylaminoethylamino)-6-methylpyrimidine, whose di-HCl salt, with 2.5 mols. H2O, m. 239-41°. III (2.85 g.), 1.78 g. p-O2NC6H4NH2, 1.5 cc. concentrated HCl, and 15 cc. H2O, refluxed 1 hr., 1.5 cc. HCl and 10 cc. H2O added, and the refluxing continued 1 hr., give 4 g. 4-p-nitroanilino-2-(2-pyridylamino)-6-methylpyrimidine, as the di-HCl salt, with 0.5 mol. H2O, yellow, decompose above 320°; 4-p-chloro analog, as the di-HCl salt, m. 268-70° (4 g. from 2.9 g. III). 4-Chloro-2-p-chloroanilino-6-methylpyrimidine (IV) (16 g.) and 7.9 g. I, heated 10 hrs. at 125-35°, give 4.5 g. of the di-HCl salt, m. 284-7°, of 2-p-chloroanilino-4-(2-pyridylamino)-6-methylpyrimidine, m. 143°. 4-Chloro-2-(2-diethylaminoethylamino)-6-methylpyrimidine (V) (5.5 g.), I, 25 cc. 10 N HCl, and 25 cc. H2O, refluxed 4 hrs., give 2.5 g. 4-(2-pyridylamino)-2-(2-diethylaminoethylamino)-6-methylpyrimidine as the di-HCl salt (with 3.5 mols. H2O), m. 150° (decomposition). IV and V could not be condensed with 2-amino-4,6-dimethylpyrimidine. Diguanidine sulfate (43.4 g.) in 50 cc. EtOH and 40 cc. 11 N NaOH, treated with 28.6 g. AcCH2CO2Et and kept 48 hrs. at room temperature, gives 26 g. 4-hydroxy-2-guanidino-6-methylpyrimidine (VI); 11.6 g. VI and 15 cc. Ac2CH2 in 60 cc. AcOH, refluxed 8 hrs., yield 13.8 g. 6'-hydroxy-4,4',6-trimethyl-2,2'-dipyrimidylamine (VII), m. 266-7°; 8 g. VII and 16 cc. POCl3, heated 0.5 hr. at 100°, give 7 g. of the 6'-Cl compound (VIII), m. 172-3°; 4.5 g. VIII and 10 cc. Et2NCH2CH2NH2, heated 15 hrs. at 130-40°, give 4.3 g. of the di-HI salt, with 1.5 mols. H2O,

pale yellow, m. 247-50°, of the 6'-(2-diethylaminoethylamino) compound; the 6'-dimethylamino analog of VII forms a HBr salt, with 1.5 mols. H<sub>2</sub>O, m. 288-90°. VI (8.4 g.), 9.6 g. AcCH<sub>2</sub>CO<sub>2</sub>Et, and 150 cc. MeOH containing 4.6 g. Na, refluxed 16 hrs., give 10.3 g. 6,6'-dihydroxy-4,4'-dimethyl-2,2'-dipyrimidylamine, m. above 330° (decomposition); 12 g. of the crude product yields 9.4 g. of the 6,6'-di-Cl compound, pale yellow, m. 178-9°; 6,6'-bis(dimethylamino) compound, with 0.25 mol. PhMe, m. 155-6°; 6,6'-bis(isopropylamino) compound, m. 226-7°. The amino derivs. are devoid of antimalarial activity.

IT 856851-88-2, Pyrimidine, 4-(2-diethylaminoethylamino)-6-methyl-2-(2-pyridylamino)-, dihydrochloride  
(preparation of)  
RN 856851-88-2 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED



● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

=> => b hcao

FILE 'HCAOLD' ENTERED AT 10:33:16 ON 16 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all 140 tot

L40 ANSWER 1 OF 2 HCAOLD COPYRIGHT 2006 ACS on STN

AN CA65:15397b CAOLD

TI (disubstituted-amino)ethoxyphenylamines, ethers, and sulfides

AU English, Jackson P.; Bach, F. L., Jr.; Gordon, S.

PA American Cyanamid Co.

DT Patent

IT	1095-05-2	1099-26-9	1100-66-9	1103-54-4	1234-24-8	1234-25-9
	1238-12-6	1240-59-1	1241-12-9	1444-23-1	1444-24-2	
	1795-72-8	1797-51-9	2101-60-2	7628-72-0	7678-22-0	

L40 ANSWER 2 OF 2 HCAOLD COPYRIGHT 2006 ACS on STN

AN CA62:14692e CAOLD

TI S-carbothioalkylthiamine

AU Takamizawa, Akira; Hirai, K.

PA Shionogi & Co., Ltd.

DT Patent

TI aminoethoxyphenyl derivs. (disubstituted)

PA American Cyanamid Co.

DT Patent

PATENT NO.	KIND	DATE
JP--64019812		1964
NL---6410914		
BE----653274		
FR---1436566		
1083-49-4	1095-05-2	1099-26-9
1234-24-8	1238-12-6	1240-59-1
1243-61-4	1444-23-1	1444-24-2
2101-60-2	2101-61-3	97833-57-3

PI JP--64019812

PI NL---6410914

BE----653274

FR---1436566

IT 1083-49-4 1095-05-2 1099-26-9 1100-66-9 1103-54-4 1219-79-0

1234-24-8 1238-12-6 1240-59-1 1241-11-8 1241-12-9

1243-61-4 1444-23-1 1444-24-2 1795-72-8 1797-51-9 2086-14-8

2101-60-2 2101-61-3 97833-57-3

=> b reg;d ide can l41 tot

FILE 'REGISTRY' ENTERED AT 10:33:30 ON 16 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2

DICTIONARY FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L41 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN

RN 2101-60-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN Pyridine, 4-[ $\beta$ -(diethylamino)-p-phenetidino]- (7CI, 8CI) (CA INDEX NAME)


OTHER NAMES:

CN Pyridine, 4-[p-[2-(diethylamino)ethoxy]anilino]-

FS 3D CONCORD

MF C17 H23 N3 O

LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 68:49453

REFERENCE 2: 67:99762

REFERENCE 3: 67:43822

REFERENCE 4: 65:82319

REFERENCE 5: 62:82617

L41 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN

RN 1240-59-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2-Pyridinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-3-nitro- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Pyridine, 2-[β-(diethylamino)-p-phenetidino]-3-nitro- (7CI, 8CI)

FS 3D CONCORD

MF C17 H22 N4 O3

LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 68:49453

REFERENCE 2: 67:99762

REFERENCE 3: 67:43822

REFERENCE 4: 65:82319

REFERENCE 5: 62:82617

=> b hcap

FILE 'HCAPLUS' ENTERED AT 10:33:33 ON 16 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Aug 2006 VOL 145 ISS 8  
FILE LAST UPDATED: 15 Aug 2006 (20060815/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr 142 tot

L42 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:482319 HCAPLUS

DN 65:82319

OREF 65:15397a-d

TI (Disubstituted-amino) ethoxyphenylamines, ethers, and sulfides

IN English, Jackson P.; Bach, Frederick L., Jr.; Gordon, Samuel

PA American Cyanamid Co.

SO 9 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB---1034538		19660629	GB	19640904
AB	The title compds. p-RZC6H4OCHR1CR2R3X (I) and their salts are hypocholesteremic agents. Thus a solution of p-(2-diethylaminoethoxy)aniline (II) (4.2 g.) and K 2-chloro-5-nitrobenzoate (3.6 g.) in 50 ml. H2O and 50 ml. EtOH was refluxed 15 hrs. and extracted with CHCl3 (2 + 100 ml.). The aqueous raffinate acidified precipitated crude 4'-(2-diethylaminoethoxy)-2-carboxy-4-nitrodiphenylamine, which was recovered and decarboxylated at 180°/0.1 mm. to afford III. Similarly prepared, without the latter decarboxylation stage, were the tabulated I. With the exception of IV, in which the OCHR1CR2R3X group is ortho to the RZ group, all the others are para. R, Z, R1 R2R3, X, m.p. or b.p./mm.; 4-O2NC6H4, NH, H, Et2N (III), 86-8°; 2,4(O2 N)2C6H3, NH, H, Et2N, 70-1°; 2,4-(H2N)2C6H3, NH, H, Et2N, 90-1°; 2,4-H2N(O2N) C6H3, NH, H, Et2N, 179-81°; 4-pyridyl, NH, H, Et2N, 125-7°; 3-nitro-2-pyridyl, NH, H, Et2N, 47-8°; 4-O2 NC6H4, O, H, Et2N, 170-5°/0.2; 4-O2NC6H4, S, H, Et2N (IV), oil; 2,6-dichloro-4-pyrimidinyl, NH, H, Et2N, 104-6°; 2-chloro-4-pyrimidinyl, NH, H, Et2N, 75-6°; 5-chloro-2-pyrimidinyl, NH, H, Et2N, 92-4°; 5-nitro-2-pyridyl, NH, H, Et2N, 143-5°; 2-benzothiazole, NH, H, Et2N, 92-4°; 5-nitro-2-pyridyl, NH, R1 = Me, Et2N 59-61°; , , R2 = R3 = H, , ; 5-chloro-2-pyrimidinyl, NH, R1 = H, Me2N, 120-1°; , , R2 = R3 = Me, , ; 5-chloro-2-pyrimidinyl, NH, H, 1-pyrrolidinyl, --.				

L42 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1965:82617 HCAPLUS

DN 62:82617

OREF 62:14692e-h,14693a-b

TI Preparation of disubstituted aminoethoxyphenyl derivatives

PA American Cyanamid Co.

SO 13 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL---6410914		19641125	1964NL-0010914	19640918
PRAI	US		19630920		

AB Disubstituted aminoethoxyphenylamines, ethers, and sulfides, useful as oral hypocholesteremic agents (active with 3-30 mg./kg./day) are prepared by standard procedures. A solution of 4.2 g. p-(2-diethylaminoethoxy)aniline (I), 3.6 g. K 2-chloro-5-nitrobenzoate, 50 ml., H<sub>2</sub>O, and 50 ml. EtOH is refluxed 15 hrs. to yield after decarboxylation at 180° and 0.1 mm. 4'-(2-diethylaminoethoxy)-4-nitrodiphenylamine, m. 86-8° (EtOH). A solution of 4.2 g. I, and 2.8 g. 2,4-dinitrofluorobenzene in 100 ml. EtOH is refluxed 3 hrs. to yield 4'-(2-diethylaminoethoxy)-2,4-dinitrodiphenylamine (II), m. 70-1° (EtOH). Similarly was prepared the 2'-isomer of II, m. 90-1°. A solution of II in EtOH was reduced at boiling temperature with (NH<sub>4</sub>)<sub>2</sub>S in EtOH to yield 4'-(2-diethylaminoethoxy)-2-amino-4-nitrodiphenylamine-2HCl, m. 179-81°. A solution of 6.3 g. 2-chloro-3-nitropyridine, and 8.3 g. I in EtOH was heated 1 hr. on a steam-bath to yield N-(3-nitro-2-pyridyl)-p-(2-diethylaminoethoxy)aniline, m. 47-8° (Et<sub>2</sub>O-petr. ether b. 30-60°). Similarly are prepared the following p-(2-diethylaminoethoxy)-anilines: N-(4-pyridyl), m. 125-7° (Et<sub>2</sub>O-petr. ether); N-(2,6-dichloro-4-pyrimidinyl), m. 104-6° (C<sub>6</sub>H<sub>6</sub>); N-(2-chloro-4-pyrimidinyl), m. 75-7°; N-(5-chloro-2-pyrimidinyl), m. 92-4° (Et<sub>2</sub>O-petr. ether); N-(5-nitro-2-pyridyl), m. 143-5° (C<sub>6</sub>H<sub>6</sub>-petr. ether); 2-benzothiazolyl, m. 92-4° (Et<sub>2</sub>O-petr. ether). A mixture of 3.3 g. p-hydroquinone, 1.2 g. NaOH, and 4.2 g. 4-nitrofluorobenzene (III) is refluxed 15 hrs. (solvent is not given) to yield 4'-hydroxy-4-nitrodiphenyl ether, which is converted with 0.7 g. NaH in toluene into the 4'-NaO analog. The latter is reacted with 4.1 g. diethylaminoethyl chloride in toluene to yield 4'-(2-diethylaminoethoxy)-4-nitrodiphenyl ether, b. 0.2 170-5°. From 4-nitrophenylsulfenyl chloride and phenol was similarly obtained 4'-(2-diethylaminoethoxy)-4-nitrodiphenyl sulfide. To 131 g. 1-diethylamino-2-propanol was added 7.2 g. NaH at 0-10°, followed by 72.3 g. III to yield p-(2-diethylamino-1-methylethoxy)nitrobenzene (IV), b. 0.3-0.4 130-5°. A solution of 12 g. IV in EtOH was reduced at room temperature with 5% Pd-C and 2.45 atmospheric H to yield p-(2-diethylamino-1-methylethoxy)aniline (V), b. 1.0 147-9°. A solution of 5.6 g. V and 3.8 g. 2-chloro-5-nitropyridine in 75 ml. EtOH was heated 2 hrs. at 70° to yield N-(5-nitro-2-pyridyl)-p-(2-diethylamino-1-methylethoxy)aniline, m. 59-61° (Et<sub>2</sub>O-petr. ether). A mixture of 6.3 g. p-(2-dimethylamino-2,2-dimethylethoxy)aniline and 3.9 g. 2,5-dichloropyrimidine was heated 15 hrs. under argon in a closed Pyrex glass tube to yield N-(5-chloro-2-pyrimidinyl)-p-(2-dimethylamino-2,2-dimethylethoxy)aniline, m. 120-1° (C<sub>6</sub>H<sub>6</sub>-petr. ether). Similarly. was prepared N-(5-chloro-2-pyrimidinyl)-p-(2-pyrrolidinoethoxy)aniline.

L42 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1965:82616 HCAPLUS

DN 62:82616

OREF 62:14692e

TI S-Carbothioalkylthiamine

IN Takamizawa, Akira; Hirai, Kentaro

PA Shionogi &amp; Co., Ltd.

SO 2 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--39019812		19640912	JP	19610214

AB To 3 cc. aqueous solution of 3.3 g. thiamine chloride hydrochloride was added 3 cc. aqueous solution of 1.2 g. NaOH and the mixture let stand 30 min. and stirred with 1.1 g. chlorocarbothioethyl to give 2.5 g. S-carbothioethylthiamine, m. 136-7° (decomposition) (C<sub>6</sub>H<sub>6</sub>). Similarly was prepared

S-carhothiopropyl- thiamine; hydrochloride m. 173-4°  
(decomposition) (EtOH). The products were useful as long-acting thiamine  
derivs.

=> d his

(FILE 'HOME' ENTERED AT 09:41:41 ON 16 AUG 2006)

FILE 'REGISTRY' ENTERED AT 09:41:57 ON 16 AUG 2006  
ACT DAV916F0/A

```

L1          STR
L2          2366 SEA FILE=REGISTRY SSS FUL L1
            -----
            DEL FRE?/A
            ACT DAV916S1/Q
            -----
L3          STR
            -----
L4          32 L3 SAM SUB=L2
L5          736 L3 FULL SUB=L2
L6          1630 L2 NOT L5
L7          STR L1
L8          50 L7 SAM SUB=L2
L9          2327 L7 FULL SUB=L2
L10         STR L7
L11         0 L10 CSS SAM SUB=L9
L12         24 L10 SAM SUB=L9
L13         STR L10
L14         24 L13 SAM SUB=L9
L15         694 L13 FULL SUB=L9
L16         171 L15 AND (NC5-C6 OR NC4-C6 OR NC2NC2-C6)/ES
            SAV TEM L9 DAV916S2/A
            SAV TEM L15 DAV916S3/A

```

FILE 'HCAPLUS' ENTERED AT 10:18:14 ON 16 AUG 2006

```

L17         96 L15
L18         3 (US2004186102 OR US2005054850)/PN OR (US2004-924181 OR WO2004-U
            E WU CHENG/AU
L19         106 E3,E22
            E WU CHENGDE/AU
L20         62 E3
            E ANDERSON C/AU
L21         161 E3,E15-17
            E BUI H/AU
L22         20 E3-8
            E BUI HUONG/AU
L23         13 E3
            E DUPRE B/AU
L24         139 E3,E8
            E GAO DAX/AU
L25         43 E5-8
            E HOLLAND G/AU
L26         41 E3,E15
            E HOLLAND GEORGE/AU
L27         55 E3,E8-9
            E KASSIR J/AU
L28         37 E4-6
            E LI W/AU
L29         1945 E3-33
            E LI WEN/AU
L30         646 LI WEN/AU
            E WANG JUN/AU
L31         2949 E3,E44
L32         1 E43

```

L33 E WANG JUNMEI/AU  
70 E3  
L34 11 ENCYSIVE/PA,CS  
L35 5 L17 AND L18-34  
L36 91 L17 NOT L35  
L37 75 L36 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L38 69 L37 AND (PD<=20030228 OR AD<=20030228 OR PRD<=20030228)  
L39 75 L37-38

FILE 'HCAOLD' ENTERED AT 10:32:17 ON 16 AUG 2006  
L40 2 L15  
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 10:32:38 ON 16 AUG 2006  
L41 2 E1-2

FILE 'HCAOLD' ENTERED AT 10:32:49 ON 16 AUG 2006  
SEL AN L40  
EDIT /AN /OREF

FILE 'HCAPLUS' ENTERED AT 10:33:03 ON 16 AUG 2006  
L42 3 E3-4

=>